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Abstract
The manifestation of phenotype at the cellular and organismal level is determined in large part by gene
expression, or the transcription of DNA into RNA. As such, the study of the transcriptome, or the
characterization and quantification of all RNA produced in the cell, is important. Recent advances in
sequencing technology have allowed for unprecedented interrogation of the transcriptome at single-
nucleotide resolution. In the first part of this thesis, we use RNA-Sequencing (RNA-Seq) to study the human
B-cell transcriptome and determine the experimental parameters necessary for sequencing-based studies of
gene expression. We discover that deep sequencing is necessary to detect fully and quantify accurately the
complexity of human transcriptomes. Furthermore, we find that at high sequencing depths, the vast majority
of transcribed elements in human B-cells are detected.
In the second part of this thesis, we utilize the sequence information provided by RNA-Seq to analyze
systematic differences between DNA and RNA sequence. The transmission of information from DNA to
RNA is a critical process and is expected to occur in a one-to-one fashion. By comparing the DNA sequence
to RNA sequence of the same individuals, we found all 12 types of RNA-DNA sequence differences (RDDs),
the majority of which cannot be explained by known mechanisms such as RNA editing or transcriptional
infidelity. We developed computational methods to robustly identify RDDs and control for false positives
resulting from genotyping, sequencing, and alignment error. Finally, we explore the genetic basis of RDD
levels, or the proportion of reads at a site bearing the sequence difference allele. In particular, we analyzed the
levels of RNA editing in unrelated and related individuals and found that a significant portion of individual
variation in A-to-G editing levels contains a genetic component.
In summary, our results demonstrate that RNA-Seq is a powerful technique for comprehensive and
quantitative analysis of gene expression. In addition, the resolution offered by RNA-Seq enables a detailed
view of sequence differences between RNA and DNA. Future work will focus on understanding the
mechanisms and factors influencing RDDs. Our results suggest that RDD levels may be considered a
quantitative and heritable phenotype; as such, a genetic approach may be a sensible method for finding the
determinants and mechanism of RDDs.
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ABSTRACT 
 
RNA AND DNA-SEQUENCE ANALYSIS 
OF THE HUMAN TRANSCRIPTOME 
 
Jonathan M. Toung 
Frederic Bushman 
Nancy Zhang 
 
 The manifestation of phenotype at the cellular and organismal level is 
determined in large part by gene expression, or the transcription of DNA into RNA. As 
such, the study of the transcriptome, or the characterization and quantification of all RNA 
produced in the cell, is important. Recent advances in sequencing technology have 
allowed for unprecedented interrogation of the transcriptome at single-nucleotide 
resolution. In the first part of this thesis, we use RNA-Sequencing (RNA-Seq) to study 
the human B-cell transcriptome and determine the experimental parameters necessary for 
sequencing-based studies of gene expression. We discover that deep sequencing is 
necessary to detect fully and quantify accurately the complexity of human transcriptomes. 
Furthermore, we find that at high sequencing depths, the vast majority of transcribed 
elements in human B-cells are detected. 
In the second part of this thesis, we utilize the sequence information provided by 
RNA-Seq to analyze systematic differences between DNA and RNA sequence. The 
transmission of information from DNA to RNA is a critical process and is expected to 
occur in a one-to-one fashion. By comparing the DNA sequence to RNA sequence of the 
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same individuals, we found all 12 types of RNA-DNA sequence differences (RDDs), the 
majority of which cannot be explained by known mechanisms such as RNA editing or 
transcriptional infidelity. We developed computational methods to robustly identify 
RDDs and control for false positives resulting from genotyping, sequencing, and 
alignment error. Finally, we explore the genetic basis of RDD levels, or the proportion of 
reads at a site bearing the sequence difference allele. In particular, we analyzed the levels 
of RNA editing in unrelated and related individuals and found that a significant portion of 
individual variation in A-to-G editing levels contains a genetic component.  
In summary, our results demonstrate that RNA-Seq is a powerful technique for 
comprehensive and quantitative analysis of gene expression. In addition, the resolution 
offered by RNA-Seq enables a detailed view of sequence differences between RNA and 
DNA. Future work will focus on understanding the mechanisms and factors influencing 
RDDs. Our results suggest that RDD levels may be considered a quantitative and 
heritable phenotype; as such, a genetic approach may be a sensible method for finding the 
determinants and mechanism of RDDs.  
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Chapter 1. Introduction 
1.1 The study of the transcriptome 
The realization of phenotype at the cellular and organismal level is determined in 
large part by a more proximal phenotype – gene expression, or the transcription of DNA 
into RNA. As such, the study of the transcriptome, or the characterization and 
quantification of all RNA produced in the cell at a given time or under a particular 
condition, is critical for a deeper understanding of all biological pathways and processes. 
Over the past few decades, the role of complexity at the RNA level in contributing to 
disease manifestation and phenotypic variation has become increasingly more apparent 
(Cooper et al. 2009; Licatalosi & Darnell 2010). From the point of transcription, RNA is 
subject to a wide range of processes such as alternative transcription initiation (Davuluri 
et al. 2008; Moore & Proudfoot 2009), alternative polyadenylation (Di Giammartino et 
al. 2011; Lutz 2008), alternative splicing (Cooper et al. 2009; Maniatis & Tasic 2002), 
RNA editing (Gott & Emeson 2000; Knoop 2011), and other post-transcriptional 
modification events (Karijolich & Yu 2011; G. Martin & Keller 2007; Rottman et al. 
1994). In recent years, methodological advances in sequencing and bioinformatics have 
enabled genome-wide analyses of RNA at unprecedented levels of resolution and depth, 
allowing for comprehensive profiles of RNA species and variation (Djebali et al. 2012; 
Nagalakshmi et al. 2008). These developments lend insight into the contribution of RNA 
to overall biological diversity and cellular function. 
In this thesis, we study the human transcriptome using RNA-Sequencing (RNA-
Seq) technology. In particular, we quantify the expression levels of genes and their 
transcripts and determine the appropriate experimental parameters for sequencing-based 
 2 
studies. Next, we examine systematic RNA-DNA sequence differences (RDDs) – 
discrepancies between DNA and RNA that may result from RNA editing, transcriptional 
infidelity, or other unknown mechanisms. Lastly, we analyze variation in levels of RDD, 
or the percentage of transcripts at a particular site that are altered, across unrelated 
individuals and assess the degree to which this individual variation is determined by 
genetic factors. The studies performed and methodologies used in this thesis demonstrate 
the coming of a new age in modern biology where challenges lie not in the procurement 
of but rather the analysis of data. 
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1.2 Hybridization- and sequencing-based methods for transcriptome 
analysis 
Traditionally, hybridization-based methods such as microarrays were used to 
study gene expression and quantify RNA in a global manner (Schena et al. 1995). The 
main strategy for hybridization-based approaches involves incubating fluorescently 
labeled complementary DNA (cDNA) fragments with microarray chips that are fixed 
with oligonucleotide probes containing known target sequences. Gene expression levels 
are subsequently quantified by fluorescent detection of the probe-target pairs. Studies 
using microarrays have provided key insights into the genetics and regulation of gene 
expression (Brem et al. 2002; Morley et al. 2004), cancer biology (Bittner et al. 2000; 
Golub et al. 1999), and various biological processes such as cell growth (Iyer et al. 1999) 
and the cell cycle (Cho et al. 1998; Cho et al. 2001). Nonetheless, array methodologies 
are subject to limitations that include background noise resulting from cross-
hybridization (Okoniewski & Miller 2006), dependence on known targets, and small 
dynamic range. Some specialized microarrays have been designed, however, to address 
some of these issues, such as the use of genomic tiling microarrays to detect unknown 
transcripts (Bertone et al. 2004). 
To overcome the disadvantages of hybridization-based approaches, several 
sequencing-based methods have been developed to study the transcriptome. In contrast to 
microarrays, sequencing-based approaches directly determine the sequence of the 
underlying sample. Initially, Sanger sequencing of cDNA or EST libraries was used to 
determine gene sequences (Boguski et al. 1994), although this method is relatively 
expensive and low-throughput. Tag-based approaches were developed to overcome these 
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limitations and generate digital gene expression profiles in a high-throughput manner. 
These tag-based methods include serial analysis of gene expression (SAGE) (Velculescu 
et al. 1995) cap analysis of gene expression (CAGE) (Kodzius et al. 2006), and massively 
parallel signature sequencing (MPSS) (Brenner et al. 2000). In general, these approaches 
involve the introduction of recognition sites to the ends of cDNA and cutting by 
restriction endonucleases to create tags that can be isolated and cloned for high-
throughput sequencing (Harbers & Carninci 2005). These approaches, however, are 
expensive as they rely on Sanger sequencing, and their output is restricted to certain 
regions of the transcripts, limiting the analysis of alternatively-spliced isoforms. 
Recently, a high-throughput sequencing approach called RNA-Sequencing (RNA-Seq) 
has been developed that overcomes many of the shortcomings of hybridization-based 
methods and preexisting sequencing-based approaches. 
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1.3 Next-generation sequencing methods for transcriptome analysis 
Apart from providing the scientific community with a reference genome, the 
Human Genome Project spurred advancements in sequencing technology. Termed ‘next-
generation sequencing technology’, these high-throughput sequencing platforms have 
become more readily accessible to researchers within the past decade, replacing the more 
expensive capillary sequencing methods and dramatically decreasing the cost of DNA 
sequencing (Mardis 2008; Metzker 2010; Shendure & Ji 2008). The ability of next-
generation sequencing methods to provide an unprecedented amount of sequence 
information at a relatively low cost has enabled both whole-genome sequencing and de 
novo assembly of novel genomes (R. LiW. Fan, et al. 2010; Locke et al. 2011) in addition 
to whole-genome re-sequencing of organisms with reference genomes to catalogue and 
annotate genetic variants (1000 Genomes Project Consortium 2010; Bentley et al. 2008; 
J. I. Kim et al. 2009; Korbel et al. 2007; S. C. Schuster et al. 2010; J. Wang et al. 2008; 
Wheeler et al. 2008).  
In addition to the direction application of next-generation sequencing to sequencing 
of DNA (DNA-Seq), a whole host of sequencing-based assays have been developed 
using next-generation sequencing platforms to interrogate genome-wide profiles of 
mRNA (Mortazavi et al. 2008; Nagalakshmi et al. 2008), RNA secondary structure 
(Kertesz et al. 2010; Underwood et al. 2010), transcription factor binding (X. Chen et al. 
2008; Farnham 2009; Johnson et al. 2007; Wederell et al. 2008), chromatin states and 
histone modifications (Barski et al. 2007; Mikkelsen et al. 2007; Schones et al. 2008), 
DNase hypersensitivity (Boyle et al. 2008), and DNA methylation status (Cokus et al. 
2008; Meissner et al. 2008). In particular, high-throughput sequencing of RNA or RNA-
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Seq has revealed insights into the complexity of the transcriptome, uncovering new 
classes of small RNA (Lau et al. 2006; Malone & Hannon 2009; Taft et al. 2010), 
discovering novel transcripts and gene fusions (Bruno et al. 2010; Levin et al. 2009; Lu et 
al. 2010; Maher et al. 2009), and expanding the catalogue of alternatively-spliced 
transcripts (Pan et al. 2008; E. T. Wang et al. 2008). 
As of this writing, the most commonly used next-generation sequencing platforms 
are the Illumina Genome Analyzer (Bentley et al. 2008) and, more recently, the Illumina 
HiSeq machines, the Roche 454 Genome Sequencer FLX machines (Margulies et al. 
2005; Rothberg & Leamon 2008), and the SOLiD system from Life Technologies 
(McKernan et al. 2009). Other next-generation sequencing manufacturers or platforms 
include Complete Genomics (Drmanac et al. 2010), Helicos BioSciences (Braslavsky et 
al. 2003; Ozsolak et al. 2009), Ion Torrent from Life Technologies (Rothberg et al. 2011), 
and Pacific Biosciences (Eid et al. 2009). For general applications, Illumina is currently 
the market leader in the next-generation sequencing space because of low error rates and 
high yield (Luo et al. 2012; Minoche et al. 2011; Quail et al. 2012), although the various 
platforms have advantages that are better suited for different experiments. For example, 
the Roche 454 system delivers long reads necessary for many metagenomics studies 
(Turnbaugh et al. 2009; Wommack et al. 2008), Helicos sequencers allow for direct 
sequencing of RNA without conversion to cDNA (Ozsolak & Milos 2011; Ozsolak et al. 
2009), and the Pacific Biosciences platform allows for real-time monitoring of the 
sequencing reaction (Metzker 2009) and detection of modified nucleotides (Flusberg et 
al. 2010). While the exact methodology for each system differs, in general, the next-
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generation sequencing workflow involves library or template preparation, sequencing and 
imaging, and alignment and assembly.  
1.3.1 Library preparation and sequencing  
The main steps of library preparation consist of isolation of nucleic acid material, 
shearing of the sample into smaller fragments, addition of adapter sequences to allow for 
PCR amplification, and immobilization of the fragments to a surface. Illumina uses a 
technique called solid-phase amplification (Fedurco et al. 2006) whereby fragments 
hybridize to primers covalently attached to a glass slide or ‘flow cell’. Fragments are 
clonally amplified using isothermal ‘bridging’ amplification, resulting in high-density 
‘clusters’ originating from the same template (Bentley et al. 2008). In contrast, Roche 
454 and SOLiD by Life Technologies employ a different technique called emulsion PCR 
(Dressman et al. 2003) which involves bead capture of fragments and immobilization of 
the beads through chemical crosslinking (Kim et al. 2007) or deposition into wells 
(Leamon et al. 2003). 
The next steps in the workflow calls for sequencing and imaging of the clonally 
amplified templates. Illumina utilizes a strategy termed ‘cyclic reversible termination’ 
which involves repeated cycles of nucleotide incorporation, fluorescence imaging, and 
cleavage (Bentley et al. 2008; Metzker 2005). The methodology begins with the 
incorporation of a modified nucleotide containing a reversible blocking group that 
terminates DNA synthesis after addition of a single base. The identity of the incorporated 
base and an associated quality score reflecting the probability of a misidentification is 
determined through fluorescence imaging, followed by a cleavage step that removes the 
inhibitor group from the DNA chain. Roche 454 uses a method called ‘pyrosequencing’ 
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that measures the release of inorganic pyrophosphate to infer the incorporation of 
nucleotides (Ronaghi et al. 1996; Ronaghi et al. 1998). The pyrosequencing method does 
not use modified nucleotides to terminate DNA synthesis, but instead relies on the 
addition of nucleotides in limiting amounts and recording the luminescence following 
release of pyrophosphate to infer the underlying DNA sequence (Margulies et al. 2005). 
Lastly, the SOLiD system by Life Technologies uses a ‘sequencing by ligation’ approach 
that uses DNA ligase (Landegren et al. 1988) and base-encoded probes (Shendure et al. 
2005). Briefly, fluorescently labeled probes are hybridized to the complementary 
sequencing template. DNA ligase is then added, non-ligated probes are washed away, and 
the identity of the incorporated probe along with a quality score reflecting the probability 
of an incorrect call is then determined by imaging. 
1.3.2 Genome assembly and alignment 
For genome studies, the first step in the processing of sequence reads obtained from 
next-generation sequencing platforms is assembly and alignment (Flicek & Birney 2009). 
Assembly of sequencing reads is necessary in cases where a reference genome does not 
exist. Prior to the advent of next-generation sequencing data, Sanger sequencing 
technology provided long reads (~800 nucleotides or nt), and assembly algorithms 
resolved the overlap between these long reads. For the short read (36 to ~300 nt) output 
of next-generation sequencing platforms, new computational methods have been 
developed to address the assembly of fragments of small lengths (Zhang et al. 2011). 
Two main types of strategies exist for de novo assembly: string-based methods, 
implemented by a Greedy-extension algorithm, and graph-based models such as the 
overlap-layout-consensus method and the de Bruijn graph approach. Programs that use 
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string-based methods, such as QSRA (Bryant et al. 2009), VCAKE (Jeck et al. 2007), 
SHARCGS (Dohm et al. 2007), and SSAKE (Warren et al. 2007) are more appropriate 
for small genomes with short reads, whereas software that utilize overlap-layout-
consensus, such as Forge (Diguistini et al. 2009), Shorty (Hossain et al. 2009), CABOG 
(Miller et al. 2008), and Edena (Hernandez et al. 2008) are more suited for small 
genomes with long reads (Zhang et al. 2011). For larger genomes, programs that use the 
de Bruijn graph method (Idury & Waterman 1995; Pevzner et al. 1989) are more fitting; 
algorithms that use this approach include ALLPATHS-LG (Gnerre et al. 2011), 
SOAPdenovo (R. Li, H. Zhu, et al. 2010), ABySS (Simpson et al. 2009), Euler-USR 
(Chaisson et al. 2009), Velvet (Zerbino & Birney 2008), ALLPATHS (Butler et al. 2008), 
and Euler-SR (Chaisson & Pevzner 2008).  
In cases where a reference genome exists, alignment is necessary to determine the 
most likely origin for each sequencing read. Early methods relied on the use of hash-table 
data structures to index sequence data and rapidly search for alignments. One strategy, 
used by programs such as Eland (proprietary software of Illumina), RMAP (A. D. Smith 
et al. 2008), MAQ (H. Li et al. 2008), ZOOM (H. Lin et al. 2008), SeqMap (Jiang & 
Wong 2008), CloudBurst (Schatz 2009), and SHRiMP (Rumble et al. 2009), involves 
hashing the short reads and subsequently scanning through the reference genome for 
alignments. These software programs are relatively efficient in terms of memory usage, 
but they require a lookup of the entire reference genome regardless of the number of 
alignments in the dataset. The other methodology utilized by hash-based programs is to 
hash the reference genome instead. Programs that use this approach include BFAST 
(Homer et al. 2009), GSNAP (T. D. Wu & Nacu 2010), MOM (Eaves & Gao 2009), 
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PASS (Campagna et al. 2009), ProbeMatch (Y. J. Kim et al. 2009), SOAPv1 (R. Li et al. 
2008), and Stampy (Lunter & Goodson 2011). These methods use a constant amount of 
memory for a given reference genome, which may be large depending on the size and 
(Lunter & Goodson 2011) complexity of the genomic sequence. A third type of strategy 
for alignment of next-generation sequencing data indexes the reference genome using the 
Burrows-Wheeler Transform (BWT), a data compression algorithm that allows for 
memory-efficient storage and fast string matching (Burrows & Wheeler 1994). Programs 
that use this approach include Bowtie (Langmead et al. 2009), BWA (H. Li & Durbin 
2009), and SOAPv2 (R. Li, C. Yu, et al. 2009). While BWT-based aligners are fast and 
memory-efficient, they tend to be less accurate and sensitive than hash-based algorithms 
(Grant et al. 2011; Lunter & Goodson 2011). 
1.3.3 Transcriptome assembly and alignment 
For transcriptome studies, the assembly and alignment challenge is complicated by 
unequal coverage resulting from gene expression differences, strand-specific expression 
of transcripts, and alternative splicing. While the reference genome can serve as a 
scaffold in genome alignment for many model organisms, the existence of a truly 
comprehensive transcriptome database that accounts for all possible gene isoforms does 
not exist for most organisms. Thus, even for studies involving humans where a reference 
genome is available, the ability of assemblers to discover gene isoforms de novo is 
important. Transcriptome assembly programs mainly follow either a reference-based 
strategy or de novo approach, or some combination of the two (J. A. Martin & Wang 
2011). 
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The de novo approach for transcriptome assembly involves searching for 
overlapping sequence between short reads and assembling them using a de Bruijn 
approach (Pevzner et al. 2001) to form transcripts. Programs using this strategy include 
Multiple-k (Surget-Groba & Montoya-Burgos 2010), Rnnotator (J. Martin et al. 2010), 
Trans-ABySS (Robertson et al. 2010), and Trinity (Grabherr et al. 2011). De novo 
assembly for organisms with smaller genomes has been successful, although for more 
complicated eukaryotic organisms, intense computing resources are necessary. Some 
disadvantages of de novo methods include the dependence on high sequencing depths (J. 
Martin et al. 2010) and sensitivity to sequencing error and chimeric transcripts (Cocquet 
et al. 2006). 
Another strategy for transcriptome analyses of next-generation sequencing data 
uses the reference genome as a basis for guided assembly. The general strategy first 
involves alignment of the short reads to the genome using a splice-aware aligner, or 
aligner that allows for the introduction of gaps in locations of spliced introns. Examples 
of splice-aware aligners include BLAT (Kent 2002), GSNAP (T. D. Wu & Nacu 2010), 
MapSplice (K. Wang et al. 2010), QPALMA (De Bona et al. 2008), SOAPv2 (R. Li, C. 
Yu, et al. 2009), RUM (Grant et al. 2011), SpliceMap (Au et al. 2010), and TopHat 
(Trapnell et al. 2009). These various aligners use different approaches for the alignment 
of spliced reads. Early algorithms performed alignment to a transcriptome database 
consisting of known isoform transcripts supplemented with sequences surrounding 
potential exon-exon junctions (E. T. Wang et al. 2008); however, this method fails to 
detect unannotated exons and unconventional splicing events. The strategy used by 
Tophat involves a sequential approach: first, reads are aligned to the genome, second, 
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exons are inferred from regions of the genome with coverage, and lastly, reads that failed 
to align to the genome previously are mapped to junctions created between the proposed 
exons (Trapnell et al. 2009). This method performs well only for highly abundant 
isoforms, as the exons of low-expressing transcripts may not be properly identified. 
Another shortcoming of this strategy is that alignments to the genome take precedence 
over spliced alignments, which is problematic for alignments to homologous sequences in 
the genome such as processed pseudogenes. The methodology used by RUM addresses 
this issue, as RUM seeks and compares alignments to the genome and transcriptome 
(Grant et al. 2011). The approach taken by GSNAP searches for alignments to known 
junctions and also attempts to predict novel splicing events through a probabilistic model 
dependent on donor and acceptor sites in the surrounding genomic sequence (T. D. Wu & 
Nacu 2010). Comparative and benchmark analyses have been performed on these various 
splice-aware aligners, and the results indicate that GSNAP and RUM have the highest 
accuracy in terms of overall alignment and splice junction detection (Grant et al. 2011). 
Following alignment of the reads to the genome with a splice-aware aligner, reads 
that overlap are clustered to build a graph representing all possible splice variants, and 
finally, isoforms are resolved by traversing through the graph. Programs that adopt the 
reference-based approach to transcriptome assembly include Cufflinks (Trapnell et al. 
2010), G-Mo.R-Se (Denoeud et al. 2008), and Scripture (Guttman et al. 2010). Cufflinks 
assembles gene isoforms by first creating an overlap graph from all reads within a locus 
in the genome and then creates transcripts by determining the minimum number of 
traversals through the graph that explains the splice junctions observed (Trapnell et al. 
2010). In contrast, Scripture forms a graph for each chromosome, inserting edges 
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between bases connected by a splice junction, and then assembles transcripts by 
searching for traversals through the graph that are supported by statistically significant 
expression (Guttman et al. 2010). The differences in graph formation and traversal 
methods between Cufflinks and Scripture suggests that Cufflinks may be more 
conservative in isoform detection, and a recent comparison between Cufflinks and 
Scripture has shown that indeed Cufflinks has higher specificity and sensitivity for 
finding known introns (Robertson et al. 2010). 
A third approach to transcriptome assembly involves a combination of de novo and 
reference-based assembly. Algorithms that use both approaches combine the ability of de 
novo methods to find novel isoforms and the sensitivity and specificity in splice junction 
detection of referenced-based strategies. Some programs, such as Trans-ABySS 
(Robertson et al. 2010) and Oases (Schulz et al. 2012), begin by a referenced-based 
assembly of reads, followed by de novo assembly of reads that failed to align to the 
genome. For situations where a high quality reference genome does not exist, an 
alternative approach involves de novo assembly of reads into contigs and subsequent 
alignment of the contigs to the reference genome. The reference genome, and in some 
cases protein sequences, can be used to join and fill in gaps between contigs to form 
longer transcripts (Crawford et al. 2010; Surget-Groba & Montoya-Burgos 2010). 
1.3.4 Variant and genotype calling 
The goals of genome sequencing projects include the comprehensive 
characterization of genetic variation in a population (1000 Genomes Project Consortium 
2010; Ju et al. 2011; Mills et al. 2011), the analysis of genetic adaptation or molecular 
evolution (Turner et al. 2010; Xia et al. 2009; Yi et al. 2010), and the mapping of disease 
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loci (Ng, Bigham, et al. 2010; Ng, Buckingham, et al. 2010; Ng et al. 2009; O'Roak et al. 
2011; Tennessen et al. 2012). These studies, among other applications of high-throughput 
sequencing, rely critically on the accurate identification of genetic variants and 
genotyping of individual samples using next-generation sequencing data. Many 
frameworks and computational pipelines for variant and genotype calling have been 
developed. In general, they involve many steps of calibration, filtering, and statistical 
analyses. The general approach starts with methods for reducing base-calling errors in 
raw reads along with further recalibration of base quality scores, local realignment, and 
filtering of duplicate reads after assembly and alignment of reads. Variants, or sites where 
at least one of the observed bases is different from the reference, are then identified and 
the corresponding genotypes are inferred. For studies involving multiple samples, 
datasets can be pooled across individuals to increase the power of detection. Smaller 
variants, such as single-nulceotide polymorphisms (SNPs) and short insertions and 
deletions, require different algorithms and strategies than large structural variants such as 
insertions, deletions, inversions, duplications, copy-number variations (CNVs), and 
translocations. As such, many different programs aimed at different variants have been 
developed for the comprehensive analyses of DNA-Seq datasets. 
The proper identification of variants and determination of genotype is affected by 
sequencing and alignment error. Thus, various precautionary steps are taken to reduce the 
amount of false positives resulting from spurious signals in next-generation sequencing 
datasets. The first step in most frameworks for variant and genotype calling involves 
optimization of base calling procedures. After assembly and alignment of reads, further 
measures, such as quality score readjustment, local realignment, and filtering of reads 
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with low mapping scores, are taken. Base-calling algorithms generally output a base call 
in addition to a Phred quality score that represents the probability of an error in base 
calling (Ewing & Green 1998). Reports have shown, however, that these quality scores 
co-vary with sequencing platform, reaction cycle, and local sequence features (Brockman 
et al. 2008; M. Li et al. 2004; R. Li, Y. Li, et al. 2009; Nakamura et al. 2011). As such, 
various de-noising algorithms, such as Ibis (Kircher et al. 2009) and BayesCall (Kao & 
Song 2011; Kao et al. 2009) for Illumina, Pyrobayes (Quinlan et al. 2008) for Roche 454, 
Rsolid (H. Wu et al. 2010) for SOLiD, and SysCall for Illumina and SOLiD (Meacham et 
al. 2011) have been developed to reduce the error rates for base calling. After assembly 
and alignment, many variant calling pipelines remove reads aligning to multiple locations 
in the genome or reads with low mapping quality scores. In order to account for the 
correlation of sequencing error with the position of a base within the read (Balzer et al. 
2010; Minoche et al. 2011), some variant calling algorithms further recalibrate 
sequencing base quality scores (DePristo et al. 2011; H. Li et al. 2009; R. Li, Y. Li, et al. 
2009; R. Li, C. Yu, et al. 2009; McKenna et al. 2010). 
Many algorithms have been developed for the identification and genotyping of 
SNPs. Early methods for genotyping SNPs relied on filtering out bases with Phred quality 
scores less than 20 and identifying a site as heterozygous if the percentage of non-
reference bases at any given site is between 20 and 80% (Harismendy et al. 2009; J. 
Wang et al. 2008). This method is a good approximation, however, only when the 
sequencing depth is large. Furthermore, this simple cut-off approach does not take into 
account the quality scores of individual bases and it does not provide an uncertainty 
measure for the genotype inferred. Thus, several probabilistic models that take into 
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consideration various parameters such as allele frequencies and patterns of linkage 
disequilibrium have been developed to address these issues (Nielsen et al. 2011). These 
algorithms include GATK (DePristo et al. 2011; McKenna et al. 2010), MAQ (H. Li et al. 
2008), QCall (Le & Durbin 2011), Samtools (H. Li et al. 2009), SOAPv2 (R. Li, C. Yu, 
et al. 2009), and VarScan (Koboldt et al. 2009). After genotyping has been performed on 
individual samples, datasets can be pooled to filter out singletons and assemble a list of 
SNP variants. 
In addition to SNP discovery programs, many different approaches have been 
developed for the identification of short insertions and deletions (indels) and larger 
structural variants. These methods include Dindel (Albers et al. 2011), inGAP (Qi et al. 
2010), GATK (DePristo et al. 2011; McKenna et al. 2010), MoDIL (S. Lee et al. 2009), 
Samtools (H. Li et al. 2009), and VarScan (Koboldt et al. 2009) among others (Krawitz et 
al. 2010; D. R. Smith et al. 2008). For the detection of larger structural variants, 
algorithms rely critically on the use of paired-end reads, or sequencing of fragments from 
two ends of the library read, to infer deviations from expected distances or relative 
orientations between two locations in the genome (Campbell et al. 2008; Kidd et al. 2008; 
Korbel et al. 2007). This paired-end mapping technique has allowed for genome-wide 
characterization of large structural variants such as insertions, deletions, inversions, 
duplications, copy-number variations (CNVs), and translocations. Computational 
methods developed for robust detection of such variants include ABI SOLiD Software 
Tools (McKernan et al. 2009), BreakDancer (K. Chen et al. 2009), MoDIL (S. Lee et al. 
2009), PEMer (Korbel et al. 2009), Pindel (Ye et al. 2009), SegSeq (Chiang et al. 2009), 
and Variation Hunter (Hormozdiari et al. 2009).  
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1.3.5 Gene expression profiling 
Applications of next-generation sequencing technology to the study of RNA have 
led to many insights into the complexity of the transcriptome. In particular, RNA-Seq has 
been used to probe various aspects of the transcriptome such as gene expression 
(Graveley et al. 2011; Mortazavi et al. 2008; Nagalakshmi et al. 2008), alternative 
splicing (Cloonan et al. 2008; Sultan et al. 2008; Wilhelm et al. 2008), alternative 
transcription start site usage (Trapnell et al. 2010; Twine et al. 2011), and alternative 
polyadenylation (Ozsolak et al. 2010; Sandberg et al. 2008; E. T. Wang et al. 2008) 
among others. These features of the transcriptome, along with many others, are critically 
dependent on accurate methods for quantifying gene expression from RNA-Seq data. 
Reported initially in 2008, the standard measurement of gene expression is ‘FPKM’, or 
fragments per kilobase of exon model per million mapped reads (Mortazavi et al. 2008). 
This calculation of gene expression accounts for differences in input sizes across 
experiments through normalization of the total number of reads aligned and corrects for 
variation in gene size by dividing by the sum of exon lengths. Improving upon the 
standard ‘FPKM’ measurement, various other adjustments have been proposed to address 
non-uniform coverage of gene transcripts (Roberts et al. 2011) and uncertainty resulting 
from reads that align to multiple locations in the genome (B. Li et al. 2010). For studies 
of differential gene expression, different computational pipelines such as Cufflinks 
(Trapnell et al. 2012), DEGseq (L. Wang et al. 2010), DESeq (Anders & Huber 2010), 
DSS (H. Wu et al. 2012), edgeR (Robinson et al. 2010), GFOLD (Feng et al. 2012), and 
Myrna (Langmead et al. 2010) have been designed to normalize measurements across 
samples and accurately find gene transcripts that change in expression levels.
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1.4 RNA-DNA sequence differences 
The single-nucleotide resolution provided by next-generation sequencing 
technology permits detailed examination of DNA and RNA sequence. In particular, the 
interrogation of the genome and transcriptome by deep sequencing permits systematic 
comparisons between DNA and RNA sequence. In general, the transmission of sequence 
information from DNA to RNA is expected to occur in a one-to-one fashion (Crick 
1970). There are, however, known exceptions to this rule: transcriptional infidelity, or 
errors introduced by RNA polymerase during the synthesis of RNA, and RNA editing, 
the modification of RNA transcripts by various mechanisms to alter the original RNA 
sequence specified in the genome. Recently, with advances in next-generation sequencing 
technology, many researchers have performed genome-wide studies comparing DNA and 
RNA sequences from the same sample and found many more editing events than 
previously known in addition to RNA-DNA sequence differences (RDDs) that cannot be 
explained by known mechanisms. 
1.4.1 Transcriptional infidelity 
Errors introduced during transcription by RNA polymerases are rare, with an 
estimated frequency of less than 1 in 105 in bacteria and eukaryotes (Blank et al. 1986; de 
Mercoyrol et al. 1992; Rosenberger & Hilton 1983). Strategies for ensuring high 
transcriptional accuracy include discriminative substrate selection (Kireeva et al. 2008; 
Libby & Gallant 1991; Temiakov et al. 2004; Vassylyev et al. 2007) and proofreading 
capabilities (Borukhov et al. 1993; Erie et al. 1993; Izban & Luse 1992; Kuhn et al. 2007; 
Sydow & Cramer 2009). Despite these mechanisms to ensure faithful transcription, errors 
do occur, albeit at a low frequency. Misincorporation events can result from mispairing 
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of the incoming nucleotide with the template (Sydow et al. 2009), non-templated 
incorporation from an abasic template site (Damsma et al. 2007), transcription of DNA 
lesions (Brueckner et al. 2007; Damsma et al. 2007), or template misalignment (Kashkina 
et al. 2006; Pomerantz et al. 2006). Furthermore, studies on RNA polymerase show that 
misincorporation rates are correlated with the type of mismatch (Sydow et al. 2009) and 
surrounding sequence context (Kashkina et al. 2006).  
1.4.2 RNA editing 
RNA editing refers to targeted sequence alteration of the RNA transcript, 
resulting in sequence that is different from the underlying DNA template. Originally 
discovered in trypanosomes as an insertion event of four uridine residues to restore a 
reading-frame shift in the DNA (Benne et al. 1986), the term has since come to 
encompass a diverse set of sequence revisions of the RNA transcript in a wide range of 
organisms (Gott & Emeson 2000; Knoop 2011). In lower organisms, various types of 
editing mechanisms have been uncovered since the initial discovery of insertional editing 
in trypanosomes. For example, paramyxoviruses control the expression of two different 
isoforms of phosphoprotein by introducing either one or two additional guanosines in the 
mRNA transcript co-transcriptionally (Cattaneo et al. 1989; S. M. Thomas et al. 1988; 
Vidal et al. 1990a). The insertion event is always found to occur within a short stretch of 
guanosines, and thus a stuttering mechanism has been proposed in which the viral 
polymerase repeatedly copies a cytosine in the template (Vidal et al. 1990b). In 
myxomycetes, various types of co-transcriptional editing events have been discovered, 
such as C-to-U substitutions and insertions of adenosines, cytidines, uridines, and 
dinucleotides (Gott et al. 1993; Hendrickson & Silliker 2010; Horton & Landweber 2000, 
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2002; Mahendran et al. 1991). Other examples of RNA editing in lower organisms 
include pyrimidine and purine transitions, transversions of guanosine to cytidine, and 
conversions of uridine to purines among other sequence revisions in dinoflagellates 
(Dorrell & Howe 2012; Jackson et al. 2007; S. Lin et al. 2002; Zauner et al. 2004) and U-
to-C conversions in placazoa (Burger et al. 2009). 
In plants, RNA editing occurs in the form of pyrimidine exchanges in 
mitochondrial and chloroplast transcripts. Since the initial discovery of C-to-U 
substitutions to reconstitute evolutionarily conserved amino acids in wheat and evening 
primrose mitochondria (Covello & Gray 1989; Gualberto et al. 1989; Hiesel et al. 1989), 
other instances of C-to-U editing have been observed in the mitochondria of many 
different land plants (Fang et al. 2012; Hiesel et al. 1994; Malek et al. 1996; Sper-Whitis 
et al. 1996; Sper-Whitis et al. 1994; W. Wang et al. 2012). Less common than the 
commonly observed C-to-U editing, U-to-C exchanges have also been observed in the 
mitochondria hornworts (Steinhauser et al. 1999; Yoshinaga et al. 1996), lycophytes 
(Grewe et al. 2009), and some seed plants (Gualberto et al. 1990; W. Schuster et al. 
1990). Shortly after the discovery of mitochondrial RNA editing, C-to-U editing of 
chloroplasts was reported in maize (Hoch et al. 1991) and subsequently in all land plants 
with the exception of the marchantiid liverworts (Freyer et al. 1997; Inada et al. 2004; 
Kugita et al. 2003; Tillich et al. 2005; Tsudzuki et al. 2001; Wolf et al. 2004). Studies 
have demonstrated that chloroplast editing in plants is essential for protein function 
(Bock et al. 1994) and that specificity is conferred by local sequences (Bock et al. 1996; 
Chaudhuri et al. 1995; Sutton et al. 1995). Recent efforts to find the mechanism 
underlying plant organelle editing have implicated the RNA-binding pentatricopeptide 
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repeat (PPR) protein family as playing a key and necessary role (S. R. Kim et al. 2009; 
Kotera et al. 2005; Okuda et al. 2010; Robbins et al. 2009; Yu et al. 2009; Zehrmann et 
al. 2009; Zhou et al. 2009).  
In metazoa, two main types of editing are known to exist: A-to-I changes result 
from deamination of adenosine to inosine by ADAR, a family of adenosine deaminases 
that act on RNA (Nishikura 2010; Orlandi et al. 2012; Wulff & Nishikura 2010), and C-
to-U differences arise from deamination of cytidine to uridine by ABOBEC1, a member 
of the AID/APOBEC gene family (Conticello 2012; Keegan et al. 2001; Smith et al. 
2012; Wedekind et al. 2003). Inosine is recognized by the translational machinery as 
guanosine, and thus, A-to-I RNA editing by ADAR is functionally equivalent to A-to-G 
changes. Discovered initially for its ability to unwind RNA duplexes through adenosine 
deamination (Bass & Weintraub 1988), ADAR is now recognized for its involvement in 
post-transcriptional A-to-I editing of various double-stranded RNA substrates, playing a 
role in proteome diversification (Pullirsch & Jantsch 2010), regulation of gene expression 
through alternative splicing (Laurencikiene et al. 2006; Rueter et al. 1999; Schoft et al. 
2007) and RNA interference (Alon et al. 2012; Borchert et al. 2009; Kawahara et al. 
2008; Kawahara et al. 2007; Liang & Landweber 2007; Nishikura 2006; Reid et al. 2008; 
Yang et al. 2006). Early insights into the function of ADAR came from reports that a 
glutamine-to-arginine codon change in glutamate receptors controls ion flow in mouse 
brain (Sommer et al. 1991). Subsequent studies have demonstrated that ADAR likewise 
directs amino acid changes in neurotransmitters of other organisms (Hoopengardner et al. 
2003; Rosenthal & Bezanilla 2002; Seeburg & Hartner 2003) and thus plays an important 
role in nervous functions (Jepson & Reenan 2008; Jepson et al. 2012) and developmental 
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and psychiatric disorders (Bhogal et al. 2011; Grohmann et al. 2010; Sawada et al. 2009; 
Silberberg et al. 2012; Tan et al. 2009; Zhu et al. 2012). Furthermore, RNA editing by 
ADAR is necessary for proper development and normal life as ADAR-deficient 
invertebrates exhibit behavioral defects (Palladino et al. 2000; Tonkin et al. 2002), 
ADAR1-knockout mice are embryonic lethal (Q. Wang et al. 2000), and ADAR2-
knockout mice are viable but die prematurely (Higuchi et al. 2000). 
Within the past decade, different approaches have been developed to identify A-
to-I editing sites in a global manner. Prior to the development of these genome-wide 
screens, only a few genes were known to be targets of ADAR (Bass 2002; 
Hoopengardner et al. 2003; Morse & Bass 1999). An initial study aimed at global 
discovery of RNA editing sites searched in large databases of expressed sequence tags 
and found more than 12,000 sites in 1,600 genes, increasing the number of previously 
known editing sites in humans by more than two orders of magnitude (Levanon et al. 
2004). This work revealed that the majority of A-to-I editing sites in humans are located 
within noncoding regions of the gene, typically in Alu elements, a class of short 
interspersed elements (SINEs) unique to primates that comprises approximately 10% of 
the human genome (Batzer & Deininger 2002). With the emergence of next-generation 
sequencing technology, recent studies have used RNA-Seq to identify editing sites in a 
global manner across different cell types and organisms (Bahn et al. 2012; Chepelev 
2012; Ju et al. 2011; J. B. Li et al. 2009; Park et al. 2012; Peng et al. 2012; Ramaswami et 
al. 2012). These studies confirm the notion that A-to-I RNA editing in mammalian 
systems is widespread, with estimates ranging from approximately 1,000 to over 400,000 
in humans (Ramaswami et al. 2012). These studies also show that in humans, the vast 
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majority of editing sites are within noncoding regions (mainly the 3’UTR and introns) 
and that codon changes in protein sequences are rare (Kleinman et al. 2012). Expanding 
the search for editing events beyond processed mRNA transcripts, some next-generation 
sequencing studies have investigated RNA editing in different species of RNA, such as 
small RNA, lending insight into crosstalk between the ADAR and RNA intereference 
pathways (Alon et al. 2012; Warf et al. 2012; D. Wu et al. 2011). Other RNA-Seq studies 
have focused on the temporal aspect of editing by sequencing nascent RNA, discovering 
that the majority of A-to-I editing in Drosophila occurs cotranscriptionally (Rodriguez et 
al. 2012).  
The second type of RNA editing in metazoa is C-U deamination by APOBEC1 
(Keegan et al. 2001). Discovered for its role in producing two distinct forms of 
apolipoprotein B: apoB100 and the shorter isoform apoB48, which results from the 
conversion of a glutamine codon to a stop codon through C-to-U deamination in apoB 
mRNA (S. H. Chen et al. 1987; Hospattankar et al. 1987; Powell et al. 1987; Smith et al. 
1997), APOBEC1 is a zinc-dependent cytidine deaminase that achieves editing site 
specificity through local sequence motifs (Backus & Smith 1994; Hersberger & 
Innerarity 1998; Hersberger et al. 1999; Shah et al. 1991) and the RNA-binding 
“APOBEC1 complementing factor” ACF (Mehta et al. 2000). ApoB is a lipoprotein that 
plays a critical role in the transport of cholesterol and triglycerides in the plasma (Chan 
1992). In humans, C-to-U editing of apoB mRNA occurs only in the small intestine but 
not the liver (Greeve et al. 1993). ApoB100 expression in the liver plays a critical part in 
the removal of low-density lipoproteins (LDL) through the interaction of the carboxyl 
terminus of apoB100 with LDL receptors (Innerarity et al. 1990). This function of 
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apoB100 in modulating LDL levels is important in the development of atherosclerosis, as 
high LDL levels are a major risk factor for coronary heart disease (Ross 1995). In 
contrast, apoB48, which is produced in the small intestine and lacks the carboxyl 
terminus of apoB100, aids in the synthesis and secretion of chylomicrons (Kane et al. 
1980). In contrast to widespread A-to-I RNA editing, only a few additional targets of 
APOBEC1 have been identified apart from apoB mRNA, such as the editing of glycine 
receptors (Legendre et al. 2009; Meier et al. 2005), NAT1 (novel APOBEC target) mRNA 
(Yamanaka et al. 1997), and the neurofibromatosis NF1 mRNA (Skuse et al. 1996). 
Recent genome-wide studies using RNA-Seq have uncovered 32 more mRNA target sites 
of APOBEC1, all of which are in AU-rich segments of the 3’ untranslated regions (3’ 
UTR) of gene transcripts (Rosenberg et al. 2011). The localization of these editing sites 
to the 3’ UTR of transcripts may alter binding sites for RNA-binding proteins, abolish or 
create miRNA seed sequences, or affect additional post-transcriptional processes such as 
polyadenylation, subcellular localization, or translational efficiency, although further 
research into the biological impact of these editing events remains to be done. 
1.4.3 Other types of RNA-DNA sequence differences 
In addition to A-to-I editing by ADAR and C-to-U editing by APOBEC1 in 
metazoa and other types of RNA editing processes in other organisms, many researchers 
have reported the discovery of RNA-DNA sequence differences (RDDs) with unknown 
mechanisms. We refer to these RDDs as noncanonical RDD events. Initially, knowledge 
of these RDDs arose from observations of discrepancies between cloned transcripts of 
DNA versus cDNA. Examples include a C-to-U difference in the WT1 gene implicated in 
Wilms’ tumor pathology (Sharma et al. 1994), a U-to-A difference in the gene coding for 
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α-galactosidase (Novo et al. 1995), and various types of RDDs in the β amyloid precursor 
protein and ubiquitin-B protein genes of Alzheimer’s and Down patients (van Leeuwen et 
al. 1998), the transcobalamin II gene (Qian et al. 2002), the androgen receptor gene 
(Martinez et al. 2008), and in HIV mRNA of chronically infected H9 cells (Bourara et al. 
2000). In addition to these isolate examples in individual genes, genome-scale analyses of 
expressed sequence tags revealed elevated levels of non-random RDDs in cancer samples 
versus those of normal tissue (Bianchetti et al. 2012; Brulliard et al. 2007). 
With recent advances in sequencing and informatics, several groups have utilized 
next-generation sequencing technology to perform systematic and genome-wide 
comparisons of DNA and RNA sequence. In 2011, Cheung and colleagues obtained 
RNA-Seq data on a group of 27 unrelated individuals in the Centre d’Etude du 
Polymorphisme Humain (CEPH) collection (Dausset et al. 1990) for whom low-coverage 
whole-genome sequence information is available and found widespread occurrences of 
all 12 types of RDDs, the majority of which cannot be explained by known mechanisms 
(M. Li et al. 2011). A few of these noncanonical RDD events were further validated by 
Sanger sequencing and also shown to be translated into protein by mass spectrometry. 
Shortly thereafter, other groups reported similar findings of noncanonical RDD events 
using cell lines derived from different ethnic groups (Ju et al. 2011) and tissue types 
(Bahn et al. 2012). 
However, several research groups subsequently challenged the existence of 
noncanonical RDD events reported by Cheung and colleagues, contending that the vast 
majority (greater than 90%) of the observed sequence discrepancies are caused by 
technical artifacts due to misalignment, sequencing, and genotyping error (Kleinman & 
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Majewski 2012; W. Lin et al. 2012; Peng et al. 2012; Pickrell et al. 2012; Schrider et al. 
2011). To correct for these various sources of error, several research groups developed 
different filtering criteria and computational techniques for the accurate identification of 
RDDs (Kleinman et al. 2012; Peng et al. 2012; Ramaswami et al. 2012). These pipelines 
aim to account for misalignment in challenging regions of the genome such as repetitive 
sequences, pseudogenes, homologous sequences, and exon-exon junctions, and address 
experimental noise such as strand and positional bias in sequencing error. The results 
from these stringent computational pipelines indicate that A-to-G events comprise 
approximately 80 to 90% of all RDDs identified and are able to be reproducibly validated 
using Sanger sequencing technology at rates of about 90% across various studies (Peng et 
al. 2012; Ramaswami et al. 2012). In contrast, noncanonical RDD events vary from not 
being able to be confirmed by Sanger sequencing (Ramaswami et al. 2012) to validation 
rates of approximately 50% (Peng et al. 2012). As such, the debate over the existence and 
prevalence of noncanonical RDDs in humans continues persists, with evidence 
suggesting that they do occur albeit at a low frequency. Further mechanistic studies are 
needed to explain their origin and functional impact on the cell. 
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1.5 Summary 
The study of the transcriptome, or the complete set of transcribed RNA species in 
the cell at any given time under a particular set of conditions, is critical for understanding 
how expression of information in the genome is translated into overall phenotypic 
variation. Recent advances in sequencing technology have enabled genome-wide studies 
of RNA output at unprecedented depths and resolution. In Chapter 2, we explore the use 
of next-generation sequencing technology in global analyses of gene expression. In 
particular, we obtain deep RNA sequence information of cultured human B-cells to 
quantify the expression levels of all genes and their transcripts and assess the depths of 
sequencing necessary for sequencing-based studies. We provide the results of our 
transcriptome analysis as a public resource for others interested in the expression and 
structure of genes in human B-cells. Next, in Chapter 3, we examine systematic sequence 
differences between RNA and DNA of the same individual, or sequence alterations that 
may result from processes such as RNA editing, transcriptional infidelity, or other 
unknown mechanisms. In light of the ongoing debate over the prevalence and existence 
of RNA-DNA sequence differences (RDDs) mediated by unknown mechanisms, we 
perform in silico and experimental analyses to evaluate the precision and power of next-
generation sequencing technology and associated computational methods in the detection 
of RDDs in chapter 4. Using various bioinformatics algorithms and filtering methods to 
control for false positives, we develop a computational pipeline for the accurate 
identification of RDDs. Lastly, in chapter 5, we briefly evaluate the genetic basis for 
RDDs using RNA-Seq data. In particular, we first evaluate the extent to which the levels 
of RDDs, or the percentage of transcripts at a given site that differ from the underlying 
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genomic template sequence, vary across individuals and furthermore, the degree to which 
this variation is genetically determined. 
In summary, this thesis provides a resource for those interested in the study of 
transcriptomes using RNA-Seq technology and computational methods. In particular, this 
work lends insight into the analysis of gene expression and systematic detection of 
sequence variants between RNA and DNA genome-wide. The results from the gene 
expression profiling of human B-cells are available on the UCSC Genome Browser, and 
the computational pipeline for the identification of RDDs is outlined in the thesis. Lastly, 
the work on the heritability of RDDs lays the foundation for future genetic analyses of 
the determinants influencing systematic sequence differences between DNA and RNA 
sequence. 
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Chapter 2. RNA-Sequence Analysis of Human B-Cells 
2.1 Abstract 
RNA-Sequencing (RNA-Seq) allows for quantitative measurement of expression 
levels of genes and their transcripts. In this chapter, we analyzed the transcriptome of 
cultured human B-cells. In particular, we sequenced complementary DNA fragments 
(cDNA) derived from human lymphoblastoid cell lines and obtained 879 million 50 base-
pair reads comprising 44 Gigabases of sequence. The results enabled us to evaluate the 
expression profile of B-cells and to assess experimental parameters for sequencing-based 
studies. Overall, we identified 20,766 genes and 67,453 of their alternatively-spliced 
isoforms. More than 90% of genes with multiple exons are alternatively-spliced, and for 
most genes, one isoform is expressed predominantly. We observed that while 
chromosomes differ greatly in gene density, the percentage of transcribed elements in 
each chromosome is less variable. In addition, genes involved in related biological 
processes are expressed at more similar levels than genes with different functions. 
Besides the analysis of gene expression levels, we also used the data to investigate the 
effect of sequencing depth on gene expression measurements. While 100 million reads 
are sufficient to detect most expressed genes and transcripts, about 500 million reads are 
needed to measure accurately their expression levels. We provide examples in which 
deep sequencing is needed to determine the relative abundance of genes and their 
isoforms. With data from 20 individuals and about 40 million sequence reads per sample, 
we uncovered only 21 alternatively-spliced, multi-exon genes that are not in existing 
databases; this result suggests that at this sequence coverage, we can detect most known 
genes. Results from this project are available on the UCSC Genome Browser to allow 
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readers to study the expression and structure of genes in human B-cells. The majority of 
this work is adapted from previously published results (Toung et al. 2011).
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2.2 Introduction 
Cellular phenotypes are determined in large part by gene expression. Thus, a 
comprehensive catalog of gene transcripts, their structures, and abundance is critical for 
understanding how gene expression influences phenotypic manifestations. In the past, 
microarrays (DeRisi et al. 1996; Fodor et al. 1993) have been the predominant method for 
gene expression studies because of their ability to probe thousands of transcripts 
simultaneously. Although these hybridization-based approaches are high throughput, they 
are subject to biases and limitations such as the reliance on existing gene models and 
potential for cross-hybridization to probes with similar sequences. To overcome some of 
these restrictions, genomic tiling arrays and other approaches such as serial analysis of 
gene expression (Velculescu et al. 1995) and massively parallel signature sequencing 
(Brenner et al. 2000) have been developed.  
RNA-sequencing (RNA-seq) is a relatively new approach for analyzing gene 
expression; it provides digital readouts for mapping and quantifying transcriptomes 
(Bentley et al. 2008; Lister et al. 2008; Mortazavi et al. 2008; Nagalakshmi et al. 2008; 
Wilhelm et al. 2008). The method involves isolating a population of RNA, converting it 
to a library of cDNA fragments with adaptors attached, and sequencing the cDNA library 
to obtain short sequences typically 30 to 400 nucleotides in length. The short reads are 
then mapped to a reference genome or assembled de novo. The expression level for a 
gene can subsequently be determined by counting the number of reads that aligned to its 
exons. RNA-Seq studies of model organisms (Cloonan et al. 2008; Mortazavi et al. 2008) 
have revealed unknown aspects of transcriptomes through refinement of transcriptional 
start sites, discovery of 3’ UTR heterogeneity, and identification of novel upstream open 
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reading frames. Global surveys of alternative splicing show that nearly 95% of all multi-
exon genes in humans undergo alternative splicing events (Pan et al. 2008). Motivated by 
the ability of RNA-Seq technology to study gene expression, we sequenced the 
transcriptomes of human B-cells that are part of the HapMap (International HapMap 
Consortium 2005) and 1000 Genomes Projects (1000 Genomes Project Consortium 
2010). We generated 44 Gigabases of sequence to address several questions. First, we 
analyzed the gene expression landscape of human B-cells by identifying expressed 
transcripts and quantifying their expression levels. Second, we examined how sequencing 
depth affects the detection and quantification of genes and their isoforms. Lastly, we 
evaluated the potential of RNA-Seq to uncover transcribed fragments that are not in 
existing gene annotation databases. 
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2.3 Results 
2.3.1 Dataset  
We sequenced the mRNA population of cultured human B-cells from 20 
unrelated individuals from the Center d’Étude du Polymorphisme Humain (CEPH) 
collection (Dausset et al. 1990). For each sample, we obtained 44 ± 8 million 50-bp reads 
(mean ± standard deviation) (see Materials and Methods). For most of the analysis, we 
pooled the sequences to create a dataset comprising 879 million reads or 44 Gigabases of 
sequence; we refer to this dataset as the “879-million-read” dataset. 
We mapped the sequence reads to the reference human genome sequence (NCBI 
36.1/hg18 assembly) using TopHat (Trapnell et al. 2009) and Bowtie (Langmead et al. 
2009). Then, we assembled the alignments into gene transcripts and calculated their 
relative abundances using Cufflinks (Trapnell et al. 2010). We conducted two analyses: 
First, we provided Cufflinks with Gencode (v. 3c) (Harrow et al. 2006) gene annotations, 
and second, we did not use any gene annotations to find unknown gene models. We 
restricted our first analysis to levels 2 and 3 Gencode genes that are annotated as “protein 
coding” or “processed transcript”; in this study, we refer to this set of gene models as 
“Gencode”. To investigate the effect of sequencing depth on various expression profiling 
measurements, we created smaller subsets of our pooled data set, analyzing depths of 1 to 
9 million reads (in intervals of 1 million reads), 10 to 90 million reads (in intervals of 10 
million reads), and 100 to 700 million reads (in intervals of 100 million reads). 
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2.3.2 Alignment results 
In the 879-million-read dataset, 80% of the reads aligned to the human genome, 
of which 84% aligned to unique locations in the genome (Table 2.1). Fourteen percent of 
the mapped reads aligned to two to five locations in the genome, and less than 2% 
aligned to six or more locations. We excluded all reads mapping to six or more locations 
from our analyses. Although less than 3% of the human genome is composed of exons, 
83% of our uniquely mapped reads overlap Gencode exons. These results confirm that 
our poly(A)+ RNA samples are highly enriched for exonic sequences. We also studied 
fractions of the 879-million-read data set and found that the percentage of total reads 
aligning to the human genome increases proportionally with sequencing depth for input 
sizes smaller than 200 million reads, after which the value remains constant. With 1 
million reads, 75% of the reads aligned to the genome; in contrast, 80% of the reads 
aligned with 200 million reads (Table 2.1). Lastly, we found that 84% of the aligned 
reads mapped to unique locations across all sequencing depths.
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Table 2.1 RNA-Seq alignment results. Alignment statistics for the pooled 879-million-read 
dataset and smaller subsets are depicted.  
Number of 
Reads 
Sequenced 
(Millions) 
Number of 
Reads Aligned 
Number of Reads 
Aligned Uniquely 
Number of Reads 
Aligned to 2-5 
Locations 
Number of Reads 
Aligned to 6+ 
Locations 
1 753,387 (75%) 634,176 (84%) 106,142 (14%) 13,069 (2%) 
2 1,515,873 (76%) 1,277,350 (84%) 212,041 (14%) 26,482 (2%) 
3 2,282,729 (76%) 1,924,611 (84%) 318,303 (14%) 39,815 (2%) 
4 3,050,813 (76%) 2,573,536 (84%) 424,363 (14%) 52,914 (2%) 
5 3,819,893 (76%) 3,222,534 (84%) 531,167 (14%) 66,192 (2%) 
6 4,590,591 (77%) 3,873,017 (84%) 638,218 (14%) 79,356 (2%) 
7 5,361,450 (77%) 4,524,251 (84%) 744,318 (14%) 92,881 (2%) 
8 6,133,403 (77%) 5,176,244 (84%) 850,944 (14%) 106,215 (2%) 
9 6,905,747 (77%) 5,828,087 (84%) 958,025 (14%) 119,635 (2%) 
10 7,678,072 (77%) 6,480,455 (84%) 1,064,761 (14%) 132,856 (2%) 
20 15,652,328 (78%) 13,174,570 (84%) 2,210,319 (14%) 267,439 (2%) 
30 23,631,519 (79%) 19,873,435 (84%) 3,356,152 (14%) 401,932 (2%) 
40 31,613,156 (79%) 26,575,527 (84%) 4,500,716 (14%) 536,913 (2%) 
50 39,596,782 (79%) 33,275,797 (84%) 5,648,880 (14%) 672,105 (2%) 
60 47,576,773 (79%) 39,975,008 (84%) 6,795,093 (14%) 806,672 (2%) 
70 55,555,326 (79%) 46,672,758 (84%) 7,940,864 (14%) 941,704 (2%) 
80 63,533,073 (79%) 53,366,429 (84%) 9,090,087 (14%) 1,076,557 (2%) 
90 71,508,722 (79%) 60,058,715 (84%) 10,238,900 (14%) 1,211,107 (2%) 
100 79,484,383 (79%) 66,749,857 (84%) 11,388,069 (14%) 1,346,457 (2%) 
200 159,629,770 (80%) 133,939,976 (84%) 22,998,295 (14%) 2,691,499 (2%) 
300 239,550,734 (80%) 200,876,315 (84%) 34,636,304 (14%) 4,038,115 (2%) 
400 319,545,150 (80%) 267,789,138 (84%) 46,370,553 (15%) 5,385,459 (2%) 
500 399,305,262 (80%) 334,443,831 (84%) 58,125,933 (15%) 6,735,498 (2%) 
600 477,748,475 (80%) 399,783,258 (84%) 69,884,210 (15%) 8,081,007 (2%) 
700 557,037,521 (80%) 465,915,594 (84%) 81,691,919 (15%) 9,430,008 (2%) 
879 700,391,492 (80%) 585,460,567 (84%) 103,112,278 (15%) 11,818,647 (2%) 
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2.3.3 Expression landscape of human B-cells 
Using all of our sequence reads, we estimated the expression levels of genes in 
our B-cells. Expression levels are measured in “fragments per kilobase of exon model per 
million mapped reads” (FPKM) (Trapnell et al. 2010), and the expression level for a gene 
is the sum of the FPKM values of its isoforms. The distribution of gene expression values 
is right-skewed (Figure 2.1); the median and mean FPKM values are 26 and 338, 
respectively. Although we do not wish to use an arbitrary FPKM threshold to determine 
whether a transcript is expressed, analysis of all transcripts with expression levels greater 
than zero will include FPKM values that are very close to zero (bottom fifth percentile of 
transcript FPKM values = 0.003). Thus, we set an FPKM value of 0.05 as the lower 
bound in our subsequent analyses. Using this criterion, we detected 20,776 genes and 
67,453 alternatively-spliced transcripts in our B-cells. For the majority (75%) of these 
transcripts, there are sequence reads that cover at least one-quarter of their exons. The 
expression of these transcripts is supported by RNA polymerase II binding and active 
chromatin marks such as H3K27ac or H3K4me3 (Figure 2.2) (Rosenbloom et al. 2010).
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Figure 2.1 Distribution of gene expression levels in human B-cells. A histogram depicting 
expression levels for genes as defined by Gencode in units of FPKM. The distribution is skewed 
right; the median and mean FPKM values are 26 and 338, respectively. The main figure shows 
genes with FPKM values less than 1000, and the inset shows genes with FPKM values greater 
than 1000. 
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Figure 2.2 Percent of genes overlapping various ENCODE gene regulation tracks. The 
percentage of genes overlapping RNA Polymerase II (Pol2) binding sites and various chromatin 
marks (y-axis) for various FPKM percentiles (x-axis). For example, the percentage of genes with 
FPKM values greater than the 30th FPKM percentile that overlap Pol2 binding sites is 40%. We 
found that with increasing FPKM percentiles, the percentage of genes overlapping Pol2 binding 
sites increases. We saw similar patterns for chromatin marks associated with enhancers, 
promoters, and active transcription such as H3K27Ac, H3K4Me1, H3K4Me2, H3K4Me3, 
H3K9Ac. In contrast, the percentage of genes overlapping the repressive chromatin mark 
H3K27Me3 decreased with increasing FPKM thresholds. 
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We surveyed the expression landscape across chromosomes by determining the 
fraction of genes that are expressed within 1-Mb intervals (Figure 2.3) and analyzing the 
relationship between gene density and percentage of genes transcribed for each 
chromosome (Figure 2.4). The average gene density is 10 genes per Mb (standard 
deviation = 4.8), and the average percentage of genes transcribed for each chromosome is 
71% (standard deviation = 12%). We found that while chromosomes varied greatly with 
respect to gene density, they varied much less in the proportion of genes that are 
expressed. For example, while chromosome 19 is six times denser in gene content than 
chromosome 18, 87% and 82% of genes on chromosome 19 and chromosome 18 are 
expressed. 
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Figure 2.3 Distribution of expressed genes by chromosome. For each chromosome, the 
number (y-axis) of Gencode genes residing in 1-Mb intervals along the chromosome (x-axis 
depicts physical distance in megabases) is depicted. The number of genes that are expressed 
(FPKM ≥ 0.05) is colored in red, and the number of genes that are not expressed is shaded blue. 
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Figure 2.4 Gene density versus percentage of genes transcribed. For each chromosome, the 
percentage of genes expressed (y-axis) is shown versus the gene density (x-axis) (R = 0.34). We 
see that while genes vary greatly in their gene density, they differ less in the percentage of genes 
expressed. 
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We classified genes into groups based on their FPKM values: low expression 
(bottom 25th percentile; FPKM ≤ 2.3), medium expression (middle 50th percentile; 2.3 < 
FPKM ≤ 163), and high expression (top 25th percentile; FPKM > 163). Gene Ontology 
(GO) analysis (Ashburner et al. 2000) revealed that low-expressing genes are enriched 
for processes relating to cell adhesion (P = 2.9 x 10-20) and ion transport (P = 1.1 x 10-15). 
For medium-expressing genes, genes involved in transcription (P = 2.4 x 10-31) were 
found to be overrepresented. Lastly, we found high-expressing genes to be enriched in 
processes such as translation (P = 3.1 x 10-70), RNA processing (2.2 x 10-70), and RNA 
splicing (5.3 x 10-56). We did not find functional categories that were enriched in all three 
groups, suggesting that genes within a particular process are expressed at similar levels. 
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2.3.4 Alternative splicing activity in human B-cells 
We assessed the degree of alternative splicing activity in B-cells and found that 
94% of multi-exon genes express two or more spliced forms. This number is consistent 
with the estimate by Burge and colleagues (E. T. Wang et al. 2008) that greater than 90% 
of human genes across diverse tissue types express multiple isoforms. For genes with two 
or more expressed isoforms, we analyzed the relative abundance of each of the 
alternatively-spliced transcripts. We considered the transcript with the highest FPKM 
value as the “major” isoform and all other transcripts as “minor” isoforms. For every 
minor isoform of a gene, we calculated the ratio of its FPKM value to that of the major 
isoform. We found the distribution of these ratios to be right-skewed with a mean of 0.26 
(median = 0.17, standard deviation = 0.26) (Figure 2.5). These results indicate that while 
the majority of genes have several alternatively-spliced transcripts, these isoforms are not 
expressed at equivalent levels. For most genes, one isoform is expressed more highly 
than others. 
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Figure 2.5 Distribution of ‘fraction of major isoform’ values. For genes with two or more 
alternatively-spliced transcripts, we considered the transcript with the highest FPKM value as the 
“major” isoform and all others as “minor” isoforms. For each minor isoform, we calculated its 
“fraction of major isoform” value to be the ratio of its FPKM value to that of the major isoform. 
Here we plot the distribution of “fraction of major isoform” values. The distribution is right 
skewed with a mean of 0.26, median of 0.17 and standard deviation of 0.26. These results suggest 
that most genes express minor isoforms at relatively low values compared to the major isoform. 
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2.3.5 Concordance of gene expression levels by RNA-Seq and microarrays 
We compared our RNA-Seq data to microarray measurements performed on the 
same 20 unrelated CEPH individuals. The gene expression levels measured by the two 
methods are similar (R = 0.59) (Figure 2.6) and comparable to results by others. 
Mortazavi and colleagues measured a correlation of 0.69 in mice (Mortazavi et al. 2008), 
and Montgomery and colleages found a correlation of 0.80 in human cell lines 
(Montgomery et al. 2010). To investigate whether the digital counts of transcript 
abundance produced by RNA-Seq experiments offer greater dynamic range than the 
analog-style signals obtained from microarrays, we analyzed the expression levels for 
2,597 genes for which data were available for each of the 20 individuals. For each gene, 
we calculated the dynamic range and the coefficient of variation. We found the dynamic 
range to be greater in RNA-Seq than microarray measurements: 1.78 ± 0.67 versus 1.25 ± 
0.47 (mean ± standard deviation). Across the 20 individuals, the coefficient of variation 
values was also greater from RNA-Seq data: 0.13 ± 0.09 versus 0.052 ± 0.03(mean ± 
standard deviation). For the majority (90%) of the genes, the coefficient of variation is 
larger in the RNA-Seq data set (see examples in Figure 2.7). 
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Figure 2.6 Expression values from RNA-Seq and microarrays. Comparison of FPKM values 
(log2-transformed) and microarray signals for the 2597 genes detected by both platforms in 20 
unrelated CEPH individuals. For each gene, we plotted the average expression values across the 
20 individuals. Individual points are colored grey with transparency; darker dots represent 
overlapping genes. 
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Figure 2.7 RNA-Seq and microarray expression values versus coefficient of variation. 
Expression levels (scaled to facilitate comparison) as measured by microarrays (left) and RNA-
Seq (right) for various randomly chosen genes. Genes are grouped by whether the coefficient of 
variation lies in the (A) first quartile, (B) second quartile, (C) third quartile and (D) fourth 
quartile. 
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2.3.6 Effect of sequencing depth on RNA-Seq measurements 
In designing an RNA-Seq study, a parameter of interest is the sequencing depth 
needed to address various questions. To assess the relationship between sequencing depth 
and expression levels, we divided our 879 million 50-bp read data set into smaller sets 
and analyzed how the detection of a gene and the measurement of its expression level 
varies with increasing sequencing depth. 
We first assumed that our 879-million-read data set gives a comprehensive 
catalog of transcribed genes and then assessed how many genes are detected in fractions 
of those reads. We found that with 100 million reads, 81% of genes (FPKM ≥ 0.05) and 
90% of their transcripts were detected (Figure 2.8). For each additional 100 million reads, 
we were able to detect on average 3% more genes and 1% more transcripts. As expected, 
the expression level of a gene affects how readily it is detected; for example, with 100 
million reads, 80% of highly expressed genes (top 25th percentile; FPKM > 163) 
compared to 32% of the low expression genes (bottom 25th percentile; FPKM ≤ 2.3) were 
detected (Figure 2.9). 
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Figure 2.8 Number of junctions, transcripts, and genes detected at different sequencing 
depths. The numbers of genes, transcripts, and junctions detected in the 879-million-read data set 
were assumed to be the “final” values. Then, the percentages of these “final” values detected at 
various sequencing depths were determined. For example, with 100 million reads, 76% of the 
junctions, 90% of transcripts, and 81% of genes were detected. 
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Figure 2.9 Number of genes detected at various sequencing depths. The number of genes 
detected at various sequencing depths is shown. Genes are grouped according to the “final” value 
obtained in the 879-million-read dataset: low-expressing genes (bottom 25th percentile; FPKM ≤ 
2.3), medium-expressing genes (middle 50th percentile; 2.3 > FPKM ≤ 163), and high-expressing 
genes (top 25th percentile; FPKM > 163). 
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The detection of splice junctions is important as they are necessary for isoform 
assembly and quantification. Of the 269,155 Gencode junctions, 145,100 (54%) are 
detected in our 879-million read data set. This result is consistent with those reported by 
others: Blencowe and colleagues (Pan et al. 2008) detected between 128,395 and 130,854 
of known RefSeq junctions in diverse human tissues; Pritchard and colleagues (Pickrell et 
al. 2010) detected 170,293 junctions supported by spliced ESTs from GenBank in B-
cells. With 100 million reads, 76% of the 145,100 junctions were detected, after which on 
average 4% more junctions were detected for each additional 100 million reads (Figure 
2.8). 
For most studies, information beyond whether a gene is expressed or not is 
important – accurate expression levels are needed. To study the robustness of expression 
levels at various input sizes, we first assumed the expression values in our 879-million-
read data set to be the “best estimates” and then analyzed the sequencing depth necessary 
to achieve these “final” levels (Figure 2.9). For the majority (72%) of genes with FPKM 
values greater than 0.05, 500 million reads are needed for their expression values to be 
within 10% of their final measurements. With 100 million reads, only 6% of genes have 
values that are within 10% of their “final” FPKM value. Furthermore, while 100 million 
reads is sufficient for detection of the majority of genes and transcripts, the expression 
levels of genes obtained at a depth of 100 million reads deviate on average from their 
final value by 41%. These results suggest that deep sequencing is necessary for accurate 
determination of the expression level of genes. 
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Figure 2.10 Gene expression levels at different sequencing depths. The percentages of genes 
that reach values within different percentages of the ‘‘final’’ level obtained at a depth of 879 
million reads are depicted. With 100 million reads, only 6% of genes have FPKM measurements 
that are within 10% (gold line) of their “final” value compared to 72% at a depth of 500 million 
reads. 
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Next, we investigated the coverage needed to study the relative abundance of 
alternatively-spliced forms of genes. Again, we found that deep sequencing depths are 
crucial. For example, PHB (Figure 2.11) is a gene with five isoforms: PHB-001 
(ENST00000300408), PHB-002 (ENST00000419140), PHB-003 (ENST00000446735), 
PHB-004 (ENST00000393345), and PHB-201 (ENST00000434917) with FPKM values 
of 519, 96, 174, 5, and 679, respectively. The expression level for the least abundant 
isoform (PHB-004) was 20% of its final FPKM at a sequencing depth of 60 million reads. 
However, for the other four isoforms, 200 to 400 million reads were needed to obtain 
expression values within 20% of their final FPKM measurements. These results are 
surprising as one may expect deeper sequencing to allow for better quantification of 
transcripts that are expressed at lower levels; however, our data suggest that it is the 
highly expressed isoforms whose expression levels increase with larger sequencing 
depths. Furthermore, with less than 200 million reads, the 95% confidence intervals 
reported by Cufflinks for the two most highly expressed isoforms (PHB-001 and PHB-
201) overlapped each other; however, with more than 200 million reads, the confidence 
intervals for the five isoforms no longer intersected. Another example is CD74, which 
has three high-expressing variants: CD74-201 (ENST00000009530), CD74-202 
(ENST00000353334), and CD74-203 (ENST00000377795) with FPKM values of 4,690, 
54,745, and 2,252, respectively. While the expression level of the least-expressed isoform 
(CD74-203) was within 10% of its “final” FPKM with 20 million reads, the expression 
values of the other two isoforms did not reach this level until 400 million reads. Again, 
we see that the expression values of the highly expressed isoforms continued to increase 
 54 
with higher sequencing depths, whereas that for the isoform with the lowest level of 
expression was fairly constant.
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Figure 2.11 Expression levels of PHB versus sequencing depth. The expression levels of five 
alternatively-spliced transcripts of PHB are plotted at various sequencing depths. The least 
abundant isoform (blue line) of PHB reaches within 20% of its “final” FPKM value with only 60 
million reads; however, the expression values of the other four isoforms continued to increase 
with deeper sequencing. 
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Sufficient sequence coverage is not only required for accurate estimations of 
expression levels; they are also necessary to determine the relative abundance of 
isoforms. BRD4 is a gene with four isoforms: BRD4-201 (ENST00000263377), BRD4-
202 (ENST00000360016), BRD4-203 (ENST00000371835), and BRD4-204 
(ENST00000392878) with FPKM values of 200, 5, 65, and 139, respectively (Figure 
2.12). At low sequencing depths, the expression level of BRD4-204 was overestimated, 
while that of BRD4-201was underestimated; 60 million reads were needed to show that 
BRD4-201, not BRD4-204, is the most highly expressed isoform. As a final example of 
the effect of sequencing depth on expression values, we studied relative gene expression 
by using two well-characterized genes − CDKN1A, a cyclin-dependent kinase inhibitor; 
and its regulator, TP53. The “final” FPKM values for CDKN1A and TP53 were 2400 and 
676, respectively; the ratio of the expression values (CDKN1A/TP53) was 3.6. With less 
than 100 million reads, the ratio of the expression levels of the two genes ranged from 2.9 
to 15. This ratio fluctuated by as much as 300% at read depths of less than 100 million. 
However, with more than 100 million reads, the expression ratio ranged from 3.6 to 3.7, 
and the largest deviation from the ratio obtained was 4%. Thus, we conclude that deep 
sequencing is necessary to ensure the accurate quantification of relative gene expression. 
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Figure 2.12 Expression levels of BRD4 versus sequencing depth. FPKM values of four 
alternatively-spliced transcripts of BRD4 are shown. With less than 100 million reads, the 
expression level of BRD4-201 (orange line) is overestimated, while that of BRD4-204 (purple 
line) is underestimated. Error bars represent 95% confidence intervals reported by Cufflinks. 
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2.3.7 Discovery of novel gene models by RNA-Seq 
A feature of RNA-Seq is its ability to detect unknown transcripts. As such, we used 
Cufflinks without known gene models to annotate transcribed fragments and identified 
230,006 genes. The majority (77%) of these have already been identified by gene 
annotation groups such as Aceview, CCDS, Gencode, Mammalian Gene Collection, 
RefSeq, UCSC, and Vega. Of the remaining 53,939 transcribed fragments, 6,892 (13%) 
overlap RNA polymerase II binding sites (Rosenbloom et al. 2010). After filtering out 
known genes and fragments that overlap repetitive genomic regions (Self Chain and 
RepeatMasker tracks on the UCSC Genome Browser), we have 801 “unknown” genes. 
These genes have relative high expression (mean FPKM = 95), but they are quite short; 
the average length of these “unknown” genes is 0.9 kb compared to 1.8 kb for known 
genes. Furthermore, only 21 of these novel genes have alternatively-spliced transcripts; 
we show as example a multi-isoform gene on chromosome13:76902733-76925064 that 
has five alternatively-spliced transcripts and an FPKM value of 1400 (Figure 2.13). 
Support for the validity of this “unknown” gene includes an upstream 59 RNA 
polymerase II peak and overlaps with histone H3K4Me3 and H3K9Ac marks. These 
findings suggest that with our data set of about 40 million reads per sample, we detected 
most of the known genes (polyadenylated mRNAs) in B-cells.
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Figure 2.13 Newly identified gene on chromosome 13. This gene has five alternatively-spliced 
transcripts. The RNA polymerase II peak and H3K4Me3 andH3K9Ac marks are located at the 5’ 
ends of the gene. 
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2.4 Discussion 
In this chapter, we obtained 879 million 50-bp RNA-Seq reads derived from 
cultured B-cells of 20 CEPH individuals to characterize the human B-cell transcriptome 
and to determine the coverage needed for various RNA-Seq studies. We mapped 80% of 
our sequence reads to the human reference genome, of which 84% aligned to unique 
locations. We found that with 100 million reads, the number of aligned reads increased 
with sequencing depth; however, with read depths greater than 100 million, the 
percentages remained constant. In contrast, the percentage of aligned reads that map 
unambiguously to the genome was constant at 84% for all sequencing depths. 
We detected 20,776 Gencode genes and 67,453 of their alternatively-spliced 
transcripts using an FPKM threshold of 0.05. More than 90% of multi-exon genes are 
alternatively-spliced, but their isoforms are not expressed at similar levels. Rather, the 
majority of genes have one isoform that is expressed at higher levels than the other 
isoforms. In our expression analysis, we used an FPKM cutoff for expression because 
inclusion of all transcripts with FPKM values greater than zero will include some very 
small FPKM measurements. We accompany the use of this threshold with two caveats. 
First, this threshold is just a means of evaluation and should not be taken to define gene 
expression. There are transcripts with FPKM values less than 0.05 that are, indeed, 
expressed. Secondly, our results suggest that the distribution of FPKM values for genes 
and transcripts varies with respect to sequencing depth (Toung et al. 2011); therefore, the 
threshold of 0.05 should be considered concurrently with the fact that it was determined 
using a sequencing depth of 879 million reads. 
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We assumed that our 879-million pooled data set provides a comprehensive 
collection of expressed genes and transcripts and their expression levels. We found that 
with 100 million reads, we detected the majority of genes (81%) and transcripts (90%), 
but their expression levels were not sufficiently accurate. At 100 million reads, only 6% 
of genes have FPKM measurements that are within 10% of their “final” values compared 
to 72% at 500 million reads. Thus deep sequence coverage is needed for gene expression 
studies. The coverage that we report here probably represents an upper bound of the 
required depth since the increasing length of sequence reads and the use of paired-end 
reads will allow more sequences to be mapped, thus reducing the numbers of reads 
needed to obtain robust expression values. 
An enticing feature of RNA-Seq lies in its power to detect transcripts independent 
of existing information. In this study, we uncovered 801 potential “unknown” genes. 
Most of these transcribed fragments are short and comprise single exons; only 21 of these 
genes are alternatively-spliced. While these results do not necessarily undermine the 
ability to uncover unknown transcripts using RNA-seq, they suggest that with about 40 
million reads per sample, we can detect most of the known genes in human B-cells. In 
summary, recent advances in sequencing technologies have allowed us to obtain deep 
coverage of human B-cell transcriptomes at single-nucleotide resolution. Our results 
provide some guidelines for the design of gene expression studies. The B-cells in this 
study have been used in many other functional (Linsley et al. 1991; Peters et al. 1991; 
Stern et al. 1984) and genetic studies (Dixon et al. 2007; Dolan et al. 2004; Morley et al. 
2004); detailed information on gene expression and structure will extend the previous 
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analyses and facilitate future projects. Our data are available as the “B-Cell 
Transcriptome (RNA-seq)” track on the UCSC Genome Browser. 
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2.5 Materials and Methods 
2.5.1 Samples 
Immortalized lymphoblastoid cell lines for 20 European-derived individuals from 
the Utah pedigrees of the Center d’Étude du Polymorphisme Humain collection (CEPH) 
were obtained from Coriell Cell Repositories. No individuals were known to be blood 
relatives, and there is no known history of major medical illness. Specifically, the 
individuals (10 males and 10 females) are GM06985, GM07000, GM07034, GM07055, 
GM07056, GM07345, GM11832, GM11839, GM11992, GM11993, GM11994, 
GM12056, GM12145, GM12155, GM12716, GM12717, GM12750, GM12813, 
GM12872, and GM12891.  
Cells were grown to a density of 5 x 105 cells/mL in RPMI 1640 supplemented 
with 15% fetal bovine serum, 100 units/mL penicillin-streptomycin, and 2 mM L-
glutamine. Cells were harvested 24 hours after addition of fresh medium. Total RNA was 
extracted from cell pellets using the RNeasy Mini-Kit with DNase treatment (Qiagen). 
2.5.2 RNA-Sequencing 
RNA-Seq was performed as recommended by the manufacturer (Illumina). 
Briefly, poly(A) mRNA was fragmented, and first-strand cDNA was prepared using 
random hexamers. Following second-strand cDNA synthesis, end repair, addition of a 
single A base, adaptor ligation, agarose gel isolation of ~200-bp cDNA, and PCR 
amplification, the samples were sequenced using the Illumina 1G Genome Analyzer. 
2.5.3 Alignment and isoform abundance estimation 
Sequence reads were mapped using TopHat (v. 1.1.4) (Trapnell et al. 2009) with 
default settings. Data sets larger than 300 million reads were randomly split into equal 
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subsets ranging from two to four because of memory limitations. Cufflinks (v. 0.9.3) 
(Trapnell et al. 2010) was then used to assemble reads into transcripts and estimate their 
abundances. Cufflinks was run (1) with the Gencode reference annotation (v. 3c) (Harrow 
et al. 2006) to generate FPKM values for known gene models and (2) without an 
annotation file to create gene bundles representing potential novel transcribed fragments. 
2.5.4 Sampling selection of sequence reads 
Across the 20 samples, 43,819,745 ± 8,194,875 (mean ± standard deviation) reads 
were obtained. All reads from each sample were pooled to form a data set consisting of 
878,668,290 reads (879-million data set). To investigate the effect of sequencing depth 
on RNA-Seq data, we randomly selected reads from the pooled data set and created 
subsets varying from 1 to 9 million reads total (in intervals of 1 million reads), 20 to 90 
million reads total (in intervals of 10 million reads), and 100 to 700 million reads total (in 
intervals of 100 million reads). To ensure that the particular reads selected for each 
sequencing depth are fairly representative, we randomly sampled 100 million reads from 
the pooled 879-million data set 10 times and analyzed the overall alignment statistics 
obtained across the 10 random samplings. The percentage of total reads aligning to the 
genome across the 10 randomizations was 80% ± 0.005% (mean ± standard deviation), of 
which 84% ± 0.005% (mean ± standard deviation) aligned to unique locations. Overall, 
the alignment statistics are similar across the 10 random samplings, indicating that the 
particular reads chosen in each of our sample sizes is representative. Furthermore, using 
Cufflinks, we carried out analyses to ensure that expression values are not affected by the 
samplings of reads. We found that across the 10 samplings, 17,967 genes and 69,672 
transcripts were detected. Eighty-eight percent of the genes and transcripts were detected 
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in all samplings. The coefficients of variation of the FPKM values for these genes across 
the 10 data sets were 0.10 ± 0.16 at the gene-level and 0.49 ± 0.53 at the transcript-level 
(mean ± standard deviation). Thus, the expression levels of genes and transcripts in 
different samplings of 100 million reads are fairly stable. 
2.5.5 RNA-Seq and microarray analyses 
For all analyses in which RNA-Seq data were compared with microarray data 
previously generated (GSE12526), RNA-Seq data were log2-normalized. Prior to log2 
transformation, we added 2 to the FPKM values to avoid negative values after the log2 
transformation. 
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Chapter 3. RNA-DNA Sequence Differences in Humans 
3.1 Abstract 
The transmission of sequence information from DNA to RNA is a critical process. 
In this chapter, we compared RNA sequences from human B-cells of 27 individuals to 
the corresponding DNA sequences from the same individuals and uncovered more than 
10,000 exonic sites where the RNA sequences do not match that of the DNA. All 12 
possible categories of discordances were observed. These differences were nonrandom as 
many sites were found in multiple individuals and in different cell types including 
primary skin cells and brain tissues. Using mass spectrometry, we detected peptides that 
are translated from the discordant RNA sequences and thus do not correspond exactly to 
the DNA sequences. These widespread RNA-DNA differences in the human 
transcriptome provide a yet unexplored aspect of genome variation. 
This chapter contains results from a previously published report (M. Li et al. 
2011) and includes work from members of the Vivian Cheung laboratory. 
 67 
 
3.2 Introduction 
DNA encodes genetic information that is transmitted into messenger RNA 
(mRNA) and proteins that perform cellular functions. It is assumed that the sequence of 
mRNA accurately reflects that of DNA because mRNA serves as the template for 
synthesis of proteins. As such, genetic studies have mainly focused on individual 
variation in DNA sequence as the basis of differences in disease susceptibility. Prior to 
advances in sequencing technology that allow for comprehensive analysis of RNA 
sequence information, studies of mRNA focused mainly on variation in expression levels 
and not sequence differences among individuals. 
There are, however, known mechanisms that generate differences between the 
sequence of mRNA and that of the underlying genomic template. These processes 
include transcriptional infidelity (Libby & Gallant 1991; Sydow & Cramer 2009) and 
RNA editing (Bass & Weintraub 1988; S. H. Chen et al. 1987; Powell et al. 1987). 
Transcriptional errors are rare as proofreading and repair mechanisms exist to ensure high 
accuracy in RNA synthesis (M. J. Thomas et al. 1998; D. Wang et al. 2009; Zenkin et al. 
2006). RNA editing, or site-specific sequence alteration of RNA transcripts, is performed 
by enzymes that target mRNA posttranscriptionally – ADARs (adenosine deaminases 
that act on RNA) mediate A-to-I (or A-to-G) changes by deamination of adenosine to 
inosine, which is then recognized by the translation machineries as a guanosine and 
APOBECs (apolipoprotein B mRNA editing enzymes, catalytic polypeptide-like) cause 
C-to-U changes by deamination of cytidine to uridine. Previously, sequence comparisons 
and computational predictions have identified many A-to-G editing sites (Athanasiadis et 
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al. 2004; Levanon et al. 2004; J. B. Li et al. 2009; Sakurai et al. 2010). In contrast, C-to-
U changes are rare, as apolipoprotein B is one of the few known target genes of human 
APOBEC1 (Chester et al. 2000; Conticello 2008). 
We obtained sequences of DNA and RNA samples from immortalized B cells of 
27 unrelated Centre d’Etude du Polymorphisme Humain (CEPH) (Dausset et al. 1990) 
individuals, who are part of the International HapMap (International HapMap 
Consortium 2003, 2005) and the 1000 Genomes (1000 Genomes Project Consortium 
2010) projects. When we compared the DNA and RNA sequences of the same 
individuals, we found 28,766 events at over 10,000 exonic sites that differ between the 
RNA and the corresponding DNA sequences. Each of these differences was observed in 
at least two individuals, and many were seen in primary skin cells and brain tissues from 
a separate set of individuals and in expressed sequence tags (ESTs) from cDNA libraries 
of various cell types. About 43% of the differences are transversions and therefore cannot 
be the result of typical deaminase-mediated RNA editing. By mass spectrometry, we also 
found peptide sequences that correspond to the RNA variant sequences, but not the DNA 
sequences, suggesting that the RNA forms are translated into proteins. 
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3.3 Results 
3.3.1 RNA and DNA samples 
We compared the DNA and RNA sequences from B-cells of 27 unrelated CEPH 
individuals (Table 3.1). We chose these samples because much information is available 
on them, including dense DNA genotypes obtained using different technologies (Cann 
1992; Matise et al. 2003). The genomes of B-cells from the CEPH collection are stable as 
evidenced by Mendelian inheritance of genetic loci that allowed the construction of 
microsatellite- and single-nucleotide polymorphism (SNP)-based human genetic maps 
(Cann 1992; Matise et al. 2003). More recently, the International HapMap Consortium 
(International HapMap Consortium 2003, 2005) obtained millions of SNP genotypes, and 
the 1000 Genomes Project (1000 Genomes Project Consortium 2010) sequenced the 
DNA of these individuals. Comparison of genotype data from these two projects showed 
high concordance (~99%). For our analyses of RNA-DNA sequence differences, we used 
the DNA genotypes and sequences from the two projects and considered the following 
two types of sites: 
First, we considered sites that are monomorphic in the human genome. We 
defined a monomorphic site as one in which there is no evidence for sequence variation 
at that locus in dbSNP, the HapMap, and the 1000 Genomes Project. Different studies 
have analyzed these 27 and hundreds of additional individuals for DNA variants, and 
thus, if a site has not been identified as polymorphic, most likely all individuals have the 
same genotypes at these sites. However, in order to be certain of the genotypes at 
monomorphic sites in these 27 individuals, we compared their DNA sequences from the 
1000 Genomes project with the sequences of the human reference genome by traditional 
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Sanger sequencing (Sanger et al. 1977). To be included in our comparison analysis, we 
required that each site be covered by at least four reads in the 1000 Genomes Project and 
that the sequences from 1000 Genomes be the same as those of the reference genome. To 
ensure the integrity of the aliquots of B-cells that we used for analyses, we carried out 
Sanger sequencing of their DNA and found perfect concordance of sequences with data 
from the 1000 Genomes (thus also the reference genome sequences) (Table 3.2).  
Second, we considered SNP sites. For each individual, a SNP locus was included 
only if HapMap as well as the 1000 Genomes Project reported the same homozygous 
genotype. We have high confidence in these sites because despite using different 
technologies (microarray-based genotyping in HapMap and high-throughput sequencing 
in 1000 Genomes), we obtained identical genotypes in the two projects. 
We sequenced the RNA of B-cells from the 27 CEPH individuals using high-
throughput sequencing technology from Illumina (Bentley et al. 2008). The resulting 
RNA-Seq reads were mapped to Gencode genes (Harrow et al. 2006) in the reference 
human genome. In total, we generated approximately 1.1 billion reads of 50 base-pairs 
(bp) (roughly 41 million reads and 2 Gigabases of sequence per individual), of which 
about 69% mapped uniquely to the transcriptome (see Materials and Methods). To be 
confident of the base calls, for each individual, we focused our analysis on high-quality 
reads (Phred quality score ≥ 25) and sites that were covered by at least 10 uniquely 
mapped reads. We compared our sequences from these sites to RNA-Sequencing data 
from another recent study (Montgomery et al. 2010) on the same individuals sequenced 
to lower depths and found the concordance rate to be greater than 99.5%. This is 
reassuring given that the samples were prepared and sequenced in different laboratories.
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Table 3.1 Statistics on RNA-Sequencing and RNA-DNA sequence differences. Statistics on 
the RNA-Seq data and sequence differences between RNA and DNA for the 27 individuals are 
provided. 
Sample 
ID Sex 
Total reads 
sequenced 
Reads 
aligned 
uniquely 
Total bases at 
sites with 
coverage ≥ 10 
DNA 
coverage 
# of RDDs at 
homozygous 
SNP sites 
# of RDDs at 
monomorphic 
sites 
# of total 
RDDs 
GM06985 F 38,424,688 24,864,586 16,038,399 2.6 14 394 408 
GM06994 M 37,634,150 31,439,915 19,979,779 4.6 36 1208 1244 
GM07000 F 36,665,036 26,987,933 16,357,700 4.1 45 1512 1557 
GM11829 M 37,293,182 28,117,279 16,305,573 6 17 1011 1028 
GM11830 F 36,412,185 26,729,286 16,388,938 6.4 31 938 969 
GM11831 M 38,923,882 26,175,492 16,683,852 6.4 29 965 994 
GM11832 F 38,657,782 27,779,737 16,629,265 2.8 27 956 983 
GM11881 M 49,771,575 29,645,009 15,899,948 5.1 29 1462 1491 
GM11992 M 63,260,299 41,104,692 17,703,651 5.7 53 1810 1863 
GM11993 F 38,441,615 27,190,601 15,681,535 3.7 12 621 633 
GM11994 M 42,390,584 27,741,424 16,702,144 13.8 18 466 484 
GM12003 M 36,977,676 29,073,057 17,727,318 5.9 46 1384 1430 
GM12004 F 28,390,919 21,836,374 13,369,507 6.2 6 480 486 
GM12005 M 45,286,259 25,260,540 11,909,776 6.1 20 1248 1268 
GM12006 F 35,506,222 28,101,550 14,554,102 3.3 34 1070 1104 
GM12043 M 36,999,366 27,453,229 17,312,508 4.2 26 728 754 
GM12044 F 39,839,492 30,992,207 16,088,150 4.7 40 1255 1295 
GM12144 M 35,020,229 21,561,396 11,631,101 5.5 45 1334 1379 
GM12155 M 43,551,373 33,153,306 16,821,880 11.7 9 273 282 
GM12716 M 46,656,852 30,454,296 16,024,579 5.9 45 1358 1403 
GM12717 F 40,635,780 32,974,555 20,054,384 5.2 25 1339 1364 
GM12750 M 45,066,631 31,480,502 17,290,976 4.2 32 1319 1351 
GM12762 M 47,651,198 31,766,092 17,761,776 2.2 22 819 841 
GM12813 F 45,288,662 34,565,796 18,137,367 3.7 35 1179 1214 
GM12814 M 39,024,182 29,109,410 16,700,518 4.7 28 996 1024 
GM12872 M 45,367,154 17,499,200 9,290,271 4.9 42 927 969 
GM12874 M 39,588,081 20,781,628 10,406,285 4.9 29 919 948 
Total  1,108,725,054 763,839,092 429,451,282 144.5 795 27971 28766 
Mean  41,063,891 28,290,337 15,905,603 5.4 29 1036 1065 
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Table 3.2 Genotypes at monomorphic sites verified by Sanger sequencing. We verified the 
genotypes at monomorphic sites using DNA extracted from the pooled samples of cell extracts 
used in the mass spectrometry analysis. Sanger sequencing verified that all the sites are 
monomorphic. The results agree with the sequencing data from the 1000 Genomes and Human 
Genome Projects (as shown in the UCSC Genome Browser for the reference genome). 
Gene RDD Location (hg18) genomic DNA (Sanger) 
CD22 T-to-G chr19:40514815 T 
DFNA5 T-to-A chr7:24705225 T 
ENO1 T-to-C chr1:8848125 T 
FH T-to-A chr1:239747217 T 
HMGB1 T-to-A chr13:29935772 T 
HMGB1 A-to-C chr13:29935469 A 
ITPR3 A-to-C chr6:33755773 A 
RAD50 T-to-G chr5:131979610 T 
ROD1 G-to-T chr9:114026264 G 
RPL32 G-to-T chr3:12852658 G 
RPS25P8 A-to-G chr11:118393375 A 
RPS3AP47 C-to-A chr4:152243651 C 
SUPT5H G-to-T chr19:44655806 G 
TOR1AIP1 T-to-C chr1:178144365 T 
TUBA1 A-to-G chr2:219823379 A 
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3.3.2 RNA-DNA sequence differences observed 
For each of the 27 individuals, we compared the mRNA sequences from B cells 
with the corresponding DNA sequences (Figure 3.1). The comparison revealed many 
sites where the mRNA sequences differ from the corresponding DNA sequences of the 
same individual. To minimize the chance that these differences are due to sequencing 
errors, we required that at least 10% of the reads covering a site differ from the DNA 
sequence and that at least two individuals show the same RNA-DNA difference at the 
site. We call each occurrence of a difference between RNA and DNA sequences an 
“event” and the chromosomal location where such a difference occurs a “site”. Each 
person can contribute an event to the site, and thus, there could be multiple events at a 
site. Among our 27 subjects, we identified 28,766 events where the RNA sequences do 
not match those of the corresponding DNA sequences. These events are found in 10,210 
exonic sites in the human genome and reside in 4741 known genes (36% of 13,214 genes 
that are covered by 10 or more RNA-Seq reads in at least one part of the gene and in two 
or more individuals). Using gene orientation information provided by Gencode, we 
observed all 12 possible categories of base differences between RNA and the 
corresponding DNA (Figure 3.2). All 12 types of differences were found in each of the 
27 samples; the relative proportion of each type is similar across individuals. There are 
6,698 A-to-G events, which can be the result of deamination by ADAR. There are 1,220 
C-to-T differences, which can also be mediated by a deaminase. However, it is notable 
that APOBEC1 and its complementation factor A1CF are not expressed in our B-cells 
[fragments per kilobase of exon per million fragments mapped (FPKM) (Trapnell et al. 
2010) ~ 0 for both genes]. As such, it is likely that an unknown deaminase or other 
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mechanism is involved. Even for relatively well-characterized proteins such as 
APOBEC1, a recent RNA-Seq study of Apobec1−/− mice uncovered many previously 
unknown targets (Rosenberg et al. 2011). In addition, we found 12,507 transversions 
(43%), which cannot result from classic deaminase-mediated editing. Because we do not 
know the mechanism by which these differences between RNA and DNA sequences 
arise, we refer to them as RNA-DNA differences (RDDs). An example of an RDD is a C-
to-A difference on chromosome 12 (at position 54,841,626 bp) in the myosin light chain 
gene MYL6, where 16 of our subjects have C/C in their DNA but A/C in their RNA 
sequences. Another example is an A-to-C difference on chromosome 6 (at position 
44,328,823 bp) in the gene HSP90AB1 that encodes a heat shock protein, where eight 
individuals have homozygous A/A DNA genotype but have A/C in their RNA. 
Additional examples are shown in Table 3.3. These sites where RNA sequences differ 
from the corresponding DNA sequences appear to be nonrandom because the identical 
differences were found in multiple individuals: 8163 (80.0%) of the sites were found in at 
least 50% of the informative individuals (i.e. with RNA-Seq coverage ≥ 10 and DNA-Seq 
coverage ≥ 4 at the site). Some sites were found in all or nearly all informative 
individuals. For example, the DNA sequences of all 19 informative individuals at 
position 49,369,615 bp of chromosome 3 in the GPX1 gene are G/G, whereas their RNA 
sequences are G/A. The remaining individuals were not included because available data 
did not meet our inclusion criteria although the data suggest the same RDD in all 
remaining individuals: G/G in DNA, and G/A in RNA. 
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Figure 3.1 Workflow for the identification of RNA-DNA sequence differences. 
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Figure 3.2 Distribution of RNA-DNA sequence difference events across 27 individuals. The 
number of RNA-DNA sequence difference events detected in human B-cells of 27 individuals is 
shown below. 
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Table 3.3 Selected examples of sites that show RNA-DNA sequence differences in B-cells and EST clones. 
Gene Chr. Position (bp)* Type 
Number of 
informative 
individuals †‡ 
Number of 
individuals 
with RDD ‡ 
Average level 
‡§ Range ‡§ EST 
HSP90AB1 6 44,328,823 A-to-C 11 8 0.39 [0.15, 0.79] BQ355193 (head, neck),  BX413896 (B-cell) 
AZIN1 8 103,910,812 A-to-G 17 10 0.22 [0.12, 0.37] CD359333 (testis),  BF475970 (prostate) 
CNBP 3 130,372,812 A-to-T 18 16 0.13 [0.10, 0.21] EL955109 (eye),  BJ995106 (hepatoblastoma) 
MYL6 12 54,841,626 C-to-A 16 16 0.35 [0.12, 0.60] EC496428 (prostate), BG030232 (breast adenocarcinoma) 
RBM23 14 22,440,217 C-to-G 11 5 0.18 [0.11, 0.35] BQ232763 (testis, embryonic) 
RPL23 17 34,263,515 C-to-T 12 8 0.16 [0.10, 0.22] BP206252 (smooth muscle), CK128791 (embryonic stem cell) 
BLNK 10 97,957,645 G-to-A 14 7 0.14 [0.11, 0.17] BF972964 (leiomyosarcoma), BE881159 (lung carcinoma) 
C17orf70 17 77,117,583 G-to-C 2 2 0.26 [0.24, 0.28] AA625546 (melanocyte), AA564879 (prostate) 
HMGN2 1 26,674,349 G-to-T 7 4 0.22 [0.14, 0.43] BX388386 (neuroblastoma), BE091398 (breast) 
CANX 5 179,090,533 T-to-A 9 8 0.2 [0.13, 0,30] EL950052, DB558106 
EIF3K 19 43,819,430 T-to-C 19 14 0.16 [0.10, 0.27] AI250201 (ovarian carcinoma), AI345393 (lung carcinoma) 
RPL37 5 40,871,072 T-to-G 6 6 0.27 [0.16, 0.45] CF124792 (T cell),  DW459229 (liver) 
* hg 18 build of the human genome 
† minimum of 10 reads in RNA-Seq and 4 reads in DNA-Seq 
‡ in B-cells 
§ proportion of reads at site that contain RDD 
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3.3.3 EST validation of RNA-DNA sequence differences 
Computational and experimental validations also upheld the RNA-DNA 
differences we observed. First, for 120 sites (10 sites per RDD type randomly selected; 
see Table 3.3 for examples), we looked for evidence of RDD in the human EST database 
by BLAST alignment (Altschul et al. 1990) and manual inspection of each result. For 81 
of the 120 sites, we found EST clones that contain the RDD alleles. The numbers of sites 
found in human ESTs are similar across different RDD types (average 67.5%; range: 60 
to 90%). Second, we examined previously identified A-to-G editing sites (J. B. Li et al. 
2009). Fourteen of the A-to-G sites that we identified were found in their data even 
though different cell types were studied. Even the levels of editing at these sites are 
similar between the two studies (Figure 3.3). Twelve additional sites were found in both 
studies but were filtered out because they did not meet our selection criteria. 
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Figure 3.3 Comparison of A-to-G RNA editing levels in B-cells to those in cell types 
published by Church and colleagues (J. B. Li et al. 2009). 
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3.3.4 Sanger sequencing validation of RNA-DNA sequence differences 
Next, we validated our findings experimentally by Sanger sequencing of both 
DNA and RNA at 12 randomly selected sites in B-cells (2 to 9 individuals per site), 
primary skin (foreskin; 8 to 10 individuals per site), and brain cortex (6 to 10 individuals 
per site). We regrew the B-cells from our subjects and extracted DNA and mRNA from 
the same aliquots of cells. By sequencing the paired DNA and RNA samples and analysis 
of each chromatogram by two individuals independently, we confirmed 57 events in 11 
sites (Table 3.4 and Figure 3.4). In EIF2AK2, in all of the eight individuals whose 
samples were sequenced, three sites were found within 10 nucleotides (nt) (see Table 
3.4). An RNA-DNA sequence difference was not validated in one site in NDUFC2. 
Sanger sequencing is not very sensitive or quantitative; thus, we do not expect to validate 
all sites, especially those with low levels of RDD. To assess whether RDD shows cell 
type specificity, we looked for evidence of RNA-DNA sequence differences using 
primary human cells. We studied the same sites as above by Sanger sequencing of DNA 
and RNA samples from primary skin fibroblasts and brain (cortex) of a separate set of 
normal individuals (for each site, we examined the DNA and RNA of 6 to 10 samples per 
cell type). We identified 55 RDD events in primary skin cells and 62 events in brain 
cortex (Table 3.4). The results suggest that most sites are shared across cell types (Table 
3.4). However there are exceptions, as an A-to-G difference in EIF2AK2 (chromosome 2: 
37,181,512) was only found in B-cells and brain cortex but not in primary skin cells. We 
also queried the EST database for evidence of RDD (Table 3.3). The RNA alleles are 
seen in a wide range of tissues from embryonic stem cells to brain and testis; they are 
also found in tumors such as lung carcinoma and neuroblastoma.
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Table 3.4 Sanger sequencing validation of RNA-DNA sequence difference sites.  
Gene Chr. Position (bp)* Type Location 
Amino Acid 
Change 
B-cells† Primary skin fibroblast† Brain (cortex)† 
# of 
Informative 
Individuals 
# of 
Individuals 
with RDD 
# of 
Informative 
Individuals 
# of 
Individuals 
with RDD 
# of 
Informative 
Individuals 
# of 
Individuals 
with RDD 
EIF2AK2 
2 37,181,512 A-to-G 3′ UTR Not applicable 8 8 8 0 10 10 
2 37,181,517 A-to-G 3′ UTR Not applicable 8 8 8 3 10 10 
2 37,181,520 A-to-G 3′ UTR Not applicable 8 8 8 3 10 10 
2 37,181,538 A-to-G 3′ UTR Not applicable 8 8 8 6 10 10 
AZIN1‡ 8 103,910,812 A-to-G Coding, exonic S-to-G 2 2 10 0 9 8 
DPP7 9 139,128,755 C-to-T Coding, exonic 
Synonymous 
(P) 9 2 8 1 10 0 
PPWD1 5 64,894,960 G-to-A Coding, exonic E-to-K 2 2 8 8 8 8 
HLA-
DQB2 
6 32,833,537 G-to-A Coding exonic G-to-S 2 2 10 10 NE§ NE 
6 32,833,545 G-to-A Coding, exonic R-to-H 2 2 10 10 NE NE 
6 32,833,550 C-to-T Coding, exonic 
Synonymous 
(I) 2 2 10 10 NE NE 
BLCAP# 20 35,580,977 A-to-G Coding, exonic Q-to-R 6 4 10 4 6 6 
NDUFC2 11 77,468,303 C-to-G Coding, exonic L-to-V 10 0 10 0 10 0 
* hg 18 build of the human genome 
† in all cases, matched DNA and RNA from the same individuals were sequenced 
‡ also reported by Church and colleagues (J. B. Li et al. 2009) 
§ NE, not expressed 
# known site that was used as a positive control 
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Figure 3.4 Examples of Sanger sequencing validation of RNA-DNA sequence difference 
sites. Sequences of matched DNA and RNA sequences from cultured B-cells for four genes are 
shown. Each matched pair of DNA and RNA sequences was from the same individual. The 
reverse strand of EIF2AK2, AZIN1 and BLCAP was sequenced. Locations of the sites are based 
on hg18 build of the human genome. 
 
 
 
 83 
3.3.5 Proteomic evidence for RNA-DNA sequence differences 
Validation at the sequence level is important but does not address concerns such 
as the difficulty in aligning sequences that are highly similar and errors introduced by 
enzymes in reverse transcription steps. We believe that such artifacts are unlikely 
considering the consistent patterns across sequencing methods. An alternative and 
independent validation would be to ask whether the RNA variants in RDD sites are 
translated to proteins. To do so, we first searched mass spectrometry data from human 
ovarian cancer cells (Sodek et al. 2008) and leukemic cells for putative RDD sites. 
Because the levels of most RDDs are less than 100%, both DNA and the RDD forms of 
the mRNAs should be available to be translated (hereafter, we refer to mRNAs that 
correspond identically to the DNA sequences as DNA forms and those that contain an 
RDD as RNA forms). In the ovarian cancer and leukemic cells, we indeed found 
examples of proteins with peptides encoded by both DNA and RNA forms of mRNA 
(Table 3.5). Encouraged by the search results and cognizant of possible genome 
instability and thus DNA mutations in cancer cells, we carried out mass spectrometry 
analysis of our B-cells. We analyzed the proteome of our B-cells using liquid 
chromatography-tandem mass spectrometry and detected peptides for 3,217 proteins. 
Despite advances in mass spectrometry, far less than 50% of peptides can be detected in 
most studies (de Godoy et al. 2006; Michalski et al. 2011). With a false discovery rate 
(FDR) less than 1%, we identified 327 peptides that cover RDD sites: 299 and 28 of them 
correspond to the DNA and RNA forms respectively. For 17 RDD sites, peptides that 
correspond to both DNA and RNA forms were identified (Table 3.6). By BLAST 
alignment, we ensured that these 28 peptides were unique to the genes that contain the 
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RDD sites. In addition, we sequenced the DNA of the B-cells used for mass spectrometry 
and validated that the DNA sequences were the same as those of the reference genome 
but differed from the RNA sequences and thus did not encode the RNA forms of the 
peptides (Table 3.2). It is easier to detect more abundant proteins by mass spectrometry; 
for most RDD sites, the unaltered DNA forms are more abundant than variant RNA 
forms of mRNA (Figure 3.5). Thus, it is not surprising to find more peptides that 
correspond to the DNA than to the RNA sequences. However, the counts of peptides 
corresponding to the DNA and RNA forms of RDDs should not be taken as a measure of 
the proportions of DNA versus RNA forms of mRNA that are translated because 
differences in the amino acid sequences of the peptides affect the ability of mass 
spectrometry to detect them. In addition, the inability to detect a peptide does not signify 
its absence from the sample, but may instead be a function of sampling variation. The 
proteomic data provide an independent validation that mRNA sequences are not always 
identical to DNA sequences and demonstrate that RNA forms of genes are translated to 
proteins. They also show that there are peptides in human cells that are not exactly 
encoded by the DNA sequences. An example of a protein variant that results from RDD 
is a T-to-A RNA-DNA sequence difference at chr19:60,590,467 in RPL28 that leads to 
the loss of a stop codon and gain of 55 amino acids. We identified peptides corresponding 
to the 55-amino acid extension of RPL28 protein in the ovarian cancer cells and in our B 
cells (Figure 3.5). Previously identified cases of RNA editing leading to proteins that 
contain amino acids not encoded by genomic DNA, such as apolipoprotein B (S. H. Chen 
et al. 1987; Powell et al. 1987), serotonin and glutamate receptors (Burns et al. 1997; 
Lomeli et al. 1994; Maas et al. 2001) in humans, and plant ribosomal protein S12 
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(Phreaner et al. 1996), also support our hypothesis that RDD leads to protein isoforms 
that do not correspond to the DNA sequences of the encoding genes.  
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Table 3.5 Detection of peptides encoding DNA or RNA forms by mass spectrometry in 
ovarian cancer and leukemia cells at multiple RDD sites.   
Peptides detected from HOC-7 ovarian cancer cell line 
Protein Location* RDD 
Amino 
acid 
change 
DNA form of peptide RNA form of peptide 
RPL28 chr19:60590467 T-to-A STOP-to-R N/A SLIGTASEPR 
TUBA1 chr2:219823379 A-to-G E-to-G EDMAALEK EDMAALGK 
HSPA4 chr5:132459768 T-to-G V-to-G TSTVDLPIENQLLWQIDR TSTGDLPIENQLLWQIDR 
HSP90AB1 chr6:44328823 A-to-C T-to-P LVSSPCCIVTSTYGWTANMER LVSSPCCIVTSTYGWPANMER 
Peptides detected from K562 leukemia cell line 
Protein Location* RDD 
Amino 
acid 
change 
DNA form of peptide RNA form of peptide 
DHX15 chr4:24187092 T-to-A Y-to-N YYDILK NYDILK 
ENO3 chr17:4800624 T-to-G V-to-G N/D LAQSNGWGGMVSHR 
FABP3 chr1:31618424 T-to-A W-to-R N/D MVDAFLGTR 
HNRNPA3 chr2:177789664 T-to-C S-to-P N/D GGGPGNFMGR 
HNRNPL chr19:44021390 C-to-A Q-to-K AITHLNNNFMFGQK AITHLNNNFMFGKK 
MYH10 chr17:8357846 T-to-G W-to-G N/D HWQWGR 
RANBP2 chr2:108765620 T-to-A I-to-K ITMELFSNIVPR KTMELFSNIVPR 
USP34 chr2:61329192 T-to-A Y-to-N N/D LDMTPNTEDFLMGK 
ZFP91 chr11:58138282 A-to-G H-to-R N/D YLQHRIK 
* hg18 build of human genome 
N/A: not applicable 
N/D: not detected 
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Table 3.6 Peptides encoded by both the DNA and RNA forms. 
Protein Position* RDD 
Amino 
acid 
change 
DNA form† RNA form† 
AP2A2 chr11:976858 T-to-G Y-to-D YLALESMCTLASSEFSHEAVK DLALESMCTLASSEFSHEAVK 
DFNA5‡ chr7:24705225 T-to-A L-to-Q VFPLLLCITLNGLCALGR VFPQLLCITLNGLCALGR 
ENO1 chr1:8848125 T-to-C L-to-P EGLELLK EGPELLK 
ENO3 chr17:4800624 T-to-G V-to-G LAQSNGWGVMVSHR LAQSNGWGGMVSHR 
FABP3 chr1:31618424 T-to-A W-to-R MVDAFLGTWK MVDAFLGTR 
FH‡ chr1:239747217 T-to-A I-to-K IEYDTFGELK KEYDTFGELK 
HMGB1 chr13:29935772 T-to-A Y-to-N MSSYAFFVQTCR MSSNAFFVQTCR 
NACA chr12:55392932 G-to-A D-to-N DIELVMSQANVSR NIELVMSQANVSR 
NSF chr17:42161411 T-to-C V-to-A LLDYVPIGPR LLDYAPIGPR 
POLR2B chr4:57567852 T-to-A L-to-Q IISDGLK IISDGQK 
RAD50‡ chr5:131979610 T-to-G L-to-R WLQDNLTLR WRQDNLTLR 
RPL12 chr9:129250509 A-to-G N-to-D HSGNITFDEIVNIAR HSGDITFDEIVNIAR 
RPL32‡ chr3:12852658 G-to-T A-to-S AAQLAIR SAQLAIR 
RPS3AP47‡ chr4:152243651 C-to-A T-to-K EVQTNDLK EVQKNDLK 
SLC25A17 chr22:39520485 A-to-G E-to-G TTHMVLLEIIK TTHMVLLGIIK 
TUBA1‡ chr2:219823379 A-to-G E-to-G EDMAALEK EDMAALGK 
TUBB2C chr9:139257297 G-to-A G-to-D LHFFMPGFAPLTSR LHFFMPDFAPLTSR 
* hg18 build of the human genome  
† for each peptide, the amino acid that differs between the DNA and RNA forms is underlined 
Abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, 
Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. 
‡ DNA sequences of these and other proteins were verified by Sanger sequencing (Table 3.2) 
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Figure 3.5 Identification of peptides encoded by both RNA and DNA forms. (A) The RNA 
form of an RDD leads to the loss of a stop codon in RPL28 and extension of 55 amino acids. 
Peptides detected by mass spectrometry are shown in red. (B and C) Tandem mass spectrometry 
(MS-MS) data confirm the detection of peptides encoded by the RDD-containing RPL28 mRNA. 
The representative spectra of one peptide (SLIGTASEPR) from ovarian cancer cells (B) and 
cultured B-cells (C) are shown.  
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3.3.6 Variation in abundance of RNA-DNA sequence differences 
Using our selection criteria, we found that across the 27 individuals, there are 
1,065 exonic RDD events on average per sample. The number of events varied among the 
27 individuals (range: 282 to 1863) by up to six-fold (Figure 3.6). To evaluate whether 
the abundance of RDD events is correlated with depth of sequencing, we fitted a linear 
model using the number of events as the outcome variable and the number of bases 
covered by 10 or more reads as the independent variable and found that the number of 
events and sequencing depth are not dependent (P = 0.51). Similarly, the depth of DNA 
sequences from the 1000 Genomes Project cannot explain individual differences in the 
number of RDD events (P = 0.12). From these results, we conclude that we do not have 
significant evidence to show that variation in RDD frequency is determined by 
sequencing depth.  
We found no significant correlation between ADAR expression and the number of 
RDDs or the numbers of A-to-G events (P > 0.5). Thus, we conclude that either ADAR 
expression does not affect the number of editing or RDD events or that our sample size is 
not sufficient to detect the correlation. 
 
 90 
Figure 3.6 Number of RNA-DNA sequence difference events across 27 individuals. 
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3.3.7 Characteristics of RNA-DNA sequence differences 
The 10,210 sites that showed RNA-DNA sequence differences are not evenly 
distributed across the genome: chromosome 19 has the most sites, whereas chromosome 
13 has the fewest. This pattern is observed after correction for differences in size and 
gene density among chromosomes. RDD sites are significantly (P < 10-10) enriched in 
genes that play a role in helicase activity, and in protein and nucleotide binding (Table 
3.7). The 10,210 sites that showed RNA-DNA sequence differences are not evenly 
distributed within genes. About 44% (4,453 sites) are located in coding exons (10% were 
found in the last exons), 4% (386 sites) are in the 5’ untranslated regions (UTRs), and 
39% (3,977 sites) are in the 3’ UTRs (Table 3.8; those remaining cannot be classified 
because of differences in gene structures across isoforms). The results suggest that there 
are more sites in the 3’ ends than in the 5’ ends of genes. This pattern was also observed 
in deamination-mediated RNA editing (Hundley et al. 2008; Rosenberg et al. 2011). 
Seventy-one percent of the coding sites result in non-synonymous amino acid changes, 
including 2.1% that lead to the gain or loss of a stop codon in proteins. Relative to other 
structural features in genes, we found that 4% of RDD sites are within 2 nt of exon 
borders and 5% are within 30 nt of polyadenylate [poly(A)] signals (Table 3.8). Among 
RDD types, the numbers of sites near splice junctions are quite similar, but the numbers 
near poly(A) sites are more different. C-to-A and G-to-A differences are found more 
often near poly(A) sites. Sites also tended to cluster: 2,613 sites (26%) are within 25 bp 
of another RDD site, and 1,059 sites (10%) are adjacent to each other. Statistical analysis 
using a runs test supports the nonrandom locations of the sites (median P= 0.22). We did 
not find obvious patterns or associations with motifs shared across the sites, except for 
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the A-to-G and A-to-C differences that show a preference for a cytidine 5’ to the 
adenosine, as previously observed in ADAR-mediated A-to-G changes (Athanasiadis et 
al. 2004; Maas et al. 2001). 
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Table 3.7 Most significant gene ontology enrichments for genes containing RDDs. 
GO Group  
(Molecular Function) Examples P 
3'-5' DNA helicase activity BLM, ERCC3, RECQL, RECQL4, WRN 0 
protein binding ACBD3, AKT2, DENND4A, IL15, MLX 1x10‐ 79 
catalytic activity ACLY, CASP3, DHDDS, KDM2A, XRN1 3x10‐ 37 
RNA binding APTX, BARD1, EIF1, RBM4, RNASEN 5x10‐ 37 
nucleotide binding CDK2, CHD1, DARS, PIF1, U2AF1 4x10‐ 31 
ATP binding ASS1, ATP11A, CEHK1, GART, KIF11 1x10‐ 22 
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Table 3.8 Location of RNA-DNA sequence differences within genes. 
 
5’ UTR Coding Exon 3’ UTR Mixed* Splice 3’ Poly A Total 
# of sites % # of sites % # of sites % # of sites % # of sites % # of sites % 
A‐ to‐
C 23 3.8 334 55.5 153 25.4 92 15.3 20 3.3 4 0.7 602 
A‐ to‐
G 44 1.9 984 42.3 1028 44.2 272 11.7 97 4.2 174 7.5 2328 
A‐ to‐
T 26 7.2 148 41.2 104 29 81 22.6 17 4.7 7 1.9 359 
C‐ to‐
A 11 2.1 208 39.8 220 42.1 84 16.1 17 4.7 77 14.7 523 
C‐ to‐
G 17 5.8 159 53.9 79 26.8 40 13.6 25 8.5 10 3.4 295 
C‐ to‐
T 56 14.9 178 47.2 78 20.7 65 17.2 3 0.8 4 1.1 377 
G‐ to‐
A 15 2 342 44.9 292 38.3 113 14.8 46 6 73 9.6 762 
G‐ to‐
C 27 11.2 114 47.1 56 23.1 45 18.6 14 5.8 2 0.8 242 
G‐ to‐
T 43 10.8 192 48 110 27.5 55 13.8 24 6 3 0.8 400 
T‐ to‐
A 16 1.5 398 36.8 550 50.8 118 10.9 35 3.2 90 8.3 1082 
T‐ to‐
C 58 2.5 953 41.8 951 41.7 316 13.9 33 1.4 142 6.2 2278 
T‐ to‐
G 50 5.2 443 46 356 37 113 11.7 39 4.1 25 2.6 962 
Splice are sites within 2 nt of exon borders  
3’ Poly A are sites within 30 nt 3' of AAUAAA sites  
* Mixed means in some isoforms the sites are in coding exons and in other isoforms they are in UTRs  
Percentages are calculated within each RDD type. 
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3.3.8 Levels of RNA-DNA sequence differences 
We examined the percentage or proporation of mRNAs that differ in sequence 
from the corresponding DNA at a given site. For each site, to determine the RDD level, 
we counted the number of reads with a different nucleotide from that in the underlying 
DNA sequence. The distribution of the level is bimodal (Figure 3.7); the average level is 
20% (median = 13%). For some sites, RDD was detected in nearly 100% of the RNA 
sequences such as the A-to-C difference in the gene that encodes an mRNA decapping 
enzyme, DCP1A (chr3:53,297,343). Sites found in more than 50% of the informative 
individuals tend to have higher levels of RNA editing or RDD than other sites (P < 10-5; 
Figure 3.8). The levels also differ across individuals. For example, at a G-to-A site in the 
gene RHOT1, which encodes a RAS protein that plays a role in mitochondrial trafficking 
(chr17:27,526,465), in one individual, the level was 90% while in another sample, it was 
only 18%. We identified 437 sites with 10 or more informative individuals where the 
individuals with the highest levels and the lowest levels differed by two-fold or more 
(range: 2- to 8.6-fold). 
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Figure 3.7 Distribution of RNA-DNA sequence difference levels. The density of the 
distribution of RDD levels among the 27 unrelated individuals are shown here. RDD level is 
measured as the proportion of transcripts at an RDD site bearing the sequence difference allele. 
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Figure 3.8 Distribution of RDD levels by frequency of event across 27 individuals. The 
distribution of RDD levels among the 27 unrelated individuals is shown here for sites that appear 
in the majority versus minority of informative individuals. 
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3.4 Discussion 
In this study, we have uncovered thousands of exonic sites where the RNA 
sequences do not match those of the DNA sequences, including transitions and 
transversions. These findings challenge the long-standing belief that in the same 
individuals, DNA and RNA sequences are nearly identical. To increase the confidence in 
our results, we obtained the DNA, RNA, and protein sequences from different individuals 
and cell types using a range of technologies (Figure 3.9). The samples included cell lines 
and primary cells from healthy individuals and tumors. We used data from public 
resources such as EST databases, the HapMap, and 1000 Genomes Project, as well as 
those that we generated with traditional Sanger sequencing, high-throughput sequencing 
technologies, and mass spectrometry. We observed sites where the RNA and peptide 
sequences are the same but differ from the corresponding DNA sequences. The results 
support our observation that in an individual, DNA and RNA sequences from the same 
cells are not always identical and some of the variant RNA sequences are translated into 
proteins. The consistent pattern of the observations suggests that the RDDs have 
biological significance and are not just “noise”. At nearly all RDD sites, we observed 
only one RDD type across cell types and in different individuals. If the DNA sequence is 
A/A, and the RNA is A/C in one sample, in other samples, we see the same A-to-C 
difference, but not other types of differences. These results suggest that there are 
unknown aspects of transcription and/or post-transcriptional processing of RNA. These 
differences may now be studied along with those in other genomes and organisms such as 
the mitochondrial genomes of trypanosomes and chloroplasts of plants, where RNA 
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editing and modifications are relatively common (Hundley et al. 2008; Phreaner et al. 
1996). 
The underlying mechanisms for these events are largely unknown. For most of the 
cases, we do not know yet whether a different base was incorporated into the RNA during 
transcription or if these events occur post-transcriptionally. About 23% of the sites are A-
to-G differences; some of these are likely mediated by ADAR, but other, currently 
unknown, mechanisms can be involved. If it is a co-transcriptional process, then the 
signal can be in the DNA or the RNA such as secondary structures or modified 
nucleotides. In addition, as some of the RDDs are found near splice and poly(A) sites, it 
is possible that this may be a facet of systematic RNA processing steps such as splicing 
and cleavage (Rueter et al. 1995; Rueter et al. 1999). 
Our findings supplement previous studies demonstrating sequence differences 
between DNA and RNA in the human genome and show that these differences go beyond 
A-to-G transition. These findings affect our understanding of genetic variation; in 
addition to DNA sequence variation, we identify individual variation in RNA sequences. 
For monomorphic DNA sequences that show RDD, there is an overall increase in genetic 
variation. Thus, this variation not only contributes to individual variation in gene 
expression, but also diversifies the proteome because some identified sites lead to 
nonsynonymous amino acid changes. We speculate that this RNA sequence variation 
likely affects disease susceptibility and manifestations. To date, mapping studies have 
focused on identifying DNA variants as disease susceptibility alleles. Our results suggest 
that the search may need to include RNA sequence variants that are not in the DNA 
sequences. 
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Figure 3.9 Data generated and analyses conducted for RDD study. 
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3.5 Materials and Methods 
3.5.1 Samples 
We used data generated by sequencing RNA from 27 cultured B-cell lines 
obtained from Coriell (Camden, NJ, USA). These cell lines were derived from 
individuals of European descent from the Utah pedigrees of the CEPH collection, which 
have been extensively genotyped or sequenced by the International HapMap and the 1000 
Genomes Projects. All individuals are unrelated. The list of individuals is shown in Table 
3.1. The B-cells were grown to a density of 5 x 105 cells/mL in RPMI 1640 supplemented 
with 15% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin, and 
2 mmol/L L-glutamine. Foreskin tissues were collected from circumcisions of 10 healthy 
and unrelated 3-day old newborns (anonymous donors at the Hospital of the University of 
Pennsylvania). Primary fibroblasts were isolated from these foreskin tissues. Briefly, the 
tissues were sectioned and the epidermis was removed. The remaining dermis was 
incubated in 1 ml of 3 mg/ml collagenase (Roche, Indianapolis, IN, USA) in HBSS 
buffer with calcium and magnesium (Mediatech, Manassas, VA, USA) at 37°C for 30 
minutes. 1 ml of 0.5% Trypsin/EDTA (Invitrogen, Carlsbad, CA, USA) was then added, 
and the tissue was incubated at 37°C for 10 minutes. After inactivating trypsin by adding 
1 ml MEM medium (Invitrogen) with 10% fetal bovine serum (Hyclone, Logan, UT, 
USA), undigested tissue pieces were removed and fibroblasts were collected from 
suspension by centrifugation. Passage-1 fibroblasts were subsequently cultured at 37°C in 
5% CO2 in MEM medium supplemented with 10% fetal bovine serum, 2 mmol/L L-
glutamine, 100 units/mL penicillin and 100 μg/ml streptomycin, and were passaged every 
3 days. Human brain tissues were obtained from National Disease Research Interchange. 
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Tissues from cerebral cortex were collected during routine autopsy of cardiac-death 
donors within 7~12 post-mortem hours. Samples were snap-frozen and kept at -80°C 
until DNA/RNA extraction. All 10 subjects were Caucasians with age of 43~79 years, 
including both males and females. 
3.5.2 RNA-Sequencing 
RNA-Seq was performed as recommended by the manufacturer (Illumina, 
Hayward, CA, USA). Briefly, cells were harvested 24 hours after addition of fresh 
medium and total RNA was extracted using the RNeasy Mini kit with DNase treatment 
(Qiagen, Valencia, CA, USA). PolyA mRNA was isolated and fragmented. First strand 
cDNA was prepared using random hexamers. Following second strand cDNA synthesis, 
end repair, addition of a single A base, adaptor ligation, agarose gel isolation of ~200 bp 
cDNA and PCR amplification of the ~200 bp cDNA, the samples were sequenced using 
the Illumina 1G Genome Analyzer to a coverage of approximately 41 million 50-bp reads 
per sample. High quality reads were mapped to the Gencode mRNA sequences (build 
hg18) using program Bowtie (v0.12.7) (Langmead et al. 2009). We used the default 
settings of Bowtie (allowing up to two mismatches) and then extracted uniquely mapped 
reads from the obtained SAM file. 
3.5.3 Identification of RNA-DNA sequence differences 
We considered RDD events only at sites that are homozygous in the genomic 
DNA. Such sites can be either a SNP with homozygous genotype or a monomorphic site, 
which we define as sites that are not identified as SNPs in dbSNP, HapMap or the 1000 
Genomes Project. We obtained SNP sites and the corresponding genotypes from the 
HapMap and the 1000 Genomes Projects. We further required SNPs found in both the 
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HapMap and 1000 Genomes Project to be concordant. For monomorphic sites, we 
assumed that all individuals are homozygous for the reference allele in the reference 
genome. We identified RDD events by comparing genotypes derived from DNA-Seq 
with those from RNA-Seq on the same individual. For each individual, an RDD event is 
declared at a site if 1) the number of uniquely mapped reads in RNA-Seq is ≥ 10 and the 
per-base quality score for each of the bases is ≥ 25, 2) the number of uniquely mapped 
reads in DNA-Seq is ≥ 4 in the 1000 Genomes Project, 3) the individual's genotype at the 
site is homozygous, and 4) ≥ 10% of the mapped reads in RNA-Seq show an allele that 
differs from the individual's (DNA-level) genotype. We removed all sites that overlap 
with segmental duplications (Bailey et al. 2002; Bailey et al. 2001) and repetitive 
sequences (defined by RepeatMasker on the UCSC Genome Browser). 
3.5.4 EST search for RNA-DNA sequence differences 
We analyzed RDD sites where the DNA sequences are monomorphic. For each 
site, we used BLAST to search for sequences corresponding to the RNA-allele of the 
RNA-DNA sequence difference and 25 nucleotides up- and downstream of that site in 
human dbEST. An EST is found to contain the RDD allele if its sequence is identical to 
the RNA-form of the RDD site and there is no more than 1 mismatch (except for known 
SNPs) to the 51-nucleotide query sequence. The EST must also map to the gene where 
the RDD was called (the mapping is mostly according to Unigene). 
3.5.5 Sanger sequencing validation of RNA-DNA sequence differences 
To validate the sites we identified as RNA-DNA sequence differences by RNA-
Sequencing, we carried out Sanger sequencing. Genomic DNA and total RNA were 
extracted using the Qiagen AllPrep DNA/RNA kit (with DNase treatment for total RNA) 
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from B-cells and foreskin fibroblast. DNA and RNA from human brain tissues were 
extracted using Gentra Puregene Tissue Kit and RNeasy Lipid Tissue Mini kit (Qiagen), 
respectively. RNA was converted to single stranded cDNA using TaqMan reverse 
transcription reagents with oligo d(T) priming (Applied Biosystems, Foster City, CA, 
USA). PCR products (see Table 3.9) encompassing putative RDD sites were generated 
from the cDNA and sequenced using BigDye Terminator Cycle Sequencing on a 3730 
DNA Analyzer (Applied Biosystems). RDD sites were validated by visual inspection of 
sequencing traces independently by at least two individuals. 
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Table 3.9 Primer sequences used for Sanger sequencing validation of RDDs. 
Primer Name RDD Site Primer Sequence 
DPP7‐ F Chr9:139128755 5’‐ CAGGAGCGCTTCTTCCAGC‐ 3’ 
DPP7‐ R Chr9:139128755 5’‐ CCGACACCAGGAAGCGC‐ 3’ 
HLA‐ DQB2‐ F1 Chr6:32833537 5’‐ CCTAGGGTGGTCAGACTGGA‐ 3’ 
HLA‐ DQB2‐ R1 Chr6:32833537 5’‐ TTGGGTTCCTCACCTTTCTG‐ 3’ 
HLA‐ DQB2‐ F2 Chr6:32833545 5’‐ CCTAGGGTGGTCAGACTGGA‐ 3’ 
HLA‐ DQB2‐ R2 Chr6:32833545 5’‐ TTGGGTTCCTCACCTTTCTG‐ 3’ 
HLA‐ DQB2‐ F3 Chr6:32833550 5’‐ CCTAGGGTGGTCAGACTGGA‐ 3’ 
HLA‐ DQB2‐ R3 Chr6:32833550 5’‐ TTGGGTTCCTCACCTTTCTG‐ 3’ 
EIF2AK2‐ F 
Chr2:37181512 
5'‐ CCCCAAGAGCCACATGTATT‐ 3' Chr2:37181517 
Chr2:37181520 
EIF2AK2‐ R 
Chr2:37181512 
5'-CCTCAAGCTCACTGTCACCA-3' Chr2:37181517 
Chr2:37181520 
AZIN1‐ F Chr8:103910812 5'‐ TACAAGGAAGATGAGCCTCTG‐ 3' 
AZIN1‐ R Chr8:103910812 5'‐ AATAAATGGCTGGCCTCTGA‐ 3' 
BLCAP‐ F Chr20:35580977 5’‐ CCCGGCAGAGATCATGTATT‐ 3’ 
BLCAP‐ R Chr20:35580977 5’‐ AACAGTTTCCCCAGCAGCTA‐ 3’ 
PPWD1‐ F Chr5:64894960 5’‐ AGCGATTTTCAGCAGAGACG‐ 3’ 
PPWD1‐ R Chr5:64894960 5’‐ TTCCTCTTCTTGGCCAGTGT‐ 3’ 
NDUFC2‐ F Chr11:77468303 5'-ACCAGGCCTCAAGTGGAAAC‐ 3’ 
NDUFC2‐ R Chr11:77468303 5'-AGCCGTCGCGATCGG‐ 3’ 
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3.5.6 Mass spectrometry analysis of proteome 
Protein Database with RDD sites  
We made a protein database using Gencode mRNA sequences. For genes that 
display non-synonymous RDDs, protein forms predicted from both DNA sequences and 
RNA sequences were included. This database consists of 17,726 protein entries, among 
which 2,057 proteins contain RDD sites. This allows us to search for spectra of peptides 
encoded by the DNA and RNA forms of mRNAs simultaneously. Mass spectrometry 
data were searched against this database using a locally installed version of Mascot 
search engine (Perkins et al. 1999) (Matrix Science, Boston, MA, USA). In order to 
evaluate the certainty of search results and the false discovery rate, we included a decoy 
database search. The decoy database contains the reversed amino acid sequences of each 
protein contained in the original database, and thus no true matches should be expected 
(Deutsch et al. 2010). Each dataset was searched against both the original and the decoy 
databases, using the same parameters. The false discovery rate (FDR) was determined 
using the number of the matches from the original database (TP) and those from decoy 
database (FDR=FP/(TP+FP)). 
Ovarian cancer and leukemic cells 
First we mined public databases for large-scale mass spectrometry data on human 
cells. We found two comprehensive datasets on proteomic profiling of ovarian cancer 
cells (Sodek et al. 2008) and leukemic cells, K562 
(https://proteomecommons.org/dataset.jsp?i=76466). The data were downloaded from 
Proteome Commons database. The downloaded m/z XML files were converted to Mascot 
compatible format using ReAdW (Elias et al. 2005). We used the same parameters as the 
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original study (Sodek et al. 2008) for our Mascot search: Parent ion Δmass of 4 Da, 
fragment mass error of 0.4 Da, complete carbaminomethyl modification of cysteine, and 
allow one trypsin miscleavage; for the leukemic cells: parent ion Δmass of 0.3 Da, 
fragment mass error of 0.5 Da, complete carbaminomethyl modification of cysteine and 
variable N-terminal acetylation and methionine oxidation, allowing up to one trypsin 
miscleavage (same as B-cells, see below). False discovery rate is < 1% (determined by 
Mascot decoy database search). 
B-cells 
Cultured B-cells from 15 CEPH indivduals were cultured as described above (see 
section 3.4.1) for GEL/LC-MS/MS. Equal number of cells from each individual were 
pooled and lysed in 20 mM Tris HCl pH 8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-
40 (NP-40) and 2 mM EDTA. 60 μg of total protein was pre-fractionated and digested as 
described by Beer and colleagues (Beer et al. 2011). Specifically, the sample of 60 μg of 
total protein was loaded onto a 12% NuPAGE Bis-Tris gel and was run until the dye 
reached 2 cm from the bottom of the loading well. The gel was stained with Coomassie 
R250 and de-stained using methanol and water. The entire lane of protein was sliced into 
27 1-mm slices using a razor array. Gel slices were destained in 200 μl of 200 mM 
ammonium bicarbonate and 50% acetonitrile for 30 minutes with shaking at 37°C and 
then dried in a Speedvac. This was followed by incubation in 100 μl of 20 mM TCEP in 
25 mM ammonium bicarbonate (pH 8.0) for 15 minutes at 37°C. The supernatant was 
discarded and 100 μl of 40 mM iodoacetamide in 25 mM ammonium bicarbonate (pH 
8.0) was added and incubated for 30 minutes at 37°C. The supernatant was again 
discarded and the gel slices were washed twice with 200 μl of 25 mM ammonium 
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bicarbonate in H2O and once with 25 mM ammonium bicarbonate in 50% acetonitrile. 
The gel slices were dried and then rehydrated with 20μl of 0.02 μg/μl modified Trypsin 
(Promega, Madison, WI, USA) in 40 mM ammonium bicarbonate overnight with shaking 
at 37°C. The supernatant was then transferred to a clean tube and the gel slices were 
incubated in 20 μl of 40 mM ammonium bicarbonate for 30 min at 37°C. The 
supernatants were combined and 4 μl of acetic acid was added. Extracted tryptic peptides 
were injected onto a nanocapillary reverse-phase column (75 μm column terminating in a 
nanospray 15 μm tip) directly coupled to a LTQ-Orbitrap mass spectrometer (Thermo 
Scientific, Pittsburgh, PA, USA). The MS/MS data was acquired using a top six method. 
Each fraction of tryptic peptides was injected and analyzed in triplicates to increase the 
depth of protein detection. The raw spectra files were converted to Mascot compatible 
format using BioWorks v 3.3.1 (Thermo Scientific, Waltham, MA, USA). We used the 
same protein database as in the cancer cell analysis described above. The following 
Mascot search parameters were applied: parent ion Δmass of 0.3 Da, fragment mass error 
of 0.5 Da, complete carbaminomethyl modification of cystein and variable N-terminal 
acetylation and methionine oxidation, allowing up to one trypsin miscleavage. False 
discovery rate is <1% (determined by Mascot decoy database search); see Table S9 for 
details on search results. At FDR < 1%, 38,572 unique peptides (from 3,217 proteins) 
were detected. Among them, 11,496 peptides are from the 659 proteins that contain one 
or more RDD sites although the RDD-containing peptides were not necessarily detected. 
Among the 659 proteins, we detected 299 and 28 peptides encoded by the DNA and RNA 
forms of RDDs. As shown in Table 3.6, 17 pairs of peptides differ in one residue that 
corresponded to the RNA and DNA variants at RDD sites. An RDD site in the RPL28 
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protein led to a loss of a STOP codon and resulted in a larger protein with additional 
amino acids. We carried out BLAST search and ensured that all 28 peptides that 
correspond to the RNA forms of the RDD-containing peptides are unique to the proteins 
of interests. For these alignments, we used “nr” to search all non-redundant sequences 
(which includes CDS translations + PDB + SwissProt + PIR + PRF). All 28 RDD sites 
correspond to monomorphic sites; by Sanger sequencing of the same aliquot of B-cells 
used for mass spectrometry, we validated the sequences correspond to the reference 
genome sequence (Table 3.10). 
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Table 3.10 Primer sequences used for validating the DNA sequences of RDD sites found in 
peptides. 
Primer Name RDD Site Primer Sequence 
CD22_F Chr19:40514815 5'‐ CCCTGCTCAGGCTTGCACCC‐ 3' 
CD22_R Chr19:40514815 5'‐ GCTGCCCCCACCCTACCCTA‐ 3' 
DFNA5_F Chr7:24705225 5'‐ AGGTTTGGGATTGTGCAGCGCT‐ 3' 
DFNA5_R Chr7:24705225 5'‐ AGCCTTGGCCAGTAACACGTACT‐ 3' 
ENO1_F Chr1:8848125 5’‐ ACAGTCCCTGTGTAGCAGCTGT‐ 3’ 
ENO1_R Chr1:8848125 5’‐ GTCAGCCAGCTGGTCAGGCG‐ 3’ 
FH_F Chr1:239747217 5'‐ AGGCAAGCCAAAATTCCTTCCGGA‐ 3' 
FH_R Chr1:239747217 5'‐ GCCAACATTTCCACAAATGCCACT‐ 3' 
HMGB1_F1 Chr13:29935772 5'‐ GGAGATCCTAAGAAGCCGAGAGGCA‐3' 
HMGB1_R1 Chr13:29935772 5'‐ AGCGTCCCACTACGAGAATGCCA‐ 3' 
HMGB1_F2 Chr13:29935469 5'‐ TGGCATTCTCGTAGTGGGACGCT‐ 3' 
HMGB1_R2 Chr13:29935469 5'‐ ACGGAGGCCTCTTGGGTGCA‐ 3' 
ITPR3_F Chr6:33755773 5'‐ GTGTGACACGTGCCCCCTCC‐ 3' 
ITPR3_R Chr6:33755773 5'‐ TGTCCCCTGGCCTCCGGTTC‐ 3' 
RAD50_F Chr5:131979610 5'‐ GCACTTGCTGTCACCAGTTGCC‐ 3' 
RAD50_R Chr5:131979610 5'‐ TCTGTGCAGCAGGCTAGCAGA‐ 3' 
ROD1_F Chr9:114026264 5'‐ TGCGGCCCAGGTAGTTGACTC‐ 3' 
ROD1_R Chr9:114026264 5'‐ AGCGCCATTTTGCGATCTTTCCTG‐ 3' 
RPL32_F Chr3:12852658 5'‐ TGGTGCTGGGACTCATTGCCT‐ 3' 
RPL32_R Chr3:12852658 5'‐ TCTTCACTGCGCAGCCTGGC‐ 3' 
RPS25P8_F Chr11:118393375 5'‐ AGGGAAAGGGTGCTTCTGCCA‐ 3' 
RPS25P8_R Chr11:118393375 5'‐ GAGCTCCTGAAGGGCTGCCC‐ 3' 
RPS3AP47_F Chr4:152243651 5'‐ TGCTTCGTCTGTTCTGTGTTGGTT‐ 3' 
RPS3AP47_R Chr4:152243651 5'‐ CAAGGTTGTGTTGTGTGAGGAAGCA‐ 3' 
SUPT5H_F Chr19:44655806 5'‐ TGGCTCCCAGACGCCCATGT‐ 3' 
SUPT5H_R Chr19:44655806 5'‐ TCACCGTGACGGCGTGTTGG‐ 3' 
TOR1AIP1_F Chr1:178144365 5'‐ ACCTGCTTTGCTGTAGGAAGTGGT‐ 3' 
TOR1AIP1_R Chr1:178144365 5'‐ TGGGGCCCATTCCTGGGGAG‐ 3' 
TUBA1_F Chr2:219823379 5'‐ GCTGAGCAACACGACCGCCA‐ 3' 
TUBA1_R Chr2:219823379 5'‐ GCAGCAGCAGCATGAAGGGGA‐ 3' 
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Chapter 4. Detection Theory in Identification of RNA-DNA 
Sequence Differences Using RNA-Sequencing 
4.1 Abstract 
Advances in sequencing technology have allowed for detailed analyses of the 
transcriptome at single-nucleotide resolution, facilitating the study of RNA editing or 
sequence differences between RNA and DNA genome-wide. In humans, two types of 
post-transcriptional RNA editing processes are known to occur: A-to-I deamination by 
ADAR and C-to-U deamination by APOBEC1. In addition to these known sequence 
differences, researchers have reported the existence of all 12 types of RNA-DNA 
sequence differences (RDDs). However, the validity of these claims is debated, as many 
studies assert that technical artifacts account for the majority of these noncanonical 
sequence differences. In this chapter, we use a detection theory approach to evaluate the 
performance of RNA-Sequencing (RNA-Seq) and associated aligners in accurately 
identifying RDDs. By generating simulated RNA-Seq datasets with RDDs inserted in 
known locations, we assessed the sensitivity and false discovery rate of RDD detection. 
Overall, we found that alignment errors do not significantly influence RDD discovery in 
the absence of sequencing error, as the false negative and false discovery rates of RDD 
detection can be contained below 10% with minimal thresholds. We evaluated the impact 
of sequencing error on the false discovery rate and found that the effect of random 
sequencing errors can be mitigated with stricter thresholds on RDD identification. In 
contrast, non-random sequencing errors that occur at high levels cannot be distinguished 
from true positive RDDs and play a nontrivial impact on the false discovery rate of RDD 
detection. We also determined the performance of various filters that target false positive 
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RDDs and found them to be effective in discriminating between true and false positives. 
Lastly, we used the optimal thresholds and parameters we identified from our synthetic 
analyses to identify RDDs in a human lymphoblastoid cell line. We found approximately 
9,000 RDDs, the majority of which are A-to-G edits and likely to be mediated by ADAR. 
Moreover, we found the majority of non A-to-G RDDs to be associated with poorer 
alignments and determine that the evidence for noncanonical RDDs in humans to be 
weak. Overall, we found RNA-Seq to be a powerful technique when coupled with the 
appropriate thresholds and filters for surveying RDDs genome-wide. We aim for this 
work to provide a practical framework for those interested in the study of site-specific 
allelic differences genome-wide using high-throughput sequencing. 
 
 113 
4.2 Introduction 
Next-generation sequencing technology provides comprehensive sequence 
information. The precision afforded by RNA-Sequencing (RNA-Seq) is useful for 
studying various aspects of the transcriptome such as alternative splicing (Pan et al. 2008; 
E. T. Wang et al. 2008), RNA editing (Park et al. 2012; Peng et al. 2012), and differential 
allelic expression (DeVeale et al. 2012; Gregg et al. 2010; Heap et al. 2010; R. D. Lee et 
al. 2013). RNA editing refers to co- or post-transcriptional modification of RNA, 
resulting in a transcript that is different from the underlying genomic template. In 
humans, two types of RNA editing processes are known to occur: adenosine deamination 
by ADAR results in A-to-G edits (Bass & Weintraub 1988; Nishikura 2010) and cytidine 
deamination by APOBEC1 results in C-to-U changes (S. H. Chen et al. 1987; Smith et al. 
2012).  
In recent years, many genome-wide surveys of RNA editing in humans have been 
performed using next-generation sequencing technology (Bahn et al. 2012; Kleinman et 
al. 2012; Levanon et al. 2004; J. B. Li et al. 2009; Peng et al. 2012). In addition to the 
known A-to-G and C-to-U alterations introduced by RNA editing, researchers have 
reported the existence of RNA-DNA sequence differences (RDDs) that cannot be 
explained by known mechanisms (Bahn et al. 2012; Ju et al. 2011; M. Li et al. 2011). 
However, the validity of these results is contested, with many reports citing experimental 
and technical artifacts as the main determinants of systematic sequence differences 
between RNA and DNA (Kleinman et al. 2012; Kleinman & Majewski 2012; W. Lin et 
al. 2012; Pickrell et al. 2012; Schrider et al. 2011).  
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Previous approaches for accurate identification of RDDs mainly involved ad hoc 
filters aimed at removing false positives (Bahn et al. 2012; Kleinman et al. 2012; 
Ramaswami et al. 2012). In this study, we use a detection theory approach to evaluate the 
relative effect of misalignment and sequencing error on RDD analysis. In particular, we 
generated synthetic RNA-Seq datasets containing simulated RDDs at known locations 
and assessed the performance of various RNA-Seq aligners in accurately identifying 
RDDs. We also analyzed filtering methods for their efficacy in minimizing the false 
discovery rate of RDD detection while simultaneously maintaining high sensitivity 
values. To complement our in silico analyses, we assessed the sequencing error profile of 
a dataset comprising human cDNA clones deeply sequenced with Illumina Hi-Seq 
technology and evaluated the effect of non-random errors on the false discovery rate of 
RDD detection. Lastly, after determining the optimal thresholds and parameters for 
sequence difference analysis, we searched for the presence of RDDs in an experimental 
human RNA-Seq dataset for which deep DNA and RNA sequence information is publicly 
available. 
Overall, our report aims to explore the phenomenon of RDDs in humans as well 
as provide a framework for those interested in the study of RNA editing, RDDs, or 
differential allelic expression by elucidating the appropriate thresholds and parameters for 
accurate detection of allele-specific differences in RNA-Seq data. The synthetic datasets 
generated in this study are available at the GEO public repository. 
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4.3 Results 
4.3.1 Simulated RNA-Seq datasets 
To evaluate the performance of various alignment algorithms and filtering 
methods in detecting RDDs, we generated synthetic RNA-Seq datasets containing 
simulated RDDs at known locations (see Materials and Methods). First, we created a 
“clean” dataset (dataset 1) with no sequencing errors or intronic reads in order to evaluate 
the degree of bias introduced by alignment error alone. Next, in order to capture the 
effect of sequencing error on RDD identification, we generated a more realistic RNA-Seq 
dataset containing substitutional sequencing errors, indel polymorphisms, intronic signal, 
and lower quality bases at the tail end of reads. For our initial analyses, we assume a 
simplistic sequencing error model in which misincorporations occur randomly and 
independently at the same rate. Later, we consider the effect of sequencing error profiles 
derived from experimental Illumina Hi-Seq datasets on RDD detection. Both datasets 
contain 50 million pairs of non strand-specific reads of length 100 base pairs (bp) and 
were generated in triplicates to allow for assessment of variability of our various metrics. 
Datasets were aligned using GSNAP, RUM, and Tophat2 (see Materials and 
Methods). For both datasets, GSNAP performed the best in terms of the number of reads 
mapped in total and uniquely (Table 4.1), aligning approximately 99% of the 50 million 
read pairs. In contrast, RUM and Tophat2 aligned approximately 98% of the read pairs in 
dataset 1, but only roughly 95% in dataset 2, which contains sequencing errors. Overall, 
between 97 to 99% of the read pairs are aligned uniquely with GSNAP and RUM, 
whereas only approximately 89% of the read pairs are aligned uniquely with Tophat2. 
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Table 4.1 Alignment statistics of simulated RNA-Seq datasets. 
Dataset Aligner Statistic Value 
dataset 1 gsnap 
Number of Read Pairs Aligned 49706613 ± 5861 
Percentage of Read Pairs Aligned 99.41 ± 0.012% 
Number of Read Pairs Aligned Uniquely 49057838 ± 5548 
Percentage of Read Pairs Aligned Uniquely 98.69 ± 0.0012% 
dataset 1 rum 
Number of Read Pairs Aligned 49338154 ± 5464 
Percentage of Read Pairs Aligned 98.68 ± 0.011% 
Number of Read Pairs Aligned Uniquely 48192283 ± 5415 
Percentage of Read Pairs Aligned Uniquely 97.68 ± 0.0039% 
dataset 1 tophat2 
Number of Read Pairs Aligned 49144986 ± 6939 
Percentage of Read Pairs Aligned 98.3 ± 0.013% 
Number of Read Pairs Aligned Uniquely 43744298 ± 5756 
Percentage of Read Pairs Aligned Uniquely 89.01 ± 0.0084% 
dataset 2 gsnap 
Number of Read Pairs Aligned 49790494 ± 3376 
Percentage of Read Pairs Aligned 99.58 ± 0.0068 % 
Number of Read Pairs Aligned Uniquely 49095402 ± 4246 
Percentage of Read Pairs Aligned Uniquely 98.6 ± 0.0034 % 
dataset 2 rum 
Number of Read Pairs Aligned 47975774 ± 34932 
Percentage of Read Pairs Aligned 95.95 ± 0.07 % 
Number of Read Pairs Aligned Uniquely 46820152 ± 35128 
Percentage of Read Pairs Aligned Uniquely 97.59 ± 0.0062 % 
dataset 2 tophat2 
Number of Read Pairs Aligned 47763421 ± 77673 
Percentage of Read Pairs Aligned 95.61 ± 0.16 % 
Number of Read Pairs Aligned Uniquely 43072870 ± 73773 
Percentage of Read Pairs Aligned Uniquely 90.18 ± 0.015 % 
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4.3.2 Simulated RNA-DNA sequence differences 
For each of the two datasets, we inserted RDDs at random known locations in the 
genome (see Materials and Methods). In particular, at positions containing RDDs, a 
fraction of the total reads at the site bear a randomly chosen non-reference allele 
representing the sequence difference. Furthermore, we define the fraction of reads 
containing the non-reference base to be the RDD level. 
We generated approximately 600,000 total RDDs on average for both datasets. 
Each RDD type is equally represented, with sequence differences that originate from 
cytosine and guanosine (C>A, C>G, C>T, G>A, G>C, G>T) slightly overrepresented 
than other types. This variation results from differing base compositions throughout the 
genome, with the effect more pronounced in dataset 2, which contains reads from intronic 
regions of the genome (Figure 4.1). 
The coverage, or the total number of reads, at a given site is important in the 
analysis of RDDs as the presence and levels of RDDs at sites that are deeply sequenced 
are more likely to be robustly assessed. In order to assess the effect of sequencing depth 
on RDD detection, we stratified sites in the genome according to coverage and simulated 
equal numbers of RDDs in each group (see Materials and Methods). 
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Figure 4.1 Total number of simulated RNA-DNA sequence differences. For both datasets, 
approximately 600,000 RNA-DNA sequence differences were generated in each replicate. 
Differences in the number of each type of RNA-DNA sequence difference reflect underlying 
variation in base composition throughout the genome, as dataset 2 contains reads originating from 
intronic regions whereas dataset 1 does not. Colors refer to the three replicates generated for each 
dataset. 
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For each RDD, we chose the level, or proportion of reads carrying the non-
reference base, from a standard uniform random distribution excluding 0. However, 
because of the discrete nature of coverage, the distribution of RDD levels is not uniform 
at sites with low coverage; for sites with coverage greater than 100, the distribution of 
levels is uniform across all levels with the exception of boundary values (Figure 4.2). 
To understand the effect of hyperediting by ADAR and the observation that non-
canonical RDDs often cluster (Bahn et al. 2012), we modeled a subset of RDDs to occur 
in close proximity of one another (see Materials and Methods). Hyperediting refers to a 
type of editing by members of the ADAR family whereby approximately 50% of the 
adenosines on each strand of an RNA duplex is edited in a promiscuous fashion (Polson 
& Bass 1994). For each dataset, we generated approximately 2,000 clusters of length 100 
bp within which approximately 50% of all positions bear the same type of RDD (see 
Materials and Methods). 
Overall, in dataset 1, the average distance between neighboring RDDs is 10 bp 
(median 3 bp) for sites belonging to clusters and 815 bp (median of 58 bp) for those that 
do not. For dataset 2, which contains intronic reads, the average distance between RDDs 
is also 10 bp (median 3 bp) for sites belonging to clusters and 1565 bp (median 225 bp) 
for those that do not (Table 4.2). 
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Figure 4.2 Levels of simulated RNA-DNA sequence differences. Here we depict the 
distribution of RDD difference levels, or the proportion of reads at the sequence difference site 
that carry the sequence difference. Because of the discrete nature of RNA-Seq data, the levels of 
RDDs at sites with relatively low coverage is not uniform as shown by the blue area, which 
represents sites with coverage less than 10. For sites with coverage greater than 100 (red area), 
the density curve of sequence difference levels is fairly uniform except at boundary conditions. 
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Table 4.2 Summary statistics on distance between neighboring RNA-DNA sequence differences. 
Dataset In Cluster Number of Sites 
Distance to nearest RNA-DNA sequence difference* 
Minimum 1st Quartile Median Mean 
3rd 
Quartile Maximum 
dataset 1 TRUE 219239 1 1 3 10 5 155900 
dataset 1 FALSE 369416 1 23 58 815 146 1322700 
dataset 1 TOTAL 588654 1 4 19 515 82 1322700 
dataset 2 TRUE 222509 1 1 3 10 5 112347 
dataset 2 FALSE 376504 1 75 225 1565 869 2317667 
dataset 2 TOTAL 599013 1 4 59 987 353 2317667 
*Note: Each statistic is averaged across the 3 replicates. 
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4.3.3 Sensitivity of RNA-DNA sequence difference detection 
We began our assessment of the performance of next-generation sequencing 
technology in identifying RDDs by analyzing the sensitivity or recall rate of sequence 
difference identification. Here, we focus on the false negative rate of RDD detection and 
in subsequent analyses, we evaluate the issue of false positives. We begin by defining a 
simulated RDD as being properly identified by the aligner if at least one read bearing the 
non-reference base is mapped; later we analyze the correlation between the simulated and 
observed RDD levels. For dataset 1, we observed that overall, GSNAP detected 96.32 ± 
0.06% of the simulated RDDs, whereas RUM and Tophat2 correctly identified 95.36 ± 
0.16% and 95.04 ± 0.14%, respectively. For dataset 2, which contains sequencing errors 
and intronic reads, GSNAP identified 93.54 ± 0.10% of all simulated sites, whereas RUM 
and Tophat2 found 91.12 ± 0.13% and 90.84 ± 0.15%, respectively. 
Next, we investigated the effect of sequencing depth or coverage on the detection 
of RDDs. We observed that for both datasets, the sensitivity of detection increases with 
higher thresholds on the minimum depth of coverage (Figure 4.3). For example, the 
sensitivity of sequence difference detection using GSNAP increases from 96.32 ± 0.06% 
to 98.73 ± 0.01% in dataset 1 and even more sharply from 93.54 ± 0.10% to 98.03 ± 
0.04% in dataset 2 when sites with coverage lower than 10x are removed from 
consideration. In particular, the sensitivity of detection for sites with coverage less than 
10x is 86.11 ± 0.09% in dataset 1 and 80.38 ± 0.30% in dataset 2, versus 97.05 ± 0.14% 
in dataset 1 and 97.01 ± 0.03% for those with coverage between 10x and 20x. The 
sensitivity of RDD detection using RUM and Tophat2 increases in a similar fashion with 
higher coverage (Table 4.3).  Given the relatively low recall rate or high false negative 
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rate of RDD detection for locations with low coverage, we restrict subsequent analyses to 
sites with a minimum of 10 reads in the simulated dataset and the corresponding aligned 
datasets per GSNAP, RUM, or Tophat2.  
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Figure 4.3 Sensitivity of RNA-DNA sequence difference detection versus coverage. The 
sensitivity or recall rate of RDD identification is shown versus various thresholds on the 
minimum depth of coverage required at the site of the simulated difference. For all three aligners, 
the true positive rate increases sharply upon raising the minimum depth of coverage required for 
detection from 0 to approximately 50, after which the recall rate levels off. Colors refer to the 
aligner used for RDD detection. 
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Table 4.3 Sensitivity of RNA-DNA sequence difference detection versus coverage. 
Dataset Aligner 
Minimum Coverage 
or Total Count§ Sensitivity 
dataset 1 gsnap 0 96.32 ± 0.06% 
dataset 1 rum 0 95.36 ± 0.16% 
dataset 1 tophat2 0 95.04 ± 0.14% 
dataset 1 gsnap 10 98.73 ± 0.01% 
dataset 1 rum 10 98.52 ± 0.03% 
dataset 1 tophat2 10 98.24 ± 0.03% 
dataset 1 gsnap 50 99.27 ± 0.03% 
dataset 1 rum 50 99.34 ± 0.04% 
dataset 1 tophat2 50 99.13 ± 0.05% 
dataset 1 gsnap 100 99.49 ± 0.04% 
dataset 1 rum 100 99.57 ± 0.05% 
dataset 1 tophat2 100 99.40 ± 0.06% 
dataset 2 gsnap 0 93.54 ± 0.10% 
dataset 2 rum 0 91.12 ± 0.13% 
dataset 2 tophat2 0 90.84 ± 0.15% 
dataset 2 gsnap 10 98.03 ± 0.04% 
dataset 2 rum 10 96.99 ± 0.03% 
dataset 2 tophat2 10 96.49 ± 0.05% 
dataset 2 gsnap 50 98.97 ± 0.04% 
dataset 2 rum 50 98.60 ± 0.03% 
dataset 2 tophat2 50 98.35 ± 0.04% 
dataset 2 gsnap 100 99.21 ± 0.02% 
dataset 2 rum 100 98.99 ± 0.05% 
dataset 2 tophat2 100 98.78 ± 0.08% 
* Note: An RDD is considered properly identified if a minimum of 1 read bearing the 
sequence difference is present per the aligner. 
§ The threshold on the minimum coverage applies to the true coverage at the site of the 
underlying RDD per the simulated RNA-Seq dataset, not the observed coverage per the 
aligner.
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Next, we analyzed the effect of RDD level on the sensitivity of RDD detection. 
We binned the simulated sequence differences into 10 groups by RDD levels and 
evaluated the true positive rate for each group. We found that RDDs with levels between 
0 and 10% had the lowest recall rates, ranging from 93.05 ± 0.15% for Tophat2 to 94.87 
± 0.05% for GSNAP in dataset 1 and 86.67 ± 0.14% for Tophat2 to 91.03 ± 0.06% for 
GSNAP in dataset 2 (Table 4.4). However, for RDDs with a minimum level of 10%, the 
recall rates are fairly high, averaging 99.11 ± 0.01% in dataset 1 and 98.67 ± 0.04% in 
dataset 2 for GSNAP. Among the 3 aligners, GSNAP had the highest sensitivity values 
across all levels (Figure 4.4). Given the lower recall rates for sequence differences with 
low levels, we restrict our downstream analyses to sites with a minimum level of 10%. 
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Table 4.4 Sensitivity of RDD detection versus the level of sequence difference. 
Dataset Aligner RDD Level (%) Sensitivity 
dataset 1 gsnap 0 - 10 94.87 ± 0.05% 
dataset 1 rum 0 - 10 93.26 ± 0.08% 
dataset 1 tophat2 0 - 10 93.05 ± 0.15% 
dataset 1 gsnap 10 - 20 98.12 ± 0.04% 
dataset 1 rum 10 - 20 97.41 ± 0.07% 
dataset 1 tophat2 10 - 20 96.91 ± 0.09% 
dataset 1 gsnap 20 - 30 98.84 ± 0.06% 
dataset 1 rum 20 - 30 98.50 ± 0.03% 
dataset 1 tophat2 20 - 30 98.07 ± 0.04% 
dataset 1 gsnap 30 - 40 99.13 ± 0.02% 
dataset 1 rum 30 - 40 98.90 ± 0.04% 
dataset 1 tophat2 30 - 40 98.61 ± 0.05% 
dataset 1 gsnap 40 - 50 99.21 ± 0.06% 
dataset 1 rum 40 - 50 99.14 ± 0.06% 
dataset 1 tophat2 40 - 50 98.85 ± 0.03% 
dataset 1 gsnap 50 - 60 99.24 ± 0.03% 
dataset 1 rum 50 - 60 99.27 ± 0.02% 
dataset 1 tophat2 50 - 60 99.01 ± 0.04% 
dataset 1 gsnap 60 - 70 99.34 ± 0.03% 
dataset 1 rum 60 - 70 99.45 ± 0.01% 
dataset 1 tophat2 60 - 70 99.23 ± 0.01% 
dataset 1 gsnap 70 - 80 99.35 ± 0.04% 
dataset 1 rum 70 - 80 99.50 ± 0.07% 
dataset 1 tophat2 70 - 80 99.25 ± 0.04% 
dataset 1 gsnap 80 - 90 99.36 ± 0.03% 
dataset 1 rum 80 - 90 99.52 ± 0.02% 
dataset 1 tophat2 80 - 90 99.34 ± 0.01% 
dataset 1 gsnap 90 - 100 99.32 ± 0.07% 
dataset 1 rum 90 - 100 99.48 ± 0.04% 
dataset 1 tophat2 90 - 100 99.29 ± 0.04% 
dataset 2 gsnap 0 - 10 91.03 ± 0.06% 
dataset 2 rum 0 - 10 86.87 ± 0.08% 
dataset 2 tophat2 0 - 10 86.67 ± 0.14% 
dataset 2 gsnap 10 - 20 97.00 ± 0.08% 
dataset 2 rum 10 - 20 94.72 ± 0.07% 
dataset 2 tophat2 10 - 20 93.68 ± 0.07% 
dataset 2 gsnap 20 - 30 98.16 ± 0.10% 
dataset 2 rum 20 - 30 96.65 ± 0.07% 
dataset 2 tophat2 20 - 30 95.79 ± 0.08% 
dataset 2 gsnap 30 - 40 98.56 ± 0.11% 
dataset 2 rum 30 - 40 97.66 ± 0.04% 
dataset 2 tophat2 30 - 40 96.94 ± 0.14% 
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Dataset Aligner RDD Level (%) Sensitivity 
dataset 2 gsnap 40 - 50 98.79 ± 0.05% 
dataset 2 rum 40 - 50 98.21 ± 0.07% 
dataset 2 tophat2 40 - 50 97.66 ± 0.07% 
dataset 2 gsnap 50 - 60 98.93 ± 0.04% 
dataset 2 rum 50 - 60 98.36 ± 0.04% 
dataset 2 tophat2 50 - 60 97.95 ± 0.07% 
dataset 2 gsnap 60 - 70 99.01 ± 0.06% 
dataset 2 rum 60 - 70 98.61 ± 0.06% 
dataset 2 tophat2 60 - 70 98.21 ± 0.06% 
dataset 2 gsnap 70 - 80 99.14 ± 0.02% 
dataset 2 rum 70 - 80 98.85 ± 0.02% 
dataset 2 tophat2 70 - 80 98.53 ± 0.06% 
dataset 2 gsnap 80 - 90 99.16 ± 0.05% 
dataset 2 rum 80 - 90 98.93 ± 0.05% 
dataset 2 tophat2 80 - 90 98.69 ± 0.03% 
dataset 2 gsnap 90 - 100 99.18 ± 0.05% 
dataset 2 rum 90 - 100 98.97 ± 0.03% 
dataset 2 tophat2 90 - 100 98.72 ± 0.10% 
* Note: An RDD is considered properly identified if a minimum of 1 read bearing the 
sequence difference is present per the aligner. No threshold on the coverage is imposed. 
* Note: Sites with a true coverage value less than 10 per the simulated RNA-Seq dataset 
are removed from consideration. 
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Figure 4.4 Sensitivity of RDD detection versus the sequence difference level. Here we depict 
the true positive rate of RDD detection versus the level of sequence difference, or the proportion 
of reads at the site bearing the sequence difference allele. A minimum of 1 read bearing the RDD 
allele is sufficient for a site to be deemed correctly identified. Sites with fewer than 10 reads per 
the simulated RNA-Seq dataset are removed from consideration. Colors refer to the aligner used 
for RDD detection. 
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Next, we analyzed the effect of the repetitive nature of the sequence flanking the 
sequence difference site on the detection of RDDs. First, we evaluated the sensitivity of 
detection in regions of the genome that are deemed non-unique by BLAT (see Materials 
and Methods). We observed that the sensitivity of sequence difference detection using 
GSNAP in non-unique regions according to BLAT is lower than that in unique regions by 
approximately 5%. The average sensitivity in non-unique versus unique regions across 
the three replicates is 94.98 ± 0.11% versus 99.53 ± 2.8 x 10-3% for dataset 1 and 94.74 ± 
0.14% versus 99.25 ± 2.6 x 10-2% for dataset 2. The difference in sensitivity of detection 
between RDDs within non-unique versus unique regions using Tophat2 is similar to 
GSNAP, while interestingly that for RUM is less than approximately 1% (Figure 4.5 and 
Table 4.5). We also examined the sensitivity of RDD identification for sites lying within 
versus outside of RepeatMasker regions (Smit 1996) and observed that across the three 
replicates, the sensitivity of detection for any of the three aligners is approximately 1 to 
2% higher for those lying outside of RepeatMasker regions (Table 4.6). 
Lastly, we analyzed the effect of proximity to neighboring RDDs on sensitivity of 
detection. Short-read aligners typically have a limit on the number of mismatches relative 
to the reference permitted in a reported alignment, and thus sites with many neighboring 
sequence differences may be harder to identify. We observed that the sensitivity of 
sequence difference detection for sites that are greater than 10 bp in distance away from a 
neighboring sequence difference is roughly 1 to 3% higher for dataset 1 and 3 to 6% 
higher for dataset 2 (Table 4.7). 
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Figure 4.5 Sensitivity of RDD detection versus uniqueness of flanking genomic sequence by 
BLAT. 
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Table 4.5 Sensitivity of RDD detection in unique versus non-unique regions as determined 
by BLAT. 
Dataset Aligner Uniqueness Sensitivity 
dataset 1 gsnap Non-Unique 94.98 ± 0.11% 
dataset 1 gsnap Unique 99.53 ± 0.00% 
dataset 1 rum Non-Unique 98.82 ± 0.07% 
dataset 1 rum Unique 99.05 ± 0.04% 
dataset 1 tophat Non-Unique 94.90 ± 0.18% 
dataset 1 tophat Unique 99.13 ± 0.04% 
dataset 2 gsnap Non-Unique 94.74 ± 0.14% 
dataset 2 gsnap Unique 99.25 ± 0.03% 
dataset 2 rum Non-Unique 96.73 ± 0.10% 
dataset 2 rum Unique 98.08 ± 0.03% 
dataset 2 tophat Non-Unique 93.63 ± 0.22% 
dataset 2 tophat Unique 97.94 ± 0.02% 
* Note: Sites with a true coverage value less than 10 and true RDD level less than 10% 
per the simulated RNA-Seq dataset are not considered in this analysis. 
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Table 4.6 Sensitivity of RDD detection within RepeatMasker regions. 
Dataset Aligner Repeat Masker Sensitivity (%) 
dataset 1 gsnap In Repeat Masker Region 98.48 ± 0.11% 
dataset 1 gsnap Not In Repeat Masker Region 99.16 ± 0.02% 
dataset 1 rum In Repeat Masker Region 97.59 ± 0.16% 
dataset 1 rum Not In Repeat Masker Region 99.14 ± 0.02% 
dataset 1 tophat2 In Repeat Masker Region 97.55 ± 0.13% 
dataset 1 tophat2 Not In Repeat Masker Region 98.83 ± 0.01% 
dataset 2 gsnap In Repeat Masker Region 98.01 ± 0.12% 
dataset 2 gsnap Not In Repeat Masker Region 98.91 ± 0.02% 
dataset 2 rum In Repeat Masker Region 96.70 ± 0.18% 
dataset 2 rum Not In Repeat Masker Region 98.34 ± 0.08% 
dataset 2 tophat2 In Repeat Masker Region 96.48 ± 0.27% 
dataset 2 tophat2 Not In Repeat Masker Region 97.71 ± 0.04% 
*Note: Sites with a true coverage value less than 10 and a true RDD level less than 10% 
per the simulated RNA-Seq dataset are not considered in this analysis. 
 
 134 
Table 4.7 Sensitivity of RDD detection versus proximity to nearby RDDs. 
Dataset Aligner Distance to Nearest RDD Sensitivity (%) 
dataset 1 gsnap RDD not within 10 bp of another RDD 99.29 ± 0.01% 
dataset 1 gsnap RDD within 10 bp of another RDD 97.79 ± 0.04% 
dataset 1 rum RDD not within 10 bp of another RDD 99.35 ± 0.01% 
dataset 1 rum RDD within 10 bp of another RDD 96.75 ± 0.17% 
dataset 1 tophat RDD not within 10 bp of another RDD 99.06 ± 0.01% 
dataset 1 tophat RDD within 10 bp of another RDD 96.51 ± 0.11% 
dataset 2 gsnap RDD not within 10 bp of another RDD 99.06 ± 0.02% 
dataset 2 gsnap RDD within 10 bp of another RDD 95.66 ± 0.22% 
dataset 2 rum RDD not within 10 bp of another RDD 98.62 ± 0.01% 
dataset 2 rum RDD within 10 bp of another RDD 92.51 ± 0.12% 
dataset 2 tophat RDD not within 10 bp of another RDD 98.12 ± 0.02% 
dataset 2 tophat RDD within 10 bp of another RDD 91.75 ± 0.25% 
*Note: Sites with coverage less than 10 and an RDD level less than 10% in the simulated 
dataset are not considered in this analysis. 
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4.3.4 Correlation between true versus observed RDD levels  
In many studies, the mere detection of RDDs is not sufficient. For example, in 
studies on RNA editing or differential allelic expression, information about the degree or 
level of difference is important. Here we analyzed the correlation between true and 
observed RDD levels. Based on our previous analyses, we restricted our study to sites 
with a minimum coverage of 10x, minimum level of 10%, and minimum of 1 read 
bearing the sequence difference base. Using this threshold, we calculated the correlation 
between observed and true RDD levels to be relatively high, at approximately 98 ± 
0.03% on average across all three replicates for all three aligners and both datasets 
(Figure 4.6 and Table 4.8). Although the true and observed levels correspond well, we 
found that roughly 20 to 40% of sites in each dataset for any aligner have observed levels 
that deviate from the true values by more than 5% (Figure 4.7). In particular, we found 
that in the majority (75 to 90%) of cases in which the observed and true levels deviate by 
at least 10%, the observed level underestimates the true level. 
We hypothesized that one contributing factor to the discrepancy in RDD levels is 
the uniqueness or the ability of the region surrounding the site to be aligned accurately. 
Indeed, we found that approximately 27 to 34% of sites in which the true versus observed 
RDD levels differ by more than 30% are found in non-unique regions of the genome as 
determined by BLAT versus roughly 7 to 12% for those where the levels do not differ by 
30% or more (Table 4.9). 
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Figure 4.6 True versus observed levels of RDDs. Here we plot the true or simulated level of 
RDD versus the observed level as determined by GSNAP, RUM, or Tophat for replicate 1. Sites 
with coverage less than 10 or an RDD level less than 10% per the simulated dataset are removed 
from consideration. Overall, we observed the correlation between true and observed levels to be 
approximately 98% in both datasets and across the various aligners and replicates. 
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Table 4.8 Correlation between observed and true levels of RDDs. 
Dataset Aligner Correlation (%) 
dataset 1 gsnap 98.02 ± 0.03 
dataset 1 rum 98.02 ± 0.03 
dataset 1 tophat2 98.03 ± 0.03 
dataset 2 gsnap 98.08 ± 0.03 
dataset 2 rum 98.08 ± 0.03 
dataset 2 tophat2 98.09 ± 0.03 
*Note: Sites with coverage less than 10 and an RDD level less than 10% in the simulated 
dataset are not considered. Furthermore, sites must be identified as having at least 1 read 
bearing the sequence difference in the aligned dataset per GSNAP, RUM, or Tophat2 to 
be included in this analysis. 
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Figure 4.7 Percentage of sites with observed levels that deviate from true RDD level. Here 
we calculate the percentage of total sites in each dataset (y-axis) with observed levels that deviate 
from the true level of RDD by various amounts (x-axis). Colors refer to the aligner used for RDD 
detection. 
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Table 4.9 Percent of sites where the observed and true levels deviate by more than 30% 
versus the uniqueness of the underlying site as determined by BLAT. 
Dataset Aligner Levels differ by more than 30% 
Percent of sites that are not 
unique as determined by BLAT 
dataset 1 gsnap TRUE 27.03 ± 0.56% 
dataset 1 gsnap FALSE 8.09 ± 0.03% 
dataset 1 rum TRUE 30.98 ± 0.52% 
dataset 1 rum FALSE 7.75 ± 0.01% 
dataset 1 tophat TRUE 31.55 ± 0.44% 
dataset 1 tophat FALSE 7.78 ± 0.02% 
dataset 2 gsnap TRUE 29.20 ± 0.57% 
dataset 2 gsnap FALSE 11.38 ± 0.05% 
dataset 2 rum TRUE 33.83 ± 0.42% 
dataset 2 rum FALSE 10.65 ± 0.07% 
dataset 2 tophat TRUE 29.17 ± 0.41% 
dataset 2 tophat FALSE 11.02 ± 0.06% 
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4.3.5 Receiver operating characteristic analysis of RDD detection 
Next, we analyzed the false positive rate of RDD detection by evaluating the 
presence of differences at sites that were not simulated to represent RDDs. Using 
parameters we identified from our sensitivity analysis, we performed a receiver operating 
characteristic analysis on RDD detection genome-wide in each of the datasets (Table 
4.10). Overall, we observed that using a ‘minimum coverage of 10x, minimum level of 
10%, and minimum of 1 read bearing the RDD base’ cutoff, the false positive rate of 
sequence difference detection is low, averaging approximately 0.03% and 0.63% across 
the different aligners for datasets 1 and 2, respectively. However, given that the vast 
majority of sites in our datasets do not contain simulated sequence differences and are 
identified correctly as true negatives, these low false positives rates are not unexpected, 
as the false positive rate measures the percentage of true negatives that are incorrectly 
identified as having sequence differences. For a better understanding of the how false 
positives affect the analysis of RDDs, we evaluated the false discovery rate (FDR), or the 
percentage of sites identified as having sequence differences that in actuality are not true 
simulated differences. For dataset 1, we found the FDR to range from 1.31 ± 4.06 x 10-2 
% in Tophat2 to 5.48 ± 1.01 x 10-1% in RUM when using a ‘minimum coverage of 10x, 
minimum level of 10%, and minimum of 1 read bearing the RDD base’ threshold. These 
relatively low false discovery rates indicate that in the absence of sequencing error, 
misalignment issues do not contribute significantly to the incidence of false positives. 
With the introduction of sequencing error in dataset 2, we found that the false discovery 
rates are much higher, ranging from approximately 57% in GSNAP to 71% in Tophat2. 
These results are not surprising, as our threshold requiring only 1 read bearing the RDD 
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base will result in false positives at sites with sequencing errors. With stricter thresholds 
on RDD detection, we found that the false discovery rate decreases dramatically. 
Requiring a minimum of 2 reads bearing the sequence difference in addition to a 
minimum coverage of 10 and level of 10% reduces the FDR by a least 50% for all three 
aligners in dataset 2. In the end, we found that with a ‘minimum coverage of 20x, 
minimum level of 20%, and minimum of 4 reads containing the sequence difference 
base’ cutoff, the FDR in dataset 2 ranges from approximately 2% in GSNAP to 9% in 
RUM (Figure 4.8). 
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Table 4.10 Receiver operating characteristic analysis of RDD detection. 
Dataset Aligner Minimum coverage 
Minimum 
level 
Minimum 
RDD count Accuracy (%) 
True Positive Rate 
(%) 
False Positive Rate 
(%) 
False Discovery Rate 
(%) 
Negative Predictive 
Value (%) 
dataset 1 gsnap 0 0 1 99.90 ± 3.42E-03 98.36 ± 2.78E-02 0.09 ± 3.19E-03 8.20 ± 2.89E-01 99.98 ± 2.58E-04 
dataset 1 gsnap 10 10 1 99.97 ± 6.97E-04 98.24 ± 1.66E-02 0.02 ± 5.41E-04 1.95 ± 6.00E-02 99.98 ± 2.20E-04 
dataset 1 gsnap 10 10 2 99.97 ± 6.93E-04 98.20 ± 2.10E-02 0.02 ± 5.19E-04 1.92 ± 5.86E-02 99.98 ± 2.72E-04 
dataset 1 gsnap 20 10 2 99.97 ± 7.30E-04 98.38 ± 3.13E-02 0.01 ± 4.44E-04 1.55 ± 4.67E-02 99.99 ± 2.93E-04 
dataset 1 gsnap 10 20 2 99.96 ± 4.82E-04 97.02 ± 3.07E-02 0.01 ± 4.45E-04 1.62 ± 6.14E-02 99.98 ± 3.91E-04 
dataset 1 gsnap 20 20 4 99.97 ± 5.13E-04 97.16 ± 3.45E-02 0.01 ± 3.50E-04 1.23 ± 4.69E-02 99.98 ± 4.23E-04 
dataset 1 rum 0 0 1 99.87 ± 1.75E-03 97.76 ± 5.76E-02 0.11 ± 2.30E-03 10.46 ± 1.83E-01 99.98 ± 5.28E-04 
dataset 1 rum 10 10 1 99.93 ± 4.30E-04 97.73 ± 2.52E-02 0.05 ± 6.72E-04 5.48 ± 1.01E-01 99.98 ± 3.60E-04 
dataset 1 rum 10 10 2 99.93 ± 4.29E-04 97.68 ± 2.66E-02 0.05 ± 6.61E-04 5.45 ± 9.96E-02 99.98 ± 3.75E-04 
dataset 1 rum 20 10 2 99.94 ± 6.64E-04 97.92 ± 2.94E-02 0.04 ± 8.25E-04 5.00 ± 1.09E-01 99.98 ± 3.85E-04 
dataset 1 rum 10 20 2 99.94 ± 4.77E-04 96.21 ± 3.37E-02 0.04 ± 5.29E-04 4.51 ± 9.04E-02 99.97 ± 4.09E-04 
dataset 1 rum 20 20 4 99.94 ± 5.48E-04 96.41 ± 4.60E-02 0.03 ± 5.74E-04 3.95 ± 9.40E-02 99.97 ± 5.28E-04 
dataset 1 tophat2 0 0 1 99.86 ± 4.94E-04 88.50 ± 6.09E-02 0.03 ± 4.70E-04 3.18 ± 3.72E-02 99.89 ± 3.64E-04 
dataset 1 tophat2 10 10 1 99.96 ± 4.09E-05 96.23 ± 4.05E-02 0.01 ± 3.51E-04 1.31 ± 4.06E-02 99.97 ± 3.11E-04 
dataset 1 tophat2 10 10 2 99.95 ± 1.78E-04 95.86 ± 2.98E-02 0.01 ± 3.84E-04 1.26 ± 4.50E-02 99.96 ± 2.43E-04 
dataset 1 tophat2 20 10 2 99.97 ± 4.50E-04 97.12 ± 6.48E-02 0.01 ± 2.72E-04 1.23 ± 3.59E-02 99.98 ± 6.38E-04 
dataset 1 tophat2 10 20 2 99.96 ± 7.57E-04 95.01 ± 7.64E-02 0.01 ± 2.42E-04 0.88 ± 3.27E-02 99.96 ± 6.81E-04 
dataset 1 tophat2 20 20 4 99.96 ± 6.68E-04 95.90 ± 8.61E-02 0.01 ± 1.73E-04 0.83 ± 2.64E-02 99.97 ± 7.01E-04 
dataset 2 gsnap 0 0 1 94.12 ± 7.50E-04 97.69 ± 3.44E-02 5.89 ± 7.49E-04 98.38 ± 2.27E-03 100.00 ± 3.42E-05 
dataset 2 gsnap 10 10 1 99.52 ± 8.19E-04 98.11 ± 1.48E-02 0.47 ± 8.59E-04 57.05 ± 6.61E-02 99.99 ± 4.57E-05 
dataset 2 gsnap 10 10 2 99.93 ± 4.32E-04 97.96 ± 1.71E-02 0.06 ± 4.61E-04 14.95 ± 1.04E-01 99.99 ± 5.27E-05 
dataset 2 gsnap 20 10 2 99.97 ± 4.12E-04 98.25 ± 2.70E-02 0.02 ± 4.86E-04 5.26 ± 9.22E-02 99.99 ± 7.58E-05 
dataset 2 gsnap 10 20 2 99.98 ± 1.97E-04 96.98 ± 1.60E-02 0.01 ± 2.22E-04 3.46 ± 7.01E-02 99.99 ± 7.41E-05 
dataset 2 gsnap 20 20 4 99.98 ± 4.87E-04 97.09 ± 3.57E-02 0.01 ± 4.43E-04 2.02 ± 1.19E-01 99.99 ± 1.41E-04 
dataset 2 rum 0 0 1 93.74 ± 1.83E-03 96.52 ± 1.93E-02 6.26 ± 1.84E-03 98.54 ± 1.84E-03 100.00 ± 2.44E-05 
dataset 2 rum 10 10 1 99.41 ± 2.26E-03 97.22 ± 5.03E-02 0.58 ± 2.11E-03 64.05 ± 1.00E-01 99.99 ± 1.66E-04 
dataset 2 rum 10 10 2 99.85 ± 1.61E-03 97.03 ± 4.28E-02 0.14 ± 1.48E-03 29.87 ± 2.39E-01 99.99 ± 1.40E-04 
dataset 2 rum 20 10 2 99.91 ± 1.41E-03 97.36 ± 6.64E-02 0.08 ± 1.17E-03 18.38 ± 2.07E-01 99.99 ± 2.47E-04 
dataset 2 rum 10 20 2 99.95 ± 4.84E-04 95.55 ± 3.07E-02 0.04 ± 4.28E-04 11.12 ± 1.25E-01 99.99 ± 9.71E-05 
dataset 2 rum 20 20 4 99.96 ± 6.51E-04 95.56 ± 3.96E-02 0.03 ± 5.40E-04 8.67 ± 1.34E-01 99.99 ± 1.70E-04 
dataset 2 tophat2 0 0 1 95.13 ± 1.57E-03 81.63 ± 1.06E-01 4.84 ± 1.36E-03 97.29 ± 2.88E-03 99.97 ± 2.45E-04 
dataset 2 tophat2 10 10 1 99.14 ± 3.84E-03 95.47 ± 5.23E-02 0.85 ± 3.57E-03 71.44 ± 5.99E-02 99.98 ± 3.14E-04 
dataset 2 tophat2 10 10 2 99.82 ± 5.50E-04 94.83 ± 5.67E-02 0.17 ± 4.14E-04 32.94 ± 1.32E-01 99.98 ± 3.17E-04 
dataset 2 tophat2 20 10 2 99.93 ± 3.87E-04 96.66 ± 1.04E-01 0.06 ± 7.42E-04 14.18 ± 2.98E-01 99.99 ± 4.50E-04 
dataset 2 tophat2 10 20 2 99.96 ± 2.06E-04 93.97 ± 5.72E-02 0.02 ± 8.90E-05 6.43 ± 6.10E-02 99.98 ± 2.81E-04 
dataset 2 tophat2 20 20 4 99.98 ± 4.98E-04 95.14 ± 7.79E-02 0.01 ± 1.70E-04 2.60 ± 6.07E-02 99.99 ± 4.07E-04 
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Figure 4.8 False discovery rate of RNA-DNA sequence difference detection. Here we depict 
the false discovery rate of RDD detection under various thresholds on the coverage, level of 
sequence difference, and number of reads bearing the sequence difference base per the aligner. 
Calculations are averaged across the three replicates and error bars represent standard deviation 
values. Colors refer to the aligner used to detect RDDs. 
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4.3.6 Evaluation of filters in removing false positive RDDs 
Many previous studies on RNA editing and RDDs attempt to remove false 
positive sites using various filters (Bahn et al. 2012; Ju et al. 2011; Kleinman et al. 2012; 
Peng et al. 2012; Ramaswami et al. 2012). We investigated the effectiveness of some of 
these measures in eliminating false positives. The first filter we analyzed involves using 
BLAT to determine whether the sequence surrounding the RDD site can be aligned to 
other homologous regions of the genome (see Materials and Methods). Using a 
‘minimum coverage of 20x, minimum level of 20%, and minimum of 4 reads bearing the 
sequence difference’ to identify RDDs, we observed that the BLAT method removes 
approximately 14% and 28% of false positives found by GSNAP in datasets 1 and 2 
respectively, but only filters out roughly 1 to 5% of true positives in either datasets (Table 
4.11). As expected, we observed that the performance of the BLAT filter varies 
depending on the repetitive nature of the underlying flanking sequence. For example, 
within RepeatMasker regions, approximately 22% of false positives and 19% of true 
positives are filtered out, whereas outside of RepeatMasker regions, roughly 14% of false 
positives are removed compared to less than 1% of true positives (Table 4.11). 
Interestingly, the difference between the percentages of false versus true positives 
removed by the BLAT method is largest for RUM, followed by GSNAP and Tophat2 
(Figure 4.9). Overall, we found that the BLAT filtering approach decreased the FDR of 
RDD detection for GSNAP by approximately 13% in dataset 1 and 24% in dataset 2 
(Figure 4.10; Table 4.12). 
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Table 4.11 Percentage of true versus false positive RDDs removed by BLAT filter. 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD 
Count 
Region 
Percent of 
True Positives 
Removed 
Percent of 
False Positives 
Removed 
dataset 1 gsnap 10 10 2 Rmsk 18.59 ± 0.41 24.77 ± 4.61 
dataset 1 gsnap 10 10 2 Not in Rmsk 0.25 ± 0.02 14.56 ± 1.30 
dataset 1 gsnap 10 10 2 Total 1.55 ± 0.06 15.33 ± 1.56 
dataset 1 rum 10 10 2 Rmsk 18.37 ± 0.17 24.65 ± 5.36 
dataset 1 rum 10 10 2 Not in Rmsk 0.26 ± 0.02 27.04 ± 0.33 
dataset 1 rum 10 10 2 Total 1.52 ± 0.04 26.83 ± 0.73 
dataset 1 tophat 10 10 2 Rmsk 17.75 ± 0.54 15.49 ± 2.66 
dataset 1 tophat 10 10 2 Not in Rmsk 0.23 ± 0.01 4.80 ± 0.34 
dataset 1 tophat 10 10 2 Total 1.27 ± 0.01 5.52 ± 0.28 
dataset 1 gsnap 10 20 2 Rmsk 18.53 ± 0.46 27.00 ± 4.25 
dataset 1 gsnap 10 20 2 Not in Rmsk 0.25 ± 0.02 17.16 ± 1.34 
dataset 1 gsnap 10 20 2 Total 1.54 ± 0.06 17.89 ± 1.54 
dataset 1 rum 10 20 2 Rmsk 18.25 ± 0.20 25.79 ± 6.71 
dataset 1 rum 10 20 2 Not in Rmsk 0.25 ± 0.01 32.94 ± 0.45 
dataset 1 rum 10 20 2 Total 1.50 ± 0.04 32.36 ± 0.96 
dataset 1 tophat 10 20 2 Rmsk 17.63 ± 0.49 14.58 ± 2.17 
dataset 1 tophat 10 20 2 Not in Rmsk 0.23 ± 0.01 3.99 ± 0.33 
dataset 1 tophat 10 20 2 Total 1.26 ± 0.01 4.75 ± 0.15 
dataset 1 gsnap 20 10 2 Rmsk 18.84 ± 0.53 21.18 ± 4.18 
dataset 1 gsnap 20 10 2 Not in Rmsk 0.24 ± 0.02 11.42 ± 1.65 
dataset 1 gsnap 20 10 2 Total 1.47 ± 0.07 12.09 ± 1.84 
dataset 1 rum 20 10 2 Rmsk 18.30 ± 0.25 22.56 ± 6.05 
dataset 1 rum 20 10 2 Not in Rmsk 0.25 ± 0.01 24.80 ± 0.41 
dataset 1 rum 20 10 2 Total 1.41 ± 0.03 24.60 ± 0.70 
dataset 1 tophat 20 10 2 Rmsk 16.29 ± 0.60 15.91 ± 3.32 
dataset 1 tophat 20 10 2 Not in Rmsk 0.23 ± 0.01 4.55 ± 0.52 
dataset 1 tophat 20 10 2 Total 1.08 ± 0.00 5.31 ± 0.27 
dataset 1 gsnap 20 20 4 Rmsk 18.75 ± 0.62 21.96 ± 4.78 
dataset 1 gsnap 20 20 4 Not in Rmsk 0.23 ± 0.01 13.56 ± 1.72 
dataset 1 gsnap 20 20 4 Total 1.46 ± 0.07 14.11 ± 1.94 
dataset 1 rum 20 20 4 Rmsk 18.16 ± 0.22 23.57 ± 7.54 
dataset 1 rum 20 20 4 Not in Rmsk 0.24 ± 0.01 30.90 ± 0.54 
dataset 1 rum 20 20 4 Total 1.39 ± 0.03 30.31 ± 1.07 
dataset 1 tophat 20 20 4 Rmsk 16.03 ± 0.47 14.81 ± 2.89 
dataset 1 tophat 20 20 4 Not in Rmsk 0.23 ± 0.01 3.73 ± 0.47 
dataset 1 tophat 20 20 4 Total 1.06 ± 0.01 4.52 ± 0.19 
dataset 2 gsnap 10 10 2 Rmsk 24.77 ± 0.47 25.51 ± 0.30 
dataset 2 gsnap 10 10 2 Not in Rmsk 0.22 ± 0.02 5.87 ± 0.18 
dataset 2 gsnap 10 10 2 Total 6.43 ± 0.07 12.40 ± 0.20 
dataset 2 rum 10 10 2 Rmsk 23.18 ± 0.31 35.28 ± 0.25 
dataset 2 rum 10 10 2 Not in Rmsk 0.23 ± 0.02 14.73 ± 0.09 
dataset 2 rum 10 10 2 Total 5.86 ± 0.05 21.84 ± 0.13 
dataset 2 tophat 10 10 2 Rmsk 22.09 ± 0.29 23.39 ± 0.70 
dataset 2 tophat 10 10 2 Not in Rmsk 0.23 ± 0.02 0.73 ± 0.02 
dataset 2 tophat 10 10 2 Total 2.91 ± 0.02 4.04 ± 0.08 
dataset 2 gsnap 10 20 2 Rmsk 24.78 ± 0.39 27.37 ± 1.06 
dataset 2 gsnap 10 20 2 Not in Rmsk 0.21 ± 0.01 23.15 ± 0.43 
dataset 2 gsnap 10 20 2 Total 6.44 ± 0.05 24.23 ± 0.53 
dataset 2 rum 10 20 2 Rmsk 23.11 ± 0.25 46.08 ± 0.15 
dataset 2 rum 10 20 2 Not in Rmsk 0.22 ± 0.02 35.67 ± 0.42 
dataset 2 rum 10 20 2 Total 5.86 ± 0.04 38.71 ± 0.30 
dataset 2 tophat 10 20 2 Rmsk 22.00 ± 0.22 25.09 ± 2.05 
dataset 2 tophat 10 20 2 Not in Rmsk 0.22 ± 0.02 2.24 ± 0.17 
dataset 2 tophat 10 20 2 Total 2.89 ± 0.03 6.26 ± 0.51 
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Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD 
Count 
Region 
Percent of 
True Positives 
Removed 
Percent of 
False Positives 
Removed 
dataset 2 gsnap 20 10 2 Rmsk 24.25 ± 0.61 25.81 ± 0.79 
dataset 2 gsnap 20 10 2 Not in Rmsk 0.23 ± 0.02 12.52 ± 0.77 
dataset 2 gsnap 20 10 2 Total 4.84 ± 0.09 16.00 ± 0.68 
dataset 2 rum 20 10 2 Rmsk 22.34 ± 0.50 37.67 ± 0.76 
dataset 2 rum 20 10 2 Not in Rmsk 0.24 ± 0.02 25.60 ± 0.09 
dataset 2 rum 20 10 2 Total 4.32 ± 0.07 28.97 ± 0.20 
dataset 2 tophat 20 10 2 Rmsk 19.57 ± 1.07 22.03 ± 1.72 
dataset 2 tophat 20 10 2 Not in Rmsk 0.25 ± 0.02 1.68 ± 0.07 
dataset 2 tophat 20 10 2 Total 1.96 ± 0.10 4.08 ± 0.16 
dataset 2 gsnap 20 20 4 Rmsk 24.27 ± 0.48 28.57 ± 0.85 
dataset 2 gsnap 20 20 4 Not in Rmsk 0.22 ± 0.01 27.55 ± 1.05 
dataset 2 gsnap 20 20 4 Total 4.83 ± 0.06 27.74 ± 0.72 
dataset 2 rum 20 20 4 Rmsk 22.26 ± 0.40 43.83 ± 1.33 
dataset 2 rum 20 20 4 Not in Rmsk 0.23 ± 0.02 42.13 ± 0.34 
dataset 2 rum 20 20 4 Total 4.29 ± 0.06 42.51 ± 0.25 
dataset 2 tophat 20 20 4 Rmsk 19.56 ± 1.18 23.88 ± 5.57 
dataset 2 tophat 20 20 4 Not in Rmsk 0.23 ± 0.01 5.28 ± 0.46 
dataset 2 tophat 20 20 4 Total 1.94 ± 0.10 8.15 ± 1.27 
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Figure 4.9a Percentage of false versus true positive RDDs removed by BLAT filter for 
dataset 1. Here we depict the percentage of false positives versus true positives that are removed 
when using the BLAT filter for dataset 1. Colors refer to the aligner used for RDD detection. 
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Figure 4.9b Percentage of false versus true positive RDDs removed by BLAT filter for 
dataset 2. Here we depict the percentage of false positives versus true positives that are removed 
when using the BLAT filter for dataset 2. Colors refer to the aligner used for RDD detection. 
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Figure 4.10 Effect of BLAT filter on false discovery rate of RDD detection. Here we depict 
the effect of the BLAT filter on the FDR for various aligners and thresholds for identification of 
sequence differences. Colors refer to the aligner used for RDD detection. 
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Table 4.12 Effect of BLAT filter on false discovery rate of RDD detection. 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
FDR Before BLAT 
Filter 
FDR After BLAT 
Filter 
Percent Decrease in 
FDR 
dataset 1 gsnap 10 10 2 Rmsk 2.02 ± 0.18 1.86 ± 0.10 7.46 ± 5.45 
dataset 1 gsnap 10 10 2 Not in Rmsk 1.92 ± 0.05 1.65 ± 0.02 14.11 ± 1.27 
dataset 1 gsnap 10 10 2 Total 1.92 ± 0.06 1.66 ± 0.02 13.76 ± 1.52 
dataset 1 rum 10 10 2 Rmsk 6.06 ± 0.71 5.64 ± 1.00 7.31 ± 6.14 
dataset 1 rum 10 10 2 Not in Rmsk 5.41 ± 0.06 4.01 ± 0.06 25.77 ± 0.33 
dataset 1 rum 10 10 2 Total 5.45 ± 0.10 4.11 ± 0.11 24.65 ± 0.71 
dataset 1 tophat2 10 10 2 Rmsk 1.43 ± 0.17 1.48 ± 0.21 -2.73 ± 3.84 
dataset 1 tophat2 10 10 2 Not in Rmsk 1.24 ± 0.04 1.19 ± 0.04 4.52 ± 0.33 
dataset 1 tophat2 10 10 2 Total 1.26 ± 0.04 1.20 ± 0.05 4.25 ± 0.29 
dataset 1 gsnap 10 20 2 Rmsk 1.68 ± 0.20 1.50 ± 0.13 10.25 ± 4.92 
dataset 1 gsnap 10 20 2 Not in Rmsk 1.61 ± 0.05 1.34 ± 0.04 16.72 ± 1.31 
dataset 1 gsnap 10 20 2 Total 1.61 ± 0.06 1.35 ± 0.04 16.38 ± 1.51 
dataset 1 rum 10 20 2 Rmsk 4.97 ± 0.73 4.56 ± 1.01 8.86 ± 7.76 
dataset 1 rum 10 20 2 Not in Rmsk 4.47 ± 0.06 3.05 ± 0.06 31.78 ± 0.46 
dataset 1 rum 10 20 2 Total 4.50 ± 0.09 3.14 ± 0.11 30.35 ± 0.95 
dataset 1 tophat2 10 20 2 Rmsk 1.05 ± 0.13 1.09 ± 0.13 -3.67 ± 3.03 
dataset 1 tophat2 10 20 2 Not in Rmsk 0.87 ± 0.03 0.83 ± 0.03 3.74 ± 0.32 
dataset 1 tophat2 10 20 2 Total 0.88 ± 0.03 0.85 ± 0.03 3.50 ± 0.15 
dataset 1 gsnap 20 10 2 Rmsk 1.58 ± 0.12 1.53 ± 0.07 2.86 ± 4.50 
dataset 1 gsnap 20 10 2 Not in Rmsk 1.55 ± 0.04 1.38 ± 0.02 11.06 ± 1.61 
dataset 1 gsnap 20 10 2 Total 1.55 ± 0.05 1.39 ± 0.01 10.62 ± 1.80 
dataset 1 rum 20 10 2 Rmsk 5.82 ± 0.84 5.56 ± 1.17 4.97 ± 7.08 
dataset 1 rum 20 10 2 Not in Rmsk 4.95 ± 0.06 3.77 ± 0.06 23.68 ± 0.39 
dataset 1 rum 20 10 2 Total 5.00 ± 0.11 3.87 ± 0.12 22.61 ± 0.69 
dataset 1 tophat2 20 10 2 Rmsk 1.52 ± 0.21 1.52 ± 0.21 -0.47 ± 4.57 
dataset 1 tophat2 20 10 2 Not in Rmsk 1.21 ± 0.03 1.16 ± 0.03 4.28 ± 0.51 
dataset 1 tophat2 20 10 2 Total 1.23 ± 0.04 1.18 ± 0.04 4.22 ± 0.27 
dataset 1 gsnap 20 20 4 Rmsk 1.20 ± 0.10 1.15 ± 0.06 3.93 ± 5.10 
dataset 1 gsnap 20 20 4 Not in Rmsk 1.23 ± 0.04 1.07 ± 0.02 13.22 ± 1.70 
dataset 1 gsnap 20 20 4 Total 1.23 ± 0.05 1.07 ± 0.03 12.70 ± 1.89 
dataset 1 rum 20 20 4 Rmsk 4.54 ± 0.86 4.29 ± 1.19 6.40 ± 8.84 
dataset 1 rum 20 20 4 Not in Rmsk 3.90 ± 0.06 2.74 ± 0.05 29.89 ± 0.52 
dataset 1 rum 20 20 4 Total 3.95 ± 0.09 2.82 ± 0.11 28.49 ± 1.06 
dataset 1 tophat2 20 20 4 Rmsk 1.11 ± 0.13 1.13 ± 0.13 -1.44 ± 3.84 
dataset 1 tophat2 20 20 4 Not in Rmsk 0.82 ± 0.02 0.79 ± 0.02 3.48 ± 0.46 
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Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
FDR Before BLAT 
Filter 
FDR After BLAT 
Filter 
Percent Decrease in 
FDR 
dataset 1 tophat2 20 20 4 Total 0.83 ± 0.03 0.80 ± 0.03 3.47 ± 0.20 
dataset 2 gsnap 10 10 2 Rmsk 18.77 ± 0.17 18.62 ± 0.20 0.79 ± 0.19 
dataset 2 gsnap 10 10 2 Not in Rmsk 13.57 ± 0.13 12.90 ± 0.12 4.93 ± 0.16 
dataset 2 gsnap 10 10 2 Total 14.94 ± 0.10 14.13 ± 0.10 5.48 ± 0.14 
dataset 2 rum 10 10 2 Rmsk 37.54 ± 0.27 33.62 ± 0.29 10.45 ± 0.28 
dataset 2 rum 10 10 2 Not in Rmsk 26.95 ± 0.26 23.98 ± 0.26 11.05 ± 0.11 
dataset 2 rum 10 10 2 Total 29.87 ± 0.24 26.13 ± 0.21 12.54 ± 0.07 
dataset 2 tophat2 10 10 2 Rmsk 36.97 ± 0.07 36.58 ± 0.10 1.06 ± 0.41 
dataset 2 tophat2 10 10 2 Not in Rmsk 32.34 ± 0.15 32.23 ± 0.15 0.34 ± 0.00 
dataset 2 tophat2 10 10 2 Total 32.94 ± 0.13 32.68 ± 0.12 0.78 ± 0.05 
dataset 2 gsnap 10 20 2 Rmsk 3.48 ± 0.05 3.36 ± 0.01 3.33 ± 1.38 
dataset 2 gsnap 10 20 2 Not in Rmsk 3.45 ± 0.08 2.68 ± 0.05 22.37 ± 0.41 
dataset 2 gsnap 10 20 2 Total 3.46 ± 0.07 2.82 ± 0.04 18.48 ± 0.51 
dataset 2 rum 10 20 2 Rmsk 12.91 ± 0.33 9.42 ± 0.29 27.06 ± 0.46 
dataset 2 rum 10 20 2 Not in Rmsk 10.48 ± 0.09 7.02 ± 0.08 33.03 ± 0.42 
dataset 2 rum 10 20 2 Total 11.09 ± 0.13 7.51 ± 0.08 32.28 ± 0.28 
dataset 2 tophat2 10 20 2 Rmsk 8.94 ± 0.09 8.62 ± 0.14 3.62 ± 2.34 
dataset 2 tophat2 10 20 2 Not in Rmsk 6.04 ± 0.06 5.92 ± 0.05 1.90 ± 0.15 
dataset 2 tophat2 10 20 2 Total 6.40 ± 0.06 6.19 ± 0.03 3.25 ± 0.47 
dataset 2 gsnap 20 10 2 Rmsk 7.04 ± 0.18 6.90 ± 0.19 1.92 ± 0.74 
dataset 2 gsnap 20 10 2 Not in Rmsk 4.83 ± 0.08 4.26 ± 0.05 11.80 ± 0.74 
dataset 2 gsnap 20 10 2 Total 5.26 ± 0.09 4.67 ± 0.06 11.18 ± 0.60 
dataset 2 rum 20 10 2 Rmsk 25.42 ± 0.49 21.48 ± 0.68 15.50 ± 1.11 
dataset 2 rum 20 10 2 Not in Rmsk 16.60 ± 0.21 12.93 ± 0.17 22.13 ± 0.11 
dataset 2 rum 20 10 2 Total 18.38 ± 0.21 14.33 ± 0.20 22.07 ± 0.24 
dataset 2 tophat2 20 10 2 Rmsk 18.00 ± 0.74 17.56 ± 1.17 2.52 ± 2.83 
dataset 2 tophat2 20 10 2 Not in Rmsk 13.79 ± 0.28 13.62 ± 0.28 1.24 ± 0.05 
dataset 2 tophat2 20 10 2 Total 14.18 ± 0.30 13.92 ± 0.31 1.86 ± 0.22 
dataset 2 gsnap 20 20 4 Rmsk 1.98 ± 0.16 1.88 ± 0.17 5.57 ± 1.32 
dataset 2 gsnap 20 20 4 Not in Rmsk 2.02 ± 0.12 1.48 ± 0.07 26.99 ± 1.02 
dataset 2 gsnap 20 20 4 Total 2.02 ± 0.12 1.54 ± 0.08 23.70 ± 0.67 
dataset 2 rum 20 20 4 Rmsk 10.65 ± 0.54 7.93 ± 0.62 25.55 ± 2.02 
dataset 2 rum 20 20 4 Not in Rmsk 8.18 ± 0.10 4.92 ± 0.08 39.93 ± 0.36 
dataset 2 rum 20 20 4 Total 8.65 ± 0.13 5.38 ± 0.11 37.79 ± 0.31 
dataset 2 tophat2 20 20 4 Rmsk 4.40 ± 0.30 4.17 ± 0.34 5.16 ± 6.49 
dataset 2 tophat2 20 20 4 Not in Rmsk 2.39 ± 0.05 2.27 ± 0.05 4.95 ± 0.45 
dataset 2 tophat2 20 20 4 Total 2.57 ± 0.06 2.41 ± 0.07 6.19 ± 1.25 
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Pseudogenes are non-functioning homologs of genes that are either not expressed 
or unable to be translated into protein product, and their high sequence similarity to 
functioning genes can result in false positive sequence difference calls. We observed that 
the removal of all sequence differences lying within pseudogenes as annotated by 
Gencode version 13 (Harrow et al. 2006) decreases the FDR of RDD detection using 
GSNAP by approximately 45 to 50% in both datasets (Table 4.13).  
Misalignments near exon-exon junctions can commonly lead to the identification 
of false positive sequence differences. We evaluated the effect of such incorrectly spliced 
alignments on sequence difference detection and found that roughly 3% of the false 
positives identified by GSNAP in dataset 1 and 5% of those found in dataset 2 are in 
intronic sequences within 6 bp of exon-exon junctions. Removal of all sites in introns 
within 6 bp of splice junctions leads to a roughly 2 to 4% decrease in the false discovery 
rate for GSNAP. The other two aligners, RUM and Tophat2, are more robust to 
misalignments near splice junctions, as less than 1 to 2% of false positives detected by 
either aligner are in introns near exon-exon junctions (Table 4.14). 
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Table 4.13 Effect of removing RDDs in pseudogenes on the false discovery rate of sequence difference detection. 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count 
FDR Before 
Pseudogene Filter (%) 
FDR After Pseudogene 
Filter (%) 
Percent Decrease in 
FDR 
dataset 1 gsnap 10 10 2 1.92 ± 0.06 0.95 ± 0.05 50.72 ± 1.41 
dataset 1 rum 10 10 2 5.45 ± 0.10 2.35 ± 0.01 56.92 ± 0.94 
dataset 1 tophat2 10 10 2 1.26 ± 0.04 0.85 ± 0.03 32.50 ± 1.62 
dataset 1 gsnap 10 20 2 1.61 ± 0.06 0.74 ± 0.04 53.89 ± 1.14 
dataset 1 rum 10 20 2 4.50 ± 0.09 1.67 ± 0.01 62.98 ± 0.80 
dataset 1 tophat2 10 20 2 0.88 ± 0.03 0.57 ± 0.02 35.23 ± 1.07 
dataset 1 gsnap 20 10 2 1.55 ± 0.05 0.79 ± 0.05 49.18 ± 1.79 
dataset 1 rum 20 10 2 5.00 ± 0.11 2.24 ± 0.05 55.27 ± 1.86 
dataset 1 tophat2 20 10 2 1.23 ± 0.04 0.87 ± 0.04 28.83 ± 1.74 
dataset 1 gsnap 20 20 4 1.23 ± 0.05 0.58 ± 0.04 52.47 ± 1.73 
dataset 1 rum 20 20 4 3.95 ± 0.09 1.50 ± 0.03 62.01 ± 1.70 
dataset 1 tophat2 20 20 4 0.83 ± 0.03 0.58 ± 0.03 30.62 ± 1.48 
dataset 2 gsnap 10 10 2 14.94 ± 0.10 13.90 ± 0.11 6.99 ± 0.16 
dataset 2 rum 10 10 2 29.87 ± 0.24 25.21 ± 0.28 15.61 ± 0.26 
dataset 2 tophat2 10 10 2 32.94 ± 0.13 32.62 ± 0.14 0.96 ± 0.03 
dataset 2 gsnap 10 20 2 3.46 ± 0.07 2.39 ± 0.06 30.91 ± 0.39 
dataset 2 rum 10 20 2 11.09 ± 0.13 7.39 ± 0.16 33.40 ± 0.75 
dataset 2 tophat2 10 20 2 6.40 ± 0.06 5.98 ± 0.06 6.58 ± 0.17 
dataset 2 gsnap 20 10 2 5.26 ± 0.09 4.19 ± 0.05 20.45 ± 0.96 
dataset 2 rum 20 10 2 18.38 ± 0.21 13.44 ± 0.21 26.89 ± 0.41 
dataset 2 tophat2 20 10 2 14.18 ± 0.30 13.62 ± 0.36 3.97 ± 0.53 
dataset 2 gsnap 20 20 4 2.02 ± 0.12 1.10 ± 0.05 45.32 ± 1.81 
dataset 2 rum 20 20 4 8.65 ± 0.13 5.04 ± 0.14 41.72 ± 0.70 
dataset 2 tophat2 20 20 4 2.57 ± 0.06 2.08 ± 0.06 19.01 ± 1.00 
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Table 4.14 Effect of removing RDDs near exon junctions on the false discovery rate of sequence difference detection. 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count 
Percent of false 
positives near 
junctions 
FDR before 
filter (%) 
FDR after filter 
(%) 
Percent FDR 
decrease 
dataset 1 gsnap 10 10 2 2.64 ± 0.19 1.92 ± 0.06 1.88 ± 0.06 2.34 ± 0.19 
dataset 1 rum 10 10 2 1.12 ± 0.03 5.45 ± 0.10 5.41 ± 0.10 0.82 ± 0.02 
dataset 1 tophat2 10 10 2 0.55 ± 0.14 1.26 ± 0.04 1.25 ± 0.04 0.24 ± 0.15 
dataset 1 gsnap 10 20 2 3.20 ± 0.24 1.61 ± 0.06 1.57 ± 0.06 2.90 ± 0.24 
dataset 1 rum 10 20 2 1.35 ± 0.04 4.50 ± 0.09 4.46 ± 0.09 1.05 ± 0.04 
dataset 1 tophat2 10 20 2 0.55 ± 0.18 0.88 ± 0.03 0.87 ± 0.03 0.24 ± 0.18 
dataset 1 gsnap 20 10 2 1.85 ± 0.19 1.55 ± 0.05 1.53 ± 0.05 1.56 ± 0.19 
dataset 1 rum 20 10 2 0.72 ± 0.09 5.00 ± 0.11 4.98 ± 0.11 0.43 ± 0.08 
dataset 1 tophat2 20 10 2 0.66 ± 0.06 1.23 ± 0.04 1.22 ± 0.04 0.32 ± 0.07 
dataset 1 gsnap 20 20 4 2.29 ± 0.23 1.23 ± 0.05 1.20 ± 0.05 2.01 ± 0.22 
dataset 1 rum 20 20 4 0.83 ± 0.12 3.95 ± 0.09 3.92 ± 0.10 0.54 ± 0.11 
dataset 1 tophat2 20 20 4 0.61 ± 0.07 0.83 ± 0.03 0.83 ± 0.03 0.28 ± 0.06 
dataset 2 gsnap 10 10 2 1.47 ± 0.06 14.94 ± 0.10 14.80 ± 0.11 0.98 ± 0.06 
dataset 2 rum 10 10 2 1.20 ± 0.06 29.87 ± 0.24 29.69 ± 0.23 0.62 ± 0.04 
dataset 2 tophat2 10 10 2 0.41 ± 0.03 32.94 ± 0.13 32.93 ± 0.14 0.03 ± 0.03 
dataset 2 gsnap 10 20 2 4.50 ± 0.24 3.46 ± 0.07 3.32 ± 0.08 4.06 ± 0.23 
dataset 2 rum 10 20 2 2.53 ± 0.15 11.09 ± 0.13 10.87 ± 0.11 1.97 ± 0.14 
dataset 2 tophat2 10 20 2 0.57 ± 0.14 6.40 ± 0.06 6.39 ± 0.05 0.19 ± 0.15 
dataset 2 gsnap 20 10 2 2.42 ± 0.11 5.26 ± 0.09 5.16 ± 0.09 1.98 ± 0.09 
dataset 2 rum 20 10 2 1.39 ± 0.07 18.38 ± 0.21 18.23 ± 0.20 0.86 ± 0.06 
dataset 2 tophat2 20 10 2 0.50 ± 0.04 14.18 ± 0.30 14.16 ± 0.29 0.11 ± 0.03 
dataset 2 gsnap 20 20 4 4.47 ± 0.46 2.02 ± 0.12 1.93 ± 0.12 4.08 ± 0.43 
dataset 2 rum 20 20 4 2.02 ± 0.12 8.65 ± 0.13 8.51 ± 0.12 1.54 ± 0.12 
dataset 2 tophat2 20 20 4 0.84 ± 0.61 2.57 ± 0.06 2.56 ± 0.06 0.46 ± 0.60 
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Lastly, we analyzed the effect of implementing the various bioinformatics filters 
altogether on eliminating false positive RDDs. In analyzing the RDDs obtained using the 
‘minimum coverage of 20x, minimum level of 20%, and minimum of 4 reads containing 
the sequence difference allele’, we observed that the BLAT filtering method, removal of 
differences in pseudogenes, and elimination of intronic sites within 6 bp of exon 
junctions in combination removed nearly 30 to 70% of false positives depending on the 
aligner versus roughly 3 to 7% of true positives (Table 4.15). Overall, these various 
filters led to a decrease of approximately 50 to 70% in the FDR of RDD detection for 
GSNAP and RUM and a decrease of roughly 30% for Tophat2 (Table 4.16). While these 
various filters are successful in targeting false versus true positives for removal, a 
sizeable percentage of false positives remain. 
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Table 4.15 Percentage of true versus false positives removed by BLAT filter, pseudogene filter, and removal of intronic sites within 6 bp of 
exon junctions. 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
Percent of True Positives 
Removed 
Percent of False Positives 
Removed 
dataset 1 gsnap 10 10 2 Rmsk 21.78 ± 0.45 53.56 ± 4.58 
dataset 1 gsnap 10 10 2 Not in Rmsk 2.16 ± 0.03 60.37 ± 0.44 
dataset 1 gsnap 10 10 2 Total 3.55 ± 0.08 59.88 ± 0.68 
dataset 1 rum 10 10 2 Rmsk 21.79 ± 0.22 65.95 ± 6.68 
dataset 1 rum 10 10 2 Not in Rmsk 2.25 ± 0.04 66.58 ± 0.44 
dataset 1 rum 10 10 2 Total 3.61 ± 0.08 66.56 ± 0.56 
dataset 1 tophat2 10 10 2 Rmsk 20.75 ± 0.53 47.07 ± 5.00 
dataset 1 tophat2 10 10 2 Not in Rmsk 1.83 ± 0.01 37.22 ± 1.19 
dataset 1 tophat2 10 10 2 Total 2.95 ± 0.03 37.91 ± 1.34 
dataset 1 gsnap 10 20 2 Rmsk 21.70 ± 0.49 55.45 ± 3.15 
dataset 1 gsnap 10 20 2 Not in Rmsk 2.11 ± 0.03 64.54 ± 0.39 
dataset 1 gsnap 10 20 2 Total 3.50 ± 0.09 63.88 ± 0.34 
dataset 1 rum 10 20 2 Rmsk 21.64 ± 0.26 68.17 ± 5.38 
dataset 1 rum 10 20 2 Not in Rmsk 2.15 ± 0.04 72.45 ± 0.52 
dataset 1 rum 10 20 2 Total 3.50 ± 0.08 72.15 ± 0.45 
dataset 1 tophat2 10 20 2 Rmsk 20.58 ± 0.60 45.62 ± 2.05 
dataset 1 tophat2 10 20 2 Not in Rmsk 1.79 ± 0.01 39.18 ± 0.98 
dataset 1 tophat2 10 20 2 Total 2.90 ± 0.03 39.64 ± 1.02 
dataset 1 gsnap 20 10 2 Rmsk 21.85 ± 0.56 50.33 ± 5.77 
dataset 1 gsnap 20 10 2 Not in Rmsk 1.97 ± 0.05 56.58 ± 0.63 
dataset 1 gsnap 20 10 2 Total 3.29 ± 0.11 56.15 ± 0.96 
dataset 1 rum 20 10 2 Rmsk 21.50 ± 0.17 65.55 ± 8.86 
dataset 1 rum 20 10 2 Not in Rmsk 2.06 ± 0.05 64.39 ± 0.94 
dataset 1 rum 20 10 2 Total 3.32 ± 0.08 64.52 ± 1.31 
dataset 1 tophat2 20 10 2 Rmsk 18.90 ± 0.70 46.03 ± 4.65 
dataset 1 tophat2 20 10 2 Not in Rmsk 1.70 ± 0.02 33.60 ± 1.83 
dataset 1 tophat2 20 10 2 Total 2.61 ± 0.03 34.44 ± 1.48 
dataset 1 gsnap 20 20 4 Rmsk 21.77 ± 0.67 50.99 ± 5.82 
dataset 1 gsnap 20 20 4 Not in Rmsk 1.92 ± 0.04 60.59 ± 0.17 
dataset 1 gsnap 20 20 4 Total 3.24 ± 0.11 59.96 ± 0.55 
dataset 1 rum 20 20 4 Rmsk 21.33 ± 0.22 68.03 ± 8.08 
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Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
Percent of True Positives 
Removed 
Percent of False Positives 
Removed 
dataset 1 rum 20 20 4 Not in Rmsk 1.96 ± 0.05 70.78 ± 1.00 
dataset 1 rum 20 20 4 Total 3.21 ± 0.08 70.64 ± 1.13 
dataset 1 tophat2 20 20 4 Rmsk 18.56 ± 0.61 45.91 ± 2.00 
dataset 1 tophat2 20 20 4 Not in Rmsk 1.65 ± 0.02 34.29 ± 1.45 
dataset 1 tophat2 20 20 4 Total 2.54 ± 0.05 35.12 ± 1.16 
dataset 2 gsnap 10 10 2 Rmsk 27.10 ± 0.48 30.25 ± 0.32 
dataset 2 gsnap 10 10 2 Not in Rmsk 2.47 ± 0.06 15.38 ± 0.19 
dataset 2 gsnap 10 10 2 Total 8.70 ± 0.05 20.32 ± 0.23 
dataset 2 rum 10 10 2 Rmsk 25.82 ± 0.34 48.21 ± 0.12 
dataset 2 rum 10 10 2 Not in Rmsk 2.62 ± 0.08 31.96 ± 0.16 
dataset 2 rum 10 10 2 Total 8.31 ± 0.04 37.59 ± 0.11 
dataset 2 tophat2 10 10 2 Rmsk 25.59 ± 0.47 27.53 ± 0.67 
dataset 2 tophat2 10 10 2 Not in Rmsk 2.37 ± 0.08 4.18 ± 0.20 
dataset 2 tophat2 10 10 2 Total 5.21 ± 0.07 7.60 ± 0.13 
dataset 2 gsnap 10 20 2 Rmsk 27.09 ± 0.41 40.71 ± 1.57 
dataset 2 gsnap 10 20 2 Not in Rmsk 2.42 ± 0.05 48.04 ± 0.86 
dataset 2 gsnap 10 20 2 Total 8.67 ± 0.03 46.17 ± 0.34 
dataset 2 rum 10 20 2 Rmsk 25.64 ± 0.25 60.79 ± 0.43 
dataset 2 rum 10 20 2 Not in Rmsk 2.47 ± 0.06 58.33 ± 0.58 
dataset 2 rum 10 20 2 Total 8.18 ± 0.03 59.05 ± 0.29 
dataset 2 tophat2 10 20 2 Rmsk 25.37 ± 0.47 34.02 ± 1.71 
dataset 2 tophat2 10 20 2 Not in Rmsk 2.29 ± 0.04 10.48 ± 0.30 
dataset 2 tophat2 10 20 2 Total 5.12 ± 0.05 14.62 ± 0.46 
dataset 2 gsnap 20 10 2 Rmsk 26.81 ± 0.70 37.56 ± 1.00 
dataset 2 gsnap 20 10 2 Not in Rmsk 2.36 ± 0.08 31.41 ± 1.33 
dataset 2 gsnap 20 10 2 Total 7.05 ± 0.08 33.02 ± 1.19 
dataset 2 rum 20 10 2 Rmsk 25.35 ± 0.54 55.28 ± 0.74 
dataset 2 rum 20 10 2 Not in Rmsk 2.52 ± 0.08 47.47 ± 0.11 
dataset 2 rum 20 10 2 Total 6.73 ± 0.09 49.65 ± 0.14 
dataset 2 tophat2 20 10 2 Rmsk 23.75 ± 0.98 32.07 ± 1.83 
dataset 2 tophat2 20 10 2 Not in Rmsk 2.43 ± 0.09 7.71 ± 0.73 
dataset 2 tophat2 20 10 2 Total 4.33 ± 0.16 10.58 ± 0.66 
dataset 2 gsnap 20 20 4 Rmsk 26.81 ± 0.59 54.78 ± 0.95 
dataset 2 gsnap 20 20 4 Not in Rmsk 2.31 ± 0.06 59.40 ± 2.00 
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Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
Percent of True Positives 
Removed 
Percent of False Positives 
Removed 
dataset 2 gsnap 20 20 4 Total 7.00 ± 0.06 58.54 ± 1.80 
dataset 2 rum 20 20 4 Rmsk 25.13 ± 0.42 64.96 ± 0.89 
dataset 2 rum 20 20 4 Not in Rmsk 2.37 ± 0.06 66.82 ± 0.34 
dataset 2 rum 20 20 4 Total 6.56 ± 0.06 66.38 ± 0.13 
dataset 2 tophat2 20 20 4 Rmsk 23.53 ± 1.07 49.60 ± 7.88 
dataset 2 tophat2 20 20 4 Not in Rmsk 2.31 ± 0.05 23.43 ± 1.23 
dataset 2 tophat2 20 20 4 Total 4.18 ± 0.13 27.49 ± 0.30 
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Table 4.16 Effect of BLAT filter, pseudogene filter, and removal of intronic sites within 6 bp of exon junctions on FDR of RDD detection. 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
FDR Before BLAT 
Filter (%) 
FDR After BLAT 
Filter (%) 
Percent Decrease in 
FDR 
dataset 1 gsnap 10 10 2 Rmsk 2.02 ± 0.18 1.20 ± 0.10 40.12 ± 6.15 
dataset 1 gsnap 10 10 2 Not in Rmsk 1.92 ± 0.05 0.79 ± 0.03 59.03 ± 0.48 
dataset 1 gsnap 10 10 2 Total 1.92 ± 0.06 0.81 ± 0.03 57.93 ± 0.75 
dataset 1 rum 10 10 2 Rmsk 6.06 ± 0.71 2.70 ± 0.36 54.95 ± 8.50 
dataset 1 rum 10 10 2 Not in Rmsk 5.41 ± 0.06 1.92 ± 0.02 64.55 ± 0.45 
dataset 1 rum 10 10 2 Total 5.45 ± 0.10 1.96 ± 0.01 64.02 ± 0.59 
dataset 1 tophat2 10 10 2 Rmsk 1.43 ± 0.17 0.96 ± 0.04 32.92 ± 5.86 
dataset 1 tophat2 10 10 2 Not in Rmsk 1.24 ± 0.04 0.80 ± 0.03 35.76 ± 1.21 
dataset 1 tophat2 10 10 2 Total 1.26 ± 0.04 0.81 ± 0.03 35.73 ± 1.38 
dataset 1 gsnap 10 20 2 Rmsk 1.68 ± 0.20 0.96 ± 0.08 42.67 ± 4.34 
dataset 1 gsnap 10 20 2 Not in Rmsk 1.61 ± 0.05 0.59 ± 0.03 63.40 ± 0.41 
dataset 1 gsnap 10 20 2 Total 1.61 ± 0.06 0.61 ± 0.03 62.18 ± 0.37 
dataset 1 rum 10 20 2 Rmsk 4.97 ± 0.73 2.05 ± 0.15 58.16 ± 6.81 
dataset 1 rum 10 20 2 Not in Rmsk 4.47 ± 0.06 1.30 ± 0.01 70.91 ± 0.54 
dataset 1 rum 10 20 2 Total 4.50 ± 0.09 1.34 ± 0.01 70.19 ± 0.48 
dataset 1 tophat2 10 20 2 Rmsk 1.05 ± 0.13 0.72 ± 0.07 31.31 ± 2.05 
dataset 1 tophat2 10 20 2 Not in Rmsk 0.87 ± 0.03 0.54 ± 0.02 37.86 ± 1.00 
dataset 1 tophat2 10 20 2 Total 0.88 ± 0.03 0.55 ± 0.02 37.63 ± 1.04 
dataset 1 gsnap 20 10 2 Rmsk 1.58 ± 0.12 1.01 ± 0.15 36.05 ± 7.82 
dataset 1 gsnap 20 10 2 Not in Rmsk 1.55 ± 0.04 0.69 ± 0.03 55.32 ± 0.67 
dataset 1 gsnap 20 10 2 Total 1.55 ± 0.05 0.71 ± 0.03 54.27 ± 1.05 
dataset 1 rum 20 10 2 Rmsk 5.82 ± 0.84 2.58 ± 0.43 54.68 ± 11.28 
dataset 1 rum 20 10 2 Not in Rmsk 4.95 ± 0.06 1.86 ± 0.03 62.46 ± 0.98 
dataset 1 rum 20 10 2 Total 5.00 ± 0.11 1.89 ± 0.03 62.10 ± 1.38 
dataset 1 tophat2 20 10 2 Rmsk 1.52 ± 0.21 1.01 ± 0.06 33.12 ± 5.52 
dataset 1 tophat2 20 10 2 Not in Rmsk 1.21 ± 0.03 0.82 ± 0.04 32.18 ± 1.87 
dataset 1 tophat2 20 10 2 Total 1.23 ± 0.04 0.83 ± 0.04 32.41 ± 1.53 
dataset 1 gsnap 20 20 4 Rmsk 1.20 ± 0.10 0.76 ± 0.11 37.03 ± 7.98 
dataset 1 gsnap 20 20 4 Not in Rmsk 1.23 ± 0.04 0.50 ± 0.02 59.52 ± 0.19 
dataset 1 gsnap 20 20 4 Total 1.23 ± 0.05 0.51 ± 0.02 58.32 ± 0.62 
dataset 1 rum 20 20 4 Rmsk 4.54 ± 0.86 1.84 ± 0.21 58.28 ± 10.25 
dataset 1 rum 20 20 4 Not in Rmsk 3.90 ± 0.06 1.20 ± 0.02 69.35 ± 1.03 
dataset 1 rum 20 20 4 Total 3.95 ± 0.09 1.23 ± 0.02 68.81 ± 1.19 
dataset 1 tophat2 20 20 4 Rmsk 1.11 ± 0.13 0.74 ± 0.06 33.34 ± 2.08 
dataset 1 tophat2 20 20 4 Not in Rmsk 0.82 ± 0.02 0.55 ± 0.03 33.00 ± 1.48 
 160 
Dataset Aligner Minimum Coverage 
Minimum 
Level 
Minimum 
RDD Count Region 
FDR Before BLAT 
Filter (%) 
FDR After BLAT 
Filter (%) 
Percent Decrease in 
FDR 
dataset 1 tophat2 20 20 4 Total 0.83 ± 0.03 0.56 ± 0.03 33.24 ± 1.22 
dataset 2 gsnap 10 10 2 Rmsk 18.77 ± 0.17 18.10 ± 0.20 3.53 ± 0.17 
dataset 2 gsnap 10 10 2 Not in Rmsk 13.57 ± 0.13 11.99 ± 0.14 11.65 ± 0.23 
dataset 2 gsnap 10 10 2 Total 14.94 ± 0.10 13.30 ± 0.11 11.04 ± 0.23 
dataset 2 rum 10 10 2 Rmsk 37.54 ± 0.27 29.56 ± 0.28 21.26 ± 0.28 
dataset 2 rum 10 10 2 Not in Rmsk 26.95 ± 0.26 20.50 ± 0.26 23.96 ± 0.24 
dataset 2 rum 10 10 2 Total 29.87 ± 0.24 22.48 ± 0.22 24.75 ± 0.16 
dataset 2 tophat2 10 10 2 Rmsk 36.97 ± 0.07 36.36 ± 0.19 1.66 ± 0.59 
dataset 2 tophat2 10 10 2 Not in Rmsk 32.34 ± 0.15 31.93 ± 0.17 1.26 ± 0.09 
dataset 2 tophat2 10 10 2 Total 32.94 ± 0.13 32.38 ± 0.14 1.70 ± 0.07 
dataset 2 gsnap 10 20 2 Rmsk 3.48 ± 0.05 2.84 ± 0.04 18.15 ± 2.19 
dataset 2 gsnap 10 20 2 Not in Rmsk 3.45 ± 0.08 1.87 ± 0.07 45.88 ± 0.90 
dataset 2 gsnap 10 20 2 Total 3.46 ± 0.07 2.07 ± 0.05 40.21 ± 0.38 
dataset 2 rum 10 20 2 Rmsk 12.91 ± 0.33 7.25 ± 0.24 43.83 ± 0.76 
dataset 2 rum 10 20 2 Not in Rmsk 10.48 ± 0.09 4.77 ± 0.10 54.55 ± 0.65 
dataset 2 rum 10 20 2 Total 11.09 ± 0.13 5.27 ± 0.09 52.48 ± 0.35 
dataset 2 tophat2 10 20 2 Rmsk 8.94 ± 0.09 7.99 ± 0.17 10.66 ± 2.46 
dataset 2 tophat2 10 20 2 Not in Rmsk 6.04 ± 0.06 5.56 ± 0.05 7.91 ± 0.26 
dataset 2 tophat2 10 20 2 Total 6.40 ± 0.06 5.80 ± 0.03 9.43 ± 0.47 
dataset 2 gsnap 20 10 2 Rmsk 7.04 ± 0.18 6.06 ± 0.14 13.80 ± 0.82 
dataset 2 gsnap 20 10 2 Not in Rmsk 4.83 ± 0.08 3.44 ± 0.08 28.73 ± 1.39 
dataset 2 gsnap 20 10 2 Total 5.26 ± 0.09 3.85 ± 0.06 26.86 ± 1.20 
dataset 2 rum 20 10 2 Rmsk 25.42 ± 0.49 16.96 ± 0.68 33.30 ± 1.36 
dataset 2 rum 20 10 2 Not in Rmsk 16.60 ± 0.21 9.69 ± 0.15 41.64 ± 0.18 
dataset 2 rum 20 10 2 Total 18.38 ± 0.21 10.84 ± 0.17 41.02 ± 0.25 
dataset 2 tophat2 20 10 2 Rmsk 18.00 ± 0.74 16.37 ± 1.16 9.12 ± 3.08 
dataset 2 tophat2 20 10 2 Not in Rmsk 13.79 ± 0.28 13.14 ± 0.35 4.70 ± 0.64 
dataset 2 tophat2 20 10 2 Total 14.18 ± 0.30 13.38 ± 0.37 5.66 ± 0.60 
dataset 2 gsnap 20 20 4 Rmsk 1.98 ± 0.16 1.23 ± 0.09 37.75 ± 0.87 
dataset 2 gsnap 20 20 4 Not in Rmsk 2.02 ± 0.12 0.85 ± 0.05 57.95 ± 2.06 
dataset 2 gsnap 20 20 4 Total 2.02 ± 0.12 0.91 ± 0.05 54.92 ± 1.92 
dataset 2 rum 20 20 4 Rmsk 10.65 ± 0.54 5.29 ± 0.41 50.38 ± 1.57 
dataset 2 rum 20 20 4 Not in Rmsk 8.18 ± 0.10 2.94 ± 0.07 64.08 ± 0.40 
dataset 2 rum 20 20 4 Total 8.65 ± 0.13 3.29 ± 0.07 61.91 ± 0.20 
dataset 2 tophat2 20 20 4 Rmsk 4.40 ± 0.30 2.93 ± 0.36 33.13 ± 9.91 
dataset 2 tophat2 20 20 4 Not in Rmsk 2.39 ± 0.05 1.88 ± 0.04 21.21 ± 1.23 
dataset 2 tophat2 20 20 4 Total 2.57 ± 0.06 1.96 ± 0.05 23.84 ± 0.32 
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4.3.7 Effect of non-random sequencing errors on FDR of RDD detection 
Our analysis of the simulated RNA-Seq datasets allowed us to evaluate the 
relative contribution of alignment and sequencing error on RDD detection. In particular, 
we assumed a sequencing error profile in which errors are generated and independently. 
However, previous studies have indicated that the sequencing errors introduced by 
Illumina next-generation sequencing platforms may occur in a sequence-specific or non-
independent manner (Minoche et al. 2011; Nakamura et al. 2011). To estimate the effect 
of such non-random and non-independent sequencing errors on the identification of 
RDDs, we analyzed two replicates of a deeply sequenced dataset (approximately 2,000 to 
3,000x coverage on average) comprising 1,062 human cDNA clones (see Materials and 
Methods). We observed an overall error rate of 3.8 x 10-4 and 1.2 x 10-3 in the two 
datasets respectively across sites with a minimum coverage of 1,000x. Furthermore, we 
found that these errors are distributed in neither a random nor independent way (see 
Materials and Methods). In particular, we calculated that the frequency of errors 
introduced at levels of 20% or greater is 3.12 x 10-5 (average across two replicates). This 
frequency is comparable to the numbers of RDDs previously reported by others. As our 
methods for RDD detection cannot discriminate between such errors and RDDs, these 
non-random errors will play a nontrivial impact on the FDR of RDD detection. 
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4.3.8 Evaluation of RDDs in human lymphoblastoid cell line 
Lastly, to evaluate the performance of our pipeline on a real experimental dataset, 
we analyzed the human lymphoblastoid cell line GM12878, for which deep DNA and 
RNA sequence is readily available (Dunham et al. 2012). We used the parameters and 
thresholds as determined from our previous synthetic data analyses to identify RDDs. In 
particular, we aligned two replicates of RNA-Seq data containing approximately 120 
million 76 bp paired-end reads each using GSNAP (Table 4.17) and identified RDDs 
using a ‘minimum coverage of 20x, minimum level of 20%, and minimum of 4 reads 
containing the sequence difference base’ threshold. Sequence differences found in 
dbSNP137 (Sherry et al. 2001) were removed from consideration. Furthermore, to 
minimize the detection of sequence differences resulting from sequencing error, we 
focused our analysis on those differences that are observed in both replicates (Table 
4.18). Overall, we preliminarily identified a total of 12,480 RDDs in the two replicates. 
We separated the differences by type into two groups: A-to-G sequence differences and 
noncanonical sequence differences, or changes that cannot be explained by known 
mechanisms. We note that although C-to-T differences can be mediated by APOBEC, 
APOBEC1 is not expressed in this B-cell cell line, with an FPKM value (Trapnell et al. 
2010) of 0 in both replicates. The majority (56.38%) of the sequence differences we 
identified are A-to-G changes and likely to be mediated by RNA editing via ADAR.  
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Table 4.17 Alignment statistics for GM12878 RNA-Seq dataset. 
Replicate Statistic Value 
1 Number of Read Pairs Sequenced 117,876,320 
1 Number of Read Pairs Aligned 106,890,066 
1 Percentage of Read Pairs Aligned 90.68% 
1 Number of Read Pairs Aligned Uniquely 100,040,977 
1 Percentage of Read Pairs Aligned Uniquely 93.59% 
2 Number of Read Pairs Sequenced 131,831,897 
2 Number of Read Pairs Aligned 124,158,569 
2 Percentage of Read Pairs Aligned 94.18% 
2 Number of Read Pairs Aligned Uniquely 115,844,755 
2 Percentage of Read Pairs Aligned Uniquely 93.30% 
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Table 4.18 RNA-DNA sequence differences found in GM12878. 
  Both Replicate 1 Replicate 2 Total 
A>C  646   2,536   1,580   4,762  
A>G  7,036   5,739   10,775   23,550  
A>T  131   354   128   613  
C>A  166   360   166   692  
C>G  286   654   505   1,445  
C>T  492   843   414   1,749  
G>A  563   856   321   1,740  
G>C  200   546   330   1,076  
G>T  169   488   197   854  
T>A  132   362   137   631  
T>C  1,300   2,713   1,843   5,856  
T>G  1,359   3,488   2,636   7,483  
Total  12,480   18,939   19,032   50,451  
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We investigated whether filters we previously identified as effective in removing 
false positive RDDs could explain the sequence differences we observed. Other 
researchers have used these filters in their pipelines to accurately identify RDDs 
(Kleinman et al. 2012; Peng et al. 2012; Ramaswami et al. 2012). The filters we 
implemented include searching with BLAT for regions homologous to the sequence 
flanking the sequence difference (see Materials and Methods), removing intronic sites 
near exon-exon junctions, and eliminating differences in annotated pseudogenes or 
adjacent to homopolymer sequences. We applied the BLAT filter to sequence differences 
found outside of RepeatMasker regions, as we previously showed that this filter is not as 
effective in discriminating between true and false positives within repetitive sequences. 
We observed that approximately 47% of noncanonical differences are removed by one or 
more of these filters, whereas only roughly 14% of A-to-G sites are eliminated (Table 
4.19). The filtering steps that filtered out the greatest percentage of sites are the 
pseudogene and BLAT filters, as nearly 30% of noncanonical sites are removed by each 
filter independently. After taking into consideration all of the filters we used, a total of 
8,933 sequence differences remained, 68% of which are A-to-G edits (Figure 4.11). Of 
these 8,933 differences, the majority (72%) are located within RepeatMasker regions. 
Within RepeatMasker regions, nearly 87% of the differences are A-to-G, as is expected 
due to the phenomenon of editing in human Alu elements (Athanasiadis et al. 2004). In 
contrast, the majority (81%) of sites outside of RepeatMasker are noncanonical 
differences. The distribution of sequence differences we observed are highly concordant 
with other studies, and the most common noncanonical RDD types we observed were A-
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to-C and its complement T-to-G, as previously seen by others (Ju et al. 2011; Kleinman 
et al. 2012; Ramaswami et al. 2012).  
For the remaining RDDs that are not removed by our filtering methods, we asked 
whether features indicative of sequencing error or low-quality mapping are more 
common in noncanonical versus A-to-G sequence differences. Specifically, we noticed 
that many noncanonical sequence differences occur within regions where many of the 
reads overlapping the sequence difference site are either partially mapped via a local 
alignment with clipped bases or mapped with many mismatches (Figure 4.12). To 
investigate the mapping quality near sites of RDDs globally, we calculated for each read 
that overlaps an RDD the number of bases (out of the total 76 bp sequence) that are 
neither clipped nor aligned with a mismatch or indel; we refer to this figure as the number 
of bases aligned properly. We observed that in both replicates, for sequence differences 
in RepeatMasker, the overall number of bases that are aligned properly is higher for A-to-
G changes than for the most of the noncanonical types (Figure 4.13). For sites lying 
outside of RepeatMasker regions, we observe that the number of bases aligned properly 
for noncanonical sequence differences, excluding the more common A-to-C and T-to-G 
types, is generally lower than for that of A-to-G (Figure 4.12). 
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Table 4.19 Number of RDDs removed by various bioinformatics filters. 
  A>G Non-canonical Total 
Total before filters 7,036 5,444 12,480 
Pseudogene filter (removed) 847 (12.04%) 1,959 (35.98%) 2,806 
BLAT filter (removed) 545 (7.75%) 1,722 (31.63%) 2,267 
Homopolymer filter (removed) 32 (0.45%) 205 (3.77%) 237 
Exon junction filter (removed) 30 (0.43%) 88 (1.62%) 118 
Total after filters (remaining) 6,039 (85.83%) 2,894 (53.16%) 8,933 
Total after filters - in RmskRM327 5,560 837 6,397 
Total after filters - not in RmskRM327 479 2,057 2,536 
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Figure 4.11 Distribution of RNA-DNA sequence differences in GM12878. Here we depict the 
distribution of RDDs in GM12878 after removing sites using various filters. 
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Figure 4.12 T-to-G RNA-DNA sequence difference at chr10:102046378 (hg19). Here we 
show an image in the IGV browser (Thorvaldsdottir et al. 2012) of a T-to-G sequence differences 
at chr10:102046378 in the first replicate of the GM12878 dataset. Each grey bar represents an 
RNA-Seq read. Mismatches are depicted by colored letters. Black dashes within a read represent 
a clipped sequence; for reads in the bottom half, the string of colored bases depict clipped 
portions of the sequence. Clipped portions of alignments represent bases that are not aligned 
within a local alignment. 
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Figure 4.13 Number of properly aligned bases in reads that overlap RDDs. Here we depict 
the number of bases within each read that overlaps an RNA-DNA sequence difference site that 
are aligned properly. This number excludes bases that contain mismatches or those that are 
clipped or part of an insertion or deletion. 
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4.4 Discussion 
RNA-Sequencing is a powerful technology for genome-wide analyses of 
transcriptome information at the single-nucleotide level. The resolution afforded by next-
generation sequencing technology has allowed for genome-wide studies on RNA editing 
in humans (J. B. Li et al. 2009; Peng et al. 2012) and led to the identification of all 12 
types of sequence differences (M. Li et al. 2011). There are, however, limitations to high-
throughput sequencing, as difficulties lie in the alignment of short sequencing reads and 
errors introduced by sequencing and library preparation among other challenges. The 
relative effect of these various misalignment and sequencing errors on the identification 
of RDDs is debated, although many reports assert that the majority of noncanonical 
sequence differences observed result from technical artifacts (Kleinman & Majewski 
2012; W. Lin et al. 2012; Pickrell et al. 2012; Schrider et al. 2011). In this study, we 
dissect the various sources of error leading to false positive RDDs and evaluate their 
relative contribution. Using a detection theory approach, we generated simulated RNA-
Seq datasets containing known RDDs to evaluate the effect of alignment and sequencing 
error on RDD analysis. In the absence of sequencing error, we found that minimal 
thresholds are sufficient for sensitivity values above 95% and false discovery rates below 
5%. Moreover, we found that the RDD levels reported by the various aligners correlate 
well (R ~ 98%) with the true levels per our simulation. Upon introduction of sequencing 
errors following a random and independent distribution, we found that a threshold 
requiring a ‘minimum coverage of 20x, minimum level of 20%, and minimum of 4 reads 
bearing the RDD base’ is necessary for false discovery rates below 10% across the 
various aligners. In addition to random and independent sequencing errors, we evaluated 
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the effect of non-random sequencing errors on the analysis of RDDs and found that they 
play a large part in the inflation of false discovery rates. 
Currently, most pipelines use ad hoc filtering methods to minimize the presence 
of false positives in sequence difference studies without a full understanding of the 
efficacy of these methods or the trade-off between sensitivity and false discovery rates. 
We found that overall while the various filters used in the literature for removal of false 
positive RDDs are effective in discriminating between true and false positives, a sizeable 
percentage of false positives remain even after all filtering methods are implemented.  
Lastly, we used our pipeline for identification of RDDs to evaluate the presence 
of sequence differences in humans. Using parameters and thresholds we deemed as 
optimal, we identified approximately 9,000 RDDs, the majority (68%) of which are A-to-
G changes and likely to be mediated by ADAR. Of the noncanonical RDDs that remained 
after our filtering processes, we found A-to-C and its complement T-to-G to be most 
common. Notably, A-to-C changes have been found by others to be the most common 
sequencing error (Dohm et al. 2008; Qu et al. 2009). Furthermore, we found that the 
alignments of reads overlapping noncanonical RDDs, with the exception of A-to-C and 
T-to-G types, contain many more mismatches or clipped bases than those of A-to-G 
differences. The distribution of sequence differences we observed is highly concordant 
with previous studies, and like others (Kleinman et al. 2012; Ramaswami et al. 2013), we 
conclude that there is little evidence for widespread noncanonical editing.  
Overall, we observed that next-generation sequencing technology and current 
bioinformatics tools are a reliable and powerful technique for studying RDDs genome-
wide. Furthermore, we found that computational biology methods are an effective means 
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for evaluating the various thresholds and filtering techniques used to accurately identify 
sequence differences. Our results demonstrate that while RNA-Seq allows for precise 
detection and measurement of RDDs, current bioinformatics filters do not completely 
remove false positive calls. We aim for this study to provide a general framework for 
those interested in site-specific allelic differences in humans using RNA-Seq, and hope in 
particular that our work may shed light on the appropriate thresholds and necessary 
caution to employ for RDD analyses.  
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4.5 Materials and Methods 
4.5.1 Simulation of RNA-Seq datasets 
Simulated datasets were generated using the BEERS simulator (Grant et al. 2011). 
Data are based on human build hg19 and RefSeq transcript models (Pruitt et al. 2012), as 
aligned to the genome by UCSC (Kent et al. 2002) using BLAT (Kent 2002). The 
expression intensities are Poisson distributed with probabilities estimated from roughly 
300 million reads of human retina RNA-Seq data, as described previously (Grant et al. 
2011). Default settings result in 36,467 transcripts, of which approximately 70% are 
expressed. We simulated two types of RNA-Seq datasets. Dataset 1 was “clean” and 
designed to contain no intron signal or sequencing error. Dataset 2 was “realistic” and 
constructed with intron retention and sequencing error. We used a substitutional error rate 
of 1 in 200 (0.5%), a value comparable to observed sequencing error rates of Illumina 
Genome Analyzer IIx and HiSeq machines (Minoche et al. 2011).  Furthermore, we 
simulated poorer quality bases at the ends of reads by increasing the substitutional error 
rate to 20% in the last 10 bases for 25% of the reads. Approximately 30% of the signal in 
the dataset originates from introns. These parameters are consistent with real data 
observations. Lastly, we also included indel polymorphisms at a rate of 1 in 1000 (0.1%). 
Both datasets 1 and 2 were generated in triplicate, with each replicate containing 50 
million pairs of reads of length 100 base pairs (bp). The mean fragment length of each 
read pair is 330 bp.   
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4.5.2 Alignment of RNA-Seq datasets 
RNA-Seq datasets were aligned using GSNAP version 2012-07-20 (T. D. Wu & 
Nacu 2010), RUM version 2.0.3-02 (Grant et al. 2011), or Tophat2 version 2.0.6 
(Trapnell et al. 2009) to the human genome (build hg19). GSNAP was run with default 
options. A maximum number of 10 alignments were permitted for each read. Alignments 
to novel exon-exon junctions (per GSNAP option -N 1) and known junctions as defined 
by RefSeq (downloaded November 2, 2012) and Gencode version 13 (Harrow et al. 
2006) were accepted. Alignments with no more than the default maximum of ‘(read 
length + 2)/12 – 2’ mismatches were retained. RUM was run with the default command 
line options. Tophat2 was run with the default options. A maximum edit distance and 
mismatch count of 6 was allowed for each read. Secondary alignments up to the default 
maximum of 20 were permitted. After alignment with GSNAP, RUM, or Tophat2, non-
primary alignments and alignments placing read pairs in the incorrect orientation were 
removed. 
4.5.3 Simulation of RNA-DNA sequence differences 
For each dataset, sites in the genome are first stratified by coverage to ensure the 
placement of RDDs at locations with varying depths of coverage. The distribution of 
coverage for dataset 1, which does not contain reads originating from intronic regions of 
the genome, is fairly uniform, while for dataset 2, the distribution is skewed right (Figure 
S2); approximately 82% of sites in dataset 2 have coverage of 10x or less compared to 
approximately 20% in dataset 1. For dataset 1, we grouped sites into quartiles, 
corresponding to coverage values of approximately 0x to 14x for quartile 1, 15x to 49x 
for quartile 2, 50x to 133x for quartile 3, and 134x and above for quartile 4. For dataset 2, 
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the presence of introns results in a highly skewed right distribution for coverage. As such, 
we divided dataset 2 into one group containing sites with coverage below 10x and split 
the remaining sites into tertiles, corresponding to coverage values of approximately 11x 
to 19x for tertile 1, 20x to 48x for tertile 2, and 49x and above for tertile 3. After we 
grouped sites by coverage, we randomly inserted RDDs at different sites such that each 
coverage group contained approximately the same number of sequence differences.  
The type of RDD difference (e.g. A-to-C, A-to-G, A-to-T, etc.) was determined 
randomly and independently for each site. The RDD level, or the proportion of reads 
containing the sequence difference, was chosen randomly from a random uniform 
distribution from 0 to 1, excluding 0. 
A small subset (5%) of the simulated RDDs was randomly chosen to model 
hyperediting, or the clustering of many sequence differences in a small window. In 
particular, we designated all of the sites that are within 100 bp of the chosen site to have a 
50% chance of having the same RDD type provided that the coverage belongs to the 
same coverage group as the initial site.  
4.5.4 Repetitive regions of the genome as defined by BLAT 
As one measure of the repetitive nature of a region surrounding a sequence 
difference site, we used BLAT (Kent 2002) to search for homologous sequences in the 
genome. In particular, we extracted flanking sequences of length 51 bp, 101 bp, and 151 
bp around a given site and queried for alignments in the genome with BLAT (v.35x1). 
The settings --stepSize=5 and --repMatch=2253 were used to increase sensitivity. A 
maximum of (read length + 2)/12 – 2 mismatches per alignment, the same amount 
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permitted by GSNAP, was tolerated. Sites for which more than one alignment is found 
for one of the three flanking sequences are deemed “non-unique by BLAT”.  
4.5.5 Filtering of RNA-DNA sequence differences using BLAT 
To ensure that an RDD identified by the various aligners cannot be explained by 
homologous sequences in the genome, sequences of length 25, 50, and 75 bp upstream 
and downstream of each sequence difference site were aligned to the genome using 
BLAT (v. 35x1). The settings --stepSize=5 and --repMatch=2253 were used to 
increase sensitivity. A maximum of (read length + 2)/12 – 2 mismatches per 
alignment, the same amount allowed by GSNAP, was tolerated. An RDD was filtered out 
if any of the flanking sequences aligned to a region other than the RDD site and if that 
alignment explained the sequence difference.  
4.5.6 Analysis of non-random sequencing errors in experimental RNA-Seq 
datasets 
Note: Experimental work in this section was performed by Nicholas Lahens in the John 
Hogenesch laboratory. 
To evaluate the extent to which non-random sequencing errors can affect the false 
discovery rate of RDD detection, we analyzed two replicates of a dataset comprising 
1,062 cDNAs from the Mammalian Genome Collection (Temple et al. 2009) that were 
expressed in vitro and sequenced using Illumina HiSeq 2000 technology.  RNA was 
treated with Ribo-Zero Gold kit (Epicentre catalog no. RZHM11106) and converted into 
an Illumina RNA-Seq library with the TruSeq RNA sample prep kit (Ilumina catalog no. 
FC-122-1001). Briefly, rRNA was removed from 1 ug of IVT RNA using Ribo-Zero 
Gold kit and purified via ethanol/sodium acetate precipitation according to manufacturers 
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protocol. After drying, the RNA pellet was dissolved in 18 μL of Elute, Prime, Fragment 
mix (provided with TruSeq RNA sample prep kit). RNA was fragmented for 8 minutes 
and 17 uL of this fragmented RNA was used to make the RNA-Seq library according to 
Illumina RNA TruSeq RNA sample prep kit protocol. After fragmentation/priming, first 
strand cDNA synthesis with SuperScript II (Invitrogen catalog no. 18064014), second-
strand synthesis, end-repair, a-tailing, and adapter ligation, the library fragments were 
enriched with 15 cycles of PCR. Quality and size of library was assessed using Agilent 
2100 BioAnalyzer. Library was sequenced in replicate using Illumina HiSeq 2000 to 
obtain approximately 41 million and 32 million 100-bp paired-end reads. 
We aligned both replicates using GSNAP (see ‘Alignment of RNA-Seq datasets’ 
in Materials and Methods) to an index containing the non-spliced reference sequence of 
the 1,062 cDNAs. For each replicate, approximately 82% of the total reads were aligned 
in the correct orientation and with the expected inner distance between read pairs. The 
coverage distribution in each replicate is fairly uniform, with an average of 
approximately 2,600x and 3,000x in replicates 1 and 2, respectively (median of 2,300x in 
replicate 1 and 1,800x in replicate 2). To be confident of the sequencing and alignment 
results, we restricted our analyses to sites with a minimum coverage of 1,000x. In total, 
we obtained 4,923,509,994 and 4,195,153,516 bases of sequence at 1,209,658 and 
1,111,552 sites and observed a total of 1,877,330 and 4,902,349 sequencing errors, giving 
an overall error rate of approximately 3.8 x 10-4 and 1.2 x 10-3 in replicates 1 and 2, 
respectively. For each site, we calculated the sequencing error level to be the percentage 
of total reads at the site bearing an error. To test whether the observed sequencing errors 
occur randomly, we performed a Kolmogorov-Smirnov test, comparing the observed 
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distribution of sequencing error levels to a null distribution derived from the overall error 
rate calculated previously. We found that for both replicates, the distribution of 
sequencing error levels deviates from that expected under the null distribution (P < 0.001 
for both replicates).
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Chapter 5. Genetic Basis of RNA-DNA Sequence Differences 
5.1 Abstract 
RNA-Sequencing (RNA-Seq) delivers quantitative and comprehensive information 
on transcriptomes at the single-nucleotide level. Such detailed information on DNA and 
RNA allows for systematic identification of RNA-DNA sequence differences (RDDs) 
genome-wide. Recent studies have utilized next-generation sequencing technology to 
survey the landscape of known RNA editing processes in humans as well as detect 
sequence differences between DNA and RNA that cannot be explained by known 
mechanisms. In this chapter, we explore the genetic basis of RDDs using RNA-Seq data. 
Little is known about whether RDD levels, or the proportion of reads at an RDD site that 
bear the sequence difference allele, vary among individuals genome-wide. Previous 
studies on ADAR editing in humans have observed consistent levels of editing across 
different samples in a few genes. In this study, we develop statistical methods for 
assessing the extent to which individuals vary in their RDD levels genome-wide using 
RNA-Seq data. We also quantify the degree to which such individual variation is 
genetically determined. In designing these statistical algorithms, we take into account 
variation in sequencing coverage that is present in next-generation sequencing data. We 
also correct for multiple-testing error as we envision our tests to be used on genome-sized 
datasets. We apply our statistical algorithms to RNA-Seq data for cultured human B-cells 
derived from 27 unrelated individuals and 10 pairs of monozygotic twins in the Centre 
d’Etude du Polymorphisme Humain (CEPH) collection. Among the 27 unrelated 
individuals, which were sequenced to an average coverage of 8x each, we observed over 
120 sites in 60 genes for which A-to-G RNA editing levels vary across the unrelated 
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samples (FDR ~ 0.05). For the 10 pairs of monozygotic twins, which were sequenced to a 
depth of approximately 29x each, we found over 2,000 sites in roughly 500 genes for 
which variation in RDD levels is significantly explained by genetic differences. Our 
results provide the first genome-wide survey of variation and heritability of RDD levels 
in humans and our methods can be applied to future genetic analyses on RDDs and other 
quantitative phenotypes measured using RNA-Seq data.  
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5.2 Introduction 
Next-generation sequencing technology provides comprehensive coverage of 
genomes and transcriptomes, facilitating comprehensive comparisons of DNA and RNA 
sequence. The transmission of sequence information from DNA to RNA is a critical 
process and is expected to occur in a one-to-one fashion; however, there are known 
exceptions. In humans, these exceptions encompass two types of RNA editing: adenosine 
to inosine edits as catalyzed by ADAR (Bass & Weintraub 1988) and cytosine to uridine 
changes as mediated by APOBEC1 (Powell et al. 1987). Inosine is recognized by the 
translational machinery as guanosine, and thus ADAR-mediated editing can result in 
changes in protein sequence. RNA editing by ADAR is essential for development and 
normal function in both invertebrates and vertebrates (Higuchi et al. 2000; Palladino et al. 
2000). In addition, abnormalities in ADAR editing have been shown to be associated 
with various human disorders (Brusa et al. 1995; Kawahara et al. 2004; Silberberg et al. 
2012).  
Little is known about variation in levels of editing, the percentage of transcripts at 
an editing site that are edited, on a genome-wide scale. Previous reports have shown 
editing levels in glutamate receptors to be consistent across individuals (Paschen et al. 
1994; Wahlstedt et al. 2009). Another study examined the levels of editing in Alu repeats 
for 6 different genes across 32 human skin samples and likewise found highly consistent 
levels of editing across different individuals and tissues (Greenberger et al. 2010). In this 
chapter, we propose methods that allow for genome-wide surveys of individual variation 
in RNA editing or RDD levels and, in addition, the degree to which such variation is 
explained by genetic determinants. The methods we develop are suited for the 
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quantitative nature of RNA-Seq data and account for variation in sequencing depths 
across different samples. Also, we design our algorithms with the goal of genome-wide 
analyses and thus correct for multiple testing error.  
Our work aims to lay the foundation for future studies on the genetics of RDDs – 
both those for which the underlying mechanisms are known and those for which they are 
not. For RDDs generated by known enzymes such as ADAR and APOBEC1 editing, 
genetic analyses may shed light on the means by which such editing is regulated and 
controlled. Furthermore, with respect to noncanonical RDDs, a genetic approach 
represents one method for elucidation of the factors underlying the unknown mechanism. 
Lastly, differences in RDD levels across samples may also have functional consequences 
on cellular processes and may thus be an underlying determinant for individual 
phenotypic variation. With these motivations in mind, we propose methods for evaluating 
individual variation and heritability of RDD levels using next-generation sequencing 
data. 
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5.3 Results 
5.3.1 Individual variation in RDD levels among unrelated individuals 
We surveyed the landscape of ADAR RNA editing sites genome-wide to 
determine whether A-to-G editing or RDD levels vary among individuals. In particular, 
we obtained RNA-Seq data on 27 unrelated individuals from the Centre d’Etude du 
Polymorphisme Humain (CEPH) collection (Dausset et al. 1990). These are the same 
individuals previously used by Cheung and colleagues to identify RDDs in human B-cells 
(M. Li et al. 2011). For each individual, we aligned the RNA-Seq data using GSNAP and 
calculated RDD levels for A-to-G sites in the Database of RNA Editing in Humans 
(DARNED) (Kiran & Baranov 2010), a public collection of editing sites in humans (see 
Materials and Methods). To be confident of the RDD levels as measured by RNA-Seq 
data, we focused on sites where a sufficient number of individuals had relatively high 
coverage. In particular, we required a minimum of 10 individuals with coverage of at 
least 30x at each site under consideration. Overall, a total of 1,112 sites satisfied these 
criteria. We then asked whether the RDD levels at these sites varied across the 27 
unrelated individuals (see Materials and Methods). Using a false positive rate of 0.005 
(Figure 5.1), we identified a total of 120 sites (11%) in over 60 genes that showed 
significant individual variation in RDD levels (FDR ~ 0.05). A list of top sites 
demonstrating individual variation is shown in Table 5.1 along with a few examples in 
Figure 5.2. 
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Figure 5.1 False discovery rate versus false positive rate for identification of sites with 
significant individual variation in RDD levels. Here we calculate the false discovery rate versus 
false positive rate after correcting for multiple testing error in the test of individual variation in 
RDD levels across individuals (see Materials and Methods).  
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Table 5.1 List of top A-to-G RNA editing sites with significant variation in editing levels among 27 unrelated individuals.  
chrom position gene name feature n§ mean RDD level 
median 
RDD level 
minimum 
RDD level 
maximum 
RDD level Z‡ p value 
chr1 567242 intergenic intergenic 27 1.36 1.16 0.28 4.17 111.73 0 
chr1 1247494 CPSF3L 3UTR;CDS 22 70.75 100.00 0.00 100.00 871.71 0 
chr1 6158562 KCNAB2 CDS 22 46.52 45.73 0.00 100.00 461.98 0 
chr1 6159032 KCNAB2 3UTR 11 47.18 41.03 0.00 100.00 278.47 0 
chr1 6160563 KCNAB2 3UTR 19 75.28 98.44 0.00 100.00 639.80 0 
chr1 6160876 KCNAB2 3UTR 26 76.14 100.00 0.93 100.00 1613.90 0 
chr1 6160958 KCNAB2 3UTR 27 70.58 100.00 0.00 100.00 1623.68 0 
chr1 20978410 DDOST 3UTR 26 7.68 8.25 0.00 95.31 544.03 0 
chr1 27210721 GPN2 CDS 13 68.32 54.84 0.00 100.00 273.86 0 
chr1 31205796 LAPTM5 3UTR 27 33.45 40.41 0.00 100.00 16002.13 0 
chr1 36067677 PSMB2 3UTR 21 21.91 24.69 3.90 46.51 90.68 0 
chr1 38449910 SF3A3 CDS 23 21.95 0.00 0.00 100.00 747.22 0 
chr1 46078854 NASP 3UTR;CDS 16 18.90 20.05 0.00 100.00 282.77 0 
chr1 79108193 IFI44L 3UTR 25 1.00 0.00 0.00 9.68 146.76 0 
chr1 79108193 IFI44L 3UTR 25 1.00 0.00 0.00 9.68 146.76 0 
chr1 146650916 FMO5;PDIA3P exon 27 64.56 42.68 0.00 100.00 2622.82 0 
chr1 154897350 PMVK 3UTR 27 1.47 0.89 0.00 11.58 76.38 0 
chr1 160302244 COPA CDS 20 1.13 0.00 0.00 15.38 46.92 0 
chr1 160967938 F11R 3UTR 13 22.88 20.37 0.00 39.39 35.72 0.001 
chr1 160967938 F11R 3UTR 13 22.88 20.37 0.00 39.39 35.72 0.001 
chr1 184761188 FAM129A 3UTR 14 11.01 8.96 0.00 27.66 45.32 0 
chr1 220427469 MORF4L1P1 exon 27 10.58 0.00 0.00 53.42 1189.44 0 
chr11 35827958 TRIM44 3UTR 21 13.32 0.00 0.00 100.00 611.13 0 
chr11 60609972 CCDC86 CDS 13 12.90 0.00 0.00 52.78 230.96 0 
chr11 77790653 NDUFC2 CDS 16 74.84 98.06 0.00 100.00 483.68 0 
chr12 32880193 DNM1L exon 27 44.12 54.21 0.00 100.00 5722.95 0 
chr12 69237043 CPM;MDM2 3UTR 10 13.18 15.53 0.00 26.67 32.63 0.001 
chr12 69237043 CPM;MDM2 3UTR 10 13.18 15.53 0.00 26.67 32.63 0 
chr14 20916958 OSGEP 5UTR;CDS 18 33.80 35.49 0.00 100.00 717.23 0 
chr14 93407583 ITPK1 3UTR 12 4.07 0.00 0.00 50.00 117.38 0 
chr16 29679362 SPN 3UTR 27 6.39 5.41 0.00 15.05 76.81 0 
chr16 29680796 SPN 3UTR 24 62.24 61.42 36.11 73.91 51.65 0.001 
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chrom position gene name feature n§ mean RDD level 
median 
RDD level 
minimum 
RDD level 
maximum 
RDD level Z‡ p value 
chr16 29680922 SPN 3UTR 23 12.68 12.90 0.00 26.83 51.17 0.003 
chr16 29681216 SPN 3UTR 25 21.09 21.43 5.68 30.91 50.10 0.003 
chr16 29681216 SPN 3UTR 25 21.09 21.43 5.68 30.91 50.10 0.004 
chr16 29681303 SPN 3UTR 22 20.22 19.29 0.00 40.00 49.07 0 
chr16 29681303 SPN 3UTR 22 20.22 19.29 0.00 40.00 49.07 0.002 
chr16 57399547 CCL22 3UTR 27 0.20 0.08 0.00 1.74 53.24 0.001 
chr17 1373518 MYO1C CDS 14 62.45 49.77 31.43 100.00 304.16 0 
chr17 37920169 IKZF3 3UTR 14 40.72 42.21 15.69 65.00 36.11 0.001 
chr17 37920635 IKZF3 3UTR 19 40.61 43.59 18.18 55.26 45.16 0 
chr17 37920635 IKZF3 3UTR 19 40.61 43.59 18.18 55.26 45.16 0 
chr17 80445942 NARF exon 16 3.05 0.00 0.00 15.38 52.94 0 
chr19 2072038 MOB3A 3UTR 26 36.35 43.18 0.00 100.00 2045.37 0 
chr19 4362691 SH3GL1 CDS 19 11.40 0.00 0.00 55.00 344.37 0 
chr19 14721449 CLEC17A 3UTR 25 37.58 35.29 18.52 56.96 90.12 0 
chr19 14721449 CLEC17A 3UTR 25 37.58 35.29 18.52 56.96 90.12 0 
chr19 14721471 CLEC17A 3UTR 25 4.19 2.99 0.00 16.18 54.49 0.002 
chr19 14721471 CLEC17A 3UTR 25 4.19 2.99 0.00 16.18 54.49 0.003 
chr19 18288551 IFI30 CDS 27 1.02 0.61 0.00 3.50 142.67 0 
chr19 39322087 ECH1 CDS 26 44.86 40.60 0.00 100.00 1933.75 0 
chr19 39359229 RINL 3UTR 23 15.78 16.33 3.33 37.21 51.52 0.001 
chr19 39359229 RINL 3UTR 23 15.78 16.33 3.33 37.21 51.52 0.001 
chr19 48255804 GLTSCR2 CDS 26 42.64 38.08 0.00 100.00 2179.54 0 
chr19 48258717 GLTSCR2 CDS 26 60.37 38.65 0.00 100.00 2549.66 0 
chr19 49470064 FTL 3UTR 27 0.37 0.23 0.00 1.48 110.98 0 
chr2 87423754 ANAPC1 exon 17 11.48 0.00 0.00 53.33 287.40 0 
chr2 127808046 BIN1 CDS 13 2.63 0.00 0.00 35.85 106.55 0 
chr20 44054349 PIGT CDS 10 45.86 44.12 0.00 100.00 388.38 0 
chr21 34923319 SON CDS 22 5.24 3.93 0.00 15.63 57.23 0.001 
chr22 39414754 APOBEC3C 3UTR 27 3.53 2.22 0.00 10.73 153.65 0 
chr22 39414754 APOBEC3C 3UTR 27 3.53 2.22 0.00 10.73 153.65 0 
chr22 39414772 APOBEC3C 3UTR 27 14.26 12.09 0.91 38.78 395.52 0 
chr22 39414772 APOBEC3C 3UTR 27 14.26 12.09 0.91 38.78 395.52 0 
chr3 31678420 STT3B 3UTR 24 2.22 0.00 0.00 37.50 165.23 0 
chr3 124802231 SLC12A8 3UTR 24 50.63 50.84 0.00 100.00 2068.93 0 
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chrom position gene name feature n§ mean RDD level 
median 
RDD level 
minimum 
RDD level 
maximum 
RDD level Z‡ p value 
chr3 131102053 NUDT16 3UTR;CDS 12 3.07 0.00 0.00 37.50 81.14 0 
chr3 156259229 SSR3 3UTR 24 14.35 11.89 0.00 30.00 66.10 0 
chr3 156259229 SSR3 3UTR 24 14.35 11.89 0.00 30.00 66.10 0 
chr3 156259288 SSR3 3UTR 18 4.58 0.00 0.00 25.64 72.95 0 
chr3 156259295 SSR3 3UTR 14 4.53 3.92 0.00 12.50 35.40 0.001 
chr3 156259295 SSR3 3UTR 14 4.53 3.92 0.00 12.50 35.40 0.002 
chr4 2940462 NOP14 3UTR 19 43.85 45.95 22.22 66.67 57.32 0 
chr4 57326126 PAICS 3UTR 24 22.14 22.48 10.87 47.27 61.60 0 
chr4 57326131 PAICS 3UTR 24 11.35 11.29 3.33 27.78 66.35 0 
chr4 57326131 PAICS 3UTR 24 11.35 11.29 3.33 27.78 66.35 0 
chr4 57326186 PAICS 3UTR 26 4.97 4.21 0.61 17.02 128.19 0 
chr4 57326262 PAICS 3UTR 25 5.18 4.55 0.00 23.64 82.50 0 
chr4 57326262 PAICS 3UTR 25 5.18 4.55 0.00 23.64 82.50 0 
chr4 57326291 PAICS 3UTR 25 53.67 57.89 27.40 86.96 138.44 0 
chr4 57326291 PAICS 3UTR 25 53.67 57.89 27.40 86.96 138.44 0 
chr4 57326333 PAICS 3UTR 25 6.38 7.27 1.14 21.05 88.23 0 
chr4 57326333 PAICS 3UTR 25 6.38 7.27 1.14 21.05 88.23 0 
chr4 57326875 PAICS 3UTR 26 15.91 17.62 4.79 30.00 70.96 0 
chr4 57326879 PAICS 3UTR 26 9.28 9.40 0.00 22.86 94.01 0 
chr4 57326879 PAICS 3UTR 26 9.28 9.40 0.00 22.86 94.01 0 
chr4 57326917 PAICS 3UTR 27 6.06 5.26 0.00 22.45 73.53 0 
chr4 57327017 PAICS 3UTR 23 29.84 33.33 6.10 61.36 132.78 0 
chr4 57327017 PAICS 3UTR 23 29.84 33.33 6.10 61.36 132.78 0 
chr4 77979680 CCNI CDS 24 6.96 4.97 0.00 23.53 137.09 0 
chr4 183811670 DCTD 3UTR 26 20.75 0.00 0.00 100.00 1041.98 0 
chr5 79923293 DHFR 3UTR 15 6.36 5.36 0.00 20.59 42.91 0 
chr5 79923311 DHFR 3UTR 13 4.82 2.50 0.00 15.73 33.98 0.002 
chr5 79923311 DHFR 3UTR 13 4.82 2.50 0.00 15.73 33.98 0.001 
chr5 150639409 GM2A CDS 23 44.00 46.15 0.00 100.00 1614.33 0 
chr5 150639439 GM2A CDS 23 43.44 34.43 0.00 100.00 1480.83 0 
chr5 150647012 GM2A 3UTR; stop codon 26 24.89 33.67 0.00 100.00 1891.31 0 
chr5 150648145 GM2A 3UTR 27 4.21 3.48 0.00 9.18 74.20 0 
chr6 31238261 HLA-C 3UTR;CDS 19 0.12 0.06 0.00 3.23 51.39 0 
chr6 34556786 C6orf106 3UTR 23 1.57 0.00 0.00 8.45 48.82 0.001 
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chrom position gene name feature n§ mean RDD level 
median 
RDD level 
minimum 
RDD level 
maximum 
RDD level Z‡ p value 
chr6 41903007 CCND3 3UTR 14 46.15 45.24 0.00 100.00 397.77 0 
chr6 42856330 RPL7L1 3UTR 19 16.10 15.15 0.89 35.48 96.00 0 
chr6 153603584 intergenic intergenic 27 8.19 0.06 0.00 99.53 30351.78 0 
chr7 1976457 MAD1L1 CDS 18 20.13 0.00 0.00 100.00 591.13 0 
chr8 11702542 CTSB 3UTR 21 34.72 44.44 0.00 100.00 693.10 0 
chr8 17927327 ASAH1 CDS 24 50.94 45.49 0.00 100.00 1014.47 0 
chr8 28206275 FBXO16 3UTR;CDS 22 27.98 0.00 0.00 100.00 882.59 0 
chr8 30535953 GSR 3UTR 26 15.26 12.66 4.05 42.19 128.76 0 
chr8 30535953 GSR 3UTR 26 15.26 12.66 4.05 42.19 128.76 0 
chr8 30535980 GSR 3UTR 25 42.82 38.67 4.26 75.00 193.80 0 
chr8 30535980 GSR 3UTR 25 42.82 38.67 4.26 75.00 193.80 0 
chr8 30536016 GSR 3UTR 12 13.25 12.01 0.00 37.21 35.44 0 
chr8 30536016 GSR 3UTR 12 13.25 12.01 0.00 37.21 35.44 0.002 
chr8 30536078 GSR 3UTR 26 30.27 28.42 7.27 64.71 139.27 0 
chr8 48889659 MCM4 3UTR 26 3.39 2.91 0.00 16.22 53.68 0.002 
chr8 103841636 AZIN1 CDS 23 9.09 7.56 0.00 24.66 100.07 0 
chr9 131071533 TRUB2 3UTR 23 10.37 10.42 0.00 23.33 49.05 0.003 
chr9 132651866 FNBP1 3UTR 20 1.83 0.00 0.00 24.44 60.95 0 
chr9 134373264 PRRC2B 3UTR 18 2.72 1.04 0.00 12.82 39.10 0.001 
chrX 24095325 EIF2S3 3UTR 25 14.95 15.79 3.53 33.33 78.66 0 
§ number of individuals with a minimum coverage of 30x at the RDD site 
‡ test-statistic for evaluation of individual variation in RDD levels (see Materials and Methods) 
 
 
 190 
Figure 5.2 Examples of sites showing significant variation in A-to-G RDD or editing levels among 27 unrelated individuals. 
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5.3.2 Evaluating the genetic component of individual variation in RDD levels 
To analyze the genetic basis of variation in RDD levels, we obtained RNA-Seq 
data on 10 monozygotic (MZ) twin pairs and measured their RDD levels at sites in the 
DARNED database (see Materials and Methods). To be confident of the RDD levels, we 
restricted our analyses to RDD sites where at least 5 MZ twin pairs have a minimum 
coverage of 30x. In addition, we required a minimum of 10 samples with RDD levels 
greater than 0. In total, 10,993 sites met these criteria. For each of these sites, we assessed 
the genetic component to the variation in RDD levels (see Materials and Methods). Using 
a false positive rate of 0.01 (Figure 5.3), we identified 2,099 (19%) sites in which there is 
a significant genetic basis for variation in RDD levels (FDR ~ 0.05). These sites reside in 
approximately 500 different genes. A list of 50 top candidates is shown in Table 5.2. A 
few examples are shown in Figures 5.4 to 5.6.  
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Figure 5.3 False discovery rate versus false positive rate for evaluation of genetic basis of 
RDDs. Here we calculate the false discovery rate versus false positive rate after correcting for 
multiple testing error in the assessment of the genetic basis of RDDs in 10 pairs of MZ twins. In 
particular, the test statistic used here is an unequal variance ANOVA measurement (see Materials 
and Methods).  
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Table 5.2 List of top A-to-G sites with significant genetic component to individual variation in RNA editing levels among 10 monozygotic 
twin pairs. 
chrom end gene feature 
# of 
pairs§ 
# of 
individuals‡ SS within 
SS 
between R2 p value 
chr1 1247494 CPSF3L 3UTR;CDS 20 19 2.49 778.49 1.00 0.00 
chr1 1595074 SLC35E2B 3UTR 18 18 0.29 9.89 0.97 0.00 
chr1 1595586 SLC35E2B 3UTR 20 20 1.90 18.84 0.91 0.00 
chr1 1660887 SLC35E2 intron 12 12 0.63 28.13 0.98 0.00 
chr1 6158562 KCNAB2 CDS 20 18 3.73 1065.60 1.00 0.00 
chr1 6159032 KCNAB2 3UTR 20 20 0.41 281.44 1.00 0.00 
chr1 6160876 KCNAB2 3UTR 20 20 0.61 362.67 1.00 0.00 
chr1 6160958 KCNAB2 3UTR 20 20 0.10 476.89 1.00 0.00 
chr1 36068370 PSMB2 3UTR 20 20 7.29 76.59 0.91 0.00 
chr1 38327384 INPP5B 3UTR 20 16 3.20 157.81 0.98 0.00 
chr1 45242978 RPS8 exon 14 14 0.12 6.78 0.98 0.00 
chr1 46078630 NASP exon 10 10 0.10 28.02 1.00 0.00 
chr1 53291435 ZYG11B 3UTR 10 10 1.23 6.18 0.83 0.00 
chr1 67874859 SERBP1 3UTR 20 20 5.79 50.94 0.90 0.00 
chr1 144829580 NBPF9 3UTR 10 10 0.85 4.75 0.85 0.00 
chr1 144829720 NBPF9 3UTR 20 20 3.12 36.62 0.92 0.00 
chr1 150975108 FAM63A 5UTR;CDS 14 14 0.03 17.66 1.00 0.00 
chr1 160966351 F11R 3UTR 20 20 5.14 49.13 0.91 0.00 
chr1 160966352 F11R 3UTR 20 20 9.30 80.22 0.90 0.00 
chr1 160967938 F11R 3UTR 20 20 9.44 79.53 0.89 0.00 
chr1 184761274 FAM129A 3UTR 20 20 4.16 49.40 0.92 0.00 
chr1 184761350 FAM129A 3UTR 16 16 5.00 32.25 0.87 0.00 
chr1 184762524 FAM129A 3UTR 16 16 8.09 60.54 0.88 0.00 
chr11 5719095 TRIM22 exon 20 14 0.24 264.99 1.00 0.00 
chr11 65544382 AP5B1 3UTR 12 12 0.59 7.34 0.93 0.00 
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chrom end gene feature 
# of 
pairs§ 
# of 
individuals‡ SS within 
SS 
between R2 p value 
chr12 44181749 IRAK4 3UTR 10 10 0.70 5.71 0.89 0.00 
chr12 72096125 TMEM19 3UTR 12 12 0.97 14.12 0.94 0.00 
chr12 98942688 TMPO 3UTR 20 20 0.51 6.57 0.93 0.00 
chr12 98942695 TMPO 3UTR 20 20 8.08 87.19 0.92 0.00 
chr12 98943033 TMPO 3UTR 20 20 0.18 13.63 0.99 0.00 
chr12 122216180 RHOF 3UTR 20 11 0.00 0.04 0.92 0.00 
chr13 20247023 MPHOSPH8 3UTR 20 20 4.47 38.36 0.90 0.00 
chr13 20247116 MPHOSPH8 3UTR 20 20 2.35 23.47 0.91 0.00 
chr13 111547851 ANKRD10 intron 10 10 0.82 4.58 0.85 0.00 
chr14 20916958 OSGEP 5UTR;CDS 20 18 1.02 566.37 1.00 0.00 
chr15 41809530 RPAP1 3UTR 20 20 0.12 92.02 1.00 0.00 
chr15 64447076 SNX22 3UTR 12 12 0.39 3.50 0.90 0.00 
chr16 15795035 NDE1 intron 20 18 0.55 37.15 0.99 0.00 
chr16 28967974 NFATC2IP exon 12 12 1.08 20.93 0.95 0.00 
chr16 29679989 SPN 3UTR 20 20 0.28 22.77 0.99 0.00 
chr2 37327662 EIF2AK2 3UTR 20 20 1.93 44.96 0.96 0.00 
chr2 37328034 EIF2AK2 3UTR 20 20 9.67 107.87 0.92 0.00 
chr2 37328097 EIF2AK2 3UTR 20 20 24.44 251.67 0.91 0.00 
chr2 99812336 MRPL30 3UTR 20 20 3.63 63.80 0.95 0.00 
chr4 17803019 DCAF16 3UTR 20 20 1.24 11.01 0.90 0.00 
chr4 57327058 PAICS 3UTR 20 20 3.18 85.12 0.96 0.00 
chr4 73922926 COX18 3UTR 20 20 0.68 13.64 0.95 0.00 
chr4 73922978 COX18 3UTR 20 20 1.76 25.46 0.94 0.00 
chr4 73923097 COX18 3UTR 20 20 2.60 27.45 0.91 0.00 
chr4 73923449 COX18 3UTR 20 20 2.32 22.10 0.90 0.00 
§ number of MZ twin pairs where both members in pair have minimum coverage of 30x 
‡ number of individuals with RDD levels greater than 0 
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Figure 5.4 A-to-G editing levels for 10 pairs of monozygotic twins in the 3’ UTR of the gene F11R at chr1:160966352 (hg19) 
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Figure 5.5 A-to-G editing levels for 10 pairs of monozygotic twins in the 3’ UTR of the gene EIF2AK2 at chr2: 37327662 (hg19) 
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Figure 5.6 A-to-G editing levels for 10 pairs of monozygotic twins in the 3’ UTR of the gene PAICS at chr4:57327058 (hg19) 
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5.4 Discussion and Future Directions 
RNA-Seq provides digital and quantitative measurements of the transcriptome. 
The single-nucleotide resolution afforded by next-generation sequencing allows for 
detailed analyses of sequence differences between DNA and RNA and the precise 
measurement of the degree of these differences. In this chapter, we defined the RNA-
DNA sequence difference (RDD) level, or the proportion of transcripts at an RDD site 
bearing the sequence difference allele, as a quantitative phenotype and investigated 
whether it is variable among individuals. Our work represents the study on individual 
variation of RDD levels at the genome-wide level, as previous reports focused only on a 
few genes. Using RNA-Seq data from 27 unrelated individuals, we detected over 100 
sites in roughly 60 genes where the levels of A-to-G RNA editing among the samples 
vary more than expected under random sampling error. These samples were processed 
more than 5 years ago in 2008 and were thus sequenced to a relatively low depth of 
approximately 8x on average. We anticipate that with higher depths of sequencing and a 
larger set of individuals, we will observe a greater percentage of sites showing significant 
individual variation.  
In addition to assessing the presence of variation in RDD levels among unrelated 
individuals, we also asked whether there is a genetic basis to such variation. We obtained 
RNA-Seq data on 10 pairs of monozygotic twins and measured their A-to-G editing 
levels across the genome. We found that nearly 20% of the 10,993 sites for which we had 
sufficient RNA-Seq coverage had a significant genetic component to the variation in 
RDD levels. Our results suggest that there is a hint of heritability for RDDs in humans. 
We note that while our dataset contains only 10 pairs of individuals, we have measured 
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the RDD level phenotype for thousands of sites. We expect that with deeper sequencing 
coverage and a larger set of twin pairs, we will observe a finer estimate of the heritability 
of RDDs. 
At the time of this study, DNA-Seq data on the twin pairs was not available, and 
thus we did not explore the heritability of noncanonical RDDs. Future directions will 
involve expanding the analysis to RDDs of other types. In addition to exploring the 
heritability of RDDs for which we do not know the mechanism, we plan to understand 
the underlying polymorphisms that influence variation in A-to-G editing levels. We plan 
to identify single-nucleotide polymorphisms via DNA-Sequencing and perform a 
genome-wide association test for sites demonstrating a significant genetic component to 
the variation in RDD levels. We will also test for correlation between expression levels of 
ADAR and the editing levels of A-to-G sites. 
In summary, our work lays the foundation for future genetic analyses of RDDs. 
Our study suggests that there exists a hint of heritability in A-to-G editing levels and 
future work will focus on (1) whether a genetic basis exists for RDDs of other types, (2) 
what are the exact genetic determinants that influence variation in A-to-G editing, (3) 
what are the functional consequences of differences in editing levels, and (4) linkage and 
association analyses of RDDs to uncover the mechanisms underlying noncanonical RDDs 
if they exist. 
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5.5 Materials and Methods 
5.5.1 Samples  
For the study of individual variation in unrelated individuals, we used 27 
unrelated individuals from the Utah pedigrees of the Center d’Étude du Polymorphisme 
Humain collection (CEPH) as previously described (M. Li et al. 2011). For the study of 
the genetic basis of RDD levels, we used 10 pairs of monozygotic (MZ) twins from the 
CEPH database. See Table 5.3 for the list of individuals used in either dataset. The 
cultured B-cells were grown to a density of 5 x 105 cells/mL in RPMI 1640 supplemented 
with 15% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin, and 
2 mmol/L L-glutamine. 
5.5.2 RNA-Sequencing  
RNA-Seq libraries were prepared as recommended by Illumina. Briefly, cells 
were harvested 24 hours after addition of fresh medium, and total RNA was extracted 
using the RNeasy Mini kit with DNase treatment (Qiagen). Poly-A mRNA was isolated 
and fragmented. First strand cDNA was prepared using reverse transcriptase and random 
hexamers. After second strand cDNA synthesis, ends were repaired and a single ‘A’ base 
was added followed by adapter sequences. Library fragments were selected for an 
average size of 200 to 260 base pairs, PCR amplified, and then sequenced using the 
Illumina Genome Analyzer 1, Illumina Genome Analyzer II, or HiSeq 2000 platform 
(Table 5.3).
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Table 5.3 RNA-Sequencing statistics. 
Sample Family System† 
Number of 
Reads 
Sequenced 
Read 
Length 
Number of Reads 
Aligned 
Number of Reads 
Aligned Uniquely 
Mean 
Coverage 
Median 
Coverage 
Mean 
Coverage 
(Non 
Repeat 
Masker 
Regions) 
Median 
Coverage 
(Non 
Repeat 
Masker 
Regions) 
Unrelated Individuals (n = 27) 
GM06985 1341 1G GA 38,424,688 1x50bp 29,150,529 (76%) 22,275,984 (58%) 6 1 8 1 
GM06994 1340 1G GA 37,634,150 1x50bp 30,408,512 (81%) 23,887,949 (63%) 9 1 12 2 
GM07000 1340 1G GA 36,665,036 1x50bp 28,450,757 (78%) 21,124,653 (58%) 8 1 11 2 
GM11829 1350 1G GA 37,293,182 1x50bp 27,229,474 (73%) 20,293,401 (54%) 12 1 15 2 
GM11830 1350 1G GA 36,412,185 1x50bp 27,347,752 (75%) 20,445,547 (56%) 10 1 13 2 
GM11831 1350 1G GA 38,923,882 1x50bp 27,163,969 (70%) 20,389,054 (52%) 8 1 11 2 
GM11832 1350 1G GA 38,657,782 1x50bp 29,347,829 (76%) 22,612,842 (58%) 8 1 11 2 
GM11881 1347 1G GA 49,771,575 1x50bp 31,903,474 (64%) 24,236,979 (49%) 7 1 9 1 
GM11992 1362 1G GA 63,260,299 1x50bp 42,188,915 (67%) 30,404,083 (48%) 10 1 14 2 
GM11993 1362 1G GA 38,441,615 1x50bp 29,827,543 (78%) 22,441,894 (58%) 8 1 10 1 
GM11994 1362 1G GA 42,390,584 1x50bp 31,665,651 (75%) 23,910,152 (56%) 6 1 9 1 
GM12003 1420 1G GA 36,977,676 1x50bp 25,506,005 (69%) 19,079,343 (52%) 12 2 15 2 
GM12004 1420 1G GA 28,390,919 1x50bp 19,393,871 (68%) 14,275,512 (50%) 9 1 12 2 
GM12005 1420 1G GA 37,359,318 1x50bp 25,389,881 (68%) 18,366,252 (49%) 5 1 8 1 
GM12006 1420 1G GA 35,506,222 1x50bp 26,439,340 (74%) 19,972,831 (56%) 15 2 18 2 
GM12043 1346 1G GA 36,999,366 1x50bp 26,110,944 (71%) 20,412,688 (55%) 7 1 10 1 
GM12044 1346 1G GA 39,839,492 1x50bp 28,899,913 (73%) 21,490,915 (54%) 11 1 14 2 
GM12144 1334 1G GA 35,020,229 1x50bp 24,663,047 (70%) 18,091,383 (52%) 6 1 8 1 
GM12155 1408 1G GA 43,551,373 1x50bp 32,059,769 (74%) 24,429,087 (56%) 12 1 16 2 
GM12716 1358 1G GA 46,656,852 1x50bp 34,787,074 (75%) 26,301,181 (56%) 6 1 9 1 
GM12717 1358 1G GA 40,635,779 1x50bp 31,736,582 (78%) 24,788,870 (61%) 12 1 15 2 
GM12750 1444 1G GA 45,066,631 1x50bp 32,989,463 (73%) 25,354,509 (56%) 9 1 12 1 
GM12762 1447 1G GA 47,651,198 1x50bp 33,962,134 (71%) 25,759,636 (54%) 8 1 11 1 
GM12813 1454 1G GA 45,288,662 1x50bp 35,704,677 (79%) 27,765,787 (61%) 10 1 14 2 
GM12814 1454 1G GA 39,024,182 1x50bp 29,749,717 (76%) 22,620,609 (58%) 10 1 13 2 
GM12872 1459 1G GA 45,367,154 1x50bp 29,379,313 (65%) 22,143,485 (49%) 5 1 7 2 
GM12874 1459 1G GA 39,588,081 1x50bp 26,863,489 (68%) 19,637,631 (50%) 6 1 8 1 
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Sample Family System† 
Number of 
Reads 
Sequenced 
Read 
Length 
Number of Reads 
Aligned 
Number of Reads 
Aligned Uniquely 
Mean 
Coverage 
Median 
Coverage 
Mean 
Coverage 
(Non 
Repeat 
Masker 
Regions) 
Median 
Coverage 
(Non 
Repeat 
Masker 
Regions) 
MZ Twins (n = 20) 
GM14381 1700 HiSeq 2000 87,747,958 1x100bp 85,611,174 (98%) 72,682,214 (83%) 25 2 36 2 
GM14382 1700 HiSeq 2000 96,532,207 1x100bp 94,112,639 (97%) 79,605,763 (82%) 26 2 38 2 
GM14408 1705 HiSeq 2000 190,370,877 1x100bp 186,669,448 (98%) 160,069,233 (84%) 45 2 68 3 
GM14409 1705 HiSeq 2000 192,128,604 1x100bp 187,853,801 (98%) 159,841,274 (83%) 41 2 62 3 
GM14432 1710 HiSeq 2000 99,374,247 1x100bp 95,736,606 (96%) 82,128,151 (83%) 25 2 36 3 
GM14433 1710 HiSeq 2000 109,389,141 1x100bp 106,549,818 (97%) 91,049,099 (83%) 26 2 38 3 
GM14447 1715 HiSeq 2000 88,964,274 1x100bp 87,397,953 (98%) 74,813,313 (84%) 23 2 33 3 
GM14448 1715 HiSeq 2000 94,936,103 1x100bp 92,579,625 (98%) 79,541,620 (84%) 18 2 28 2 
GM14452 1716 HiSeq 2000 107,194,377 1x100bp 105,233,707 (98%) 87,869,309 (82%) 25 2 36 3 
GM14453 1716 HiSeq 2000 121,015,870 1x100bp 118,648,218 (98%) 102,374,991 (85%) 33 2 48 2 
GM14467 1721 HiSeq 2000 112,512,422 1x100bp 109,872,178 (98%) 93,517,681 (83%) 26 2 38 2 
GM14468 1721 HiSeq 2000 130,482,667 1x100bp 127,008,691 (97%) 106,994,341 (82%) 24 2 36 2 
GM14506 1735 HiSeq 2000 100,444,954 1x100bp 98,394,404 (98%) 81,894,039 (82%) 27 2 40 2 
GM14507 1735 HiSeq 2000 104,762,561 1x100bp 102,466,902 (98%) 86,322,550 (82%) 28 2 41 3 
GM14520 1740 HiSeq 2000 105,916,302 1x100bp 103,691,234 (98%) 85,923,974 (81%) 29 2 43 2 
GM14521 1740 HiSeq 2000 120,920,893 1x100bp 118,644,112 (98%) 99,258,597 (82%) 32 2 46 2 
GM14568 1752 HiSeq 2000 109,660,421 1x100bp 107,666,287 (98%) 92,728,585 (85%) 28 2 41 2 
GM14569 1752 HiSeq 2000 122,436,596 1x100bp 120,514,178 (98%) 103,772,291 (85%) 18 2 28 2 
GM14581 1756 HiSeq 2000 189,630,442 1x100bp 186,763,322 (98%) 156,446,506 (83%) 42 2 63 3 
GM14582 1756 HiSeq 2000 170,152,070 1x100bp 167,651,625 (99%) 139,468,387 (82%) 41 2 62 3 
† System: 1G GA = Illumina Genome Analyzer; 2G GA = Illumina Genome Analyzer 2 
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5.5.3 Alignment of RNA-Seq datasets 
RNA-Seq datasets were aligned using GSNAP version 2012-07-20 (T. D. Wu & 
Nacu 2010) to the human genome (build hg19). GSNAP was run with default options. A 
maximum number of 10 alignments were permitted for each read. Alignments to novel 
exon-exon junctions (per GSNAP option -N 1) and known junctions as defined by 
RefSeq (downloaded November 2, 2012) and Gencode version 13 (Harrow et al. 2006) 
were accepted. Alignments with no more than the default maximum of ‘(read length + 
2)/12 – 2’ mismatches were retained. Non-primary alignments and alignments placing 
read pairs in the incorrect orientation were removed from downstream analyses. 
5.5.4 Assessment of individual variation in RNA-DNA sequence difference levels 
To quantify the significance of variation in RDD levels among unrelated 
individuals, we developed a formal statistical test. In particular, we assumed that RDD 
levels follow a binomial distribution as follows: 
𝑦𝑖 ~ 𝑏𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑛𝑖 ,𝑝𝑖) 
where yi is the number of reads bearing the RDD base,  
ni is the coverage at the site, and 
pi is RDD level for individual i 
We defined the null and alternative hypotheses as follows: 
𝐻0:     𝑝1 = 𝑝1 = 𝑝1 = ⋯ = 𝑝𝑚 = 𝑝  
𝐻𝐴:     at least one 𝑝𝑖 differs  
Under the null hypothesis, the estimate for p is the average across the individuals, or: 
?̂? = 𝑦1 + 𝑦2 + ⋯+ 𝑦𝑚
𝑛1 + 𝑛2 + ⋯+ 𝑛𝑚 
We calculate the log-likelihood as the following: 
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𝐿0 = log∏ [?̂?𝑦𝑖(1 − ?̂?)𝑛−𝑦𝑖] �𝑛𝑖𝑦𝑖�𝑚𝑖=1   
𝐿𝐴 = log∏ [?̂?𝑖𝑦𝑖(1 − ?̂?𝑖)𝑛−𝑦𝑖] �𝑛𝑖𝑦𝑖�𝑚𝑖=1   
We define our test statistic Z as 2(LA – L0), or: 
𝑍 ≜��𝑦𝑖 log �?̂?𝑖?̂? � + (𝑛𝑖 − 𝑦𝑖) log �1 − ?̂?𝑖1 − ?̂? ��𝑛
𝑖=1
 
We observe that our test statistic Z is large if the variation in RDD levels is more than 
what is expected under random sampling error. 
To correct for multiple testing error, we used bootstrapping to estimate the 
sampling distribution. In particular, for each iteration j, we generated new numbers of 
reads bearing the RDD base y* for each individual m such that: 
𝑦𝑚
∗  ~ 𝑏𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑛𝑚, ?̂?) 
For each iteration j of new RDD levels, we calculated a test statistic Z*j. We rejected H0, 
or claimed that there is significant individual variation in RDD levels at this site, if our 
value of Z derived from the observed RDD levels is greater than the (1 – α)th percentile of 
Z*, where α is the false positive rate. We then calculated the false discovery rate as the 
following: 
𝐹𝐷𝑅 = number of expected false positivesnumber of RDD sites rejected ≤ 𝑁 ∗ 𝛼number of RDD sites rejected 
where N is the total number of RDD positions tested. 
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5.5.5 Assessment of genetic component to individual variation in RDD levels 
To measure the component of individual variation in RDD levels that is explained 
by genetic factors, we developed a formal statistical test based on ANOVA and the 
intraclass correlation coefficient. First we define the RDD level pij as the following: 
𝑝𝑖𝑗 = 𝑦𝑖𝑗𝑛𝑖𝑗 
where yij is the number of reads bearing the RDD base,  
nij is the coverage at the site, and 
pij is RDD level for twin pair i and individual j 
 Next, we define the average RDD level for each twin pair i as 
?̅?𝑖 = 𝑝𝑖1 + 𝑝𝑖22  
and the overall average RDD level across all individuals in the n twin pair dataset as  
?̿? = �?̅?𝑖
𝑛
𝑛
𝑖=1
 
We assume that the RDD level pij for each individual follows the model 
𝑝𝑖𝑗 = 𝜇 + 𝛼𝑖 + 𝜀𝑖𝑗 
where μ is the population RDD level, 
αi is the twin pair specific deviation 
and εi is the error term. 
We assume that αi is normally distributed with a mean of 0 and variance of σ2A. 
The total sum of squares SST is  
𝑆𝑆𝑇 = �(𝑝𝑖1 − ?̿?)2 + (𝑝𝑖2 − ?̿?)2𝑛
𝑖=1
 
The within groups (or twin pairs) sum of squares is 
 206 
𝑆𝑆𝑊𝐺 = �(𝑝𝑖1 − ?̅?𝑖)2 + (𝑝𝑖2 − ?̅?𝑖)2𝑛
𝑖=1
 
And lastly, the between groups sum of squares is 
𝑆𝑆𝐵𝐺 = 𝑆𝑆𝑇 − 𝑆𝑆𝑊𝐺 = �2(?̅?𝑖 − ?̿?)2𝑛
𝑖=1
 
 The coefficient of determination R2 is  
𝑅2 = 𝑆𝑆𝐵𝐺
𝑆𝑆𝑇
 
 Differences in sequencing depths across individuals will lead to variation in the 
sampling confidence of the true RDD level as sites with higher coverage have lower 
sampling error in RDD levels. To account such variation, we assumed that σij2 is the 
variance of the RDD level pij and that σij2 is known up to a constant or 
𝜎𝑖𝑗
2 ∝
1
𝑛𝑖𝑗
 
 In light of these differences in coverage, we formulate the sum of squares 
measurements as the following: 
𝑆𝑆𝑇′ = � (𝑝𝑖1 − ?̿?)2
𝜎𝑖1
2
𝑛
𝑖=1
+ (𝑝𝑖2 − ?̿?)2
𝜎𝑖2
2  
Furthermore, we redefine the average RDD level for twin pair i and the within groups and 
between groups sum of squares as the following: 
?̅?𝑖 = 𝜎𝑖22 𝑝𝑖1 + 𝜎𝑖12 𝑝𝑖2𝜎𝑖12 + 𝜎𝑖22  
𝑆𝑆𝑊𝐺′ = � (𝑌𝑖1 − 𝑌�𝑖)2
𝜎𝑖1
2 + (𝑌𝑖2 − 𝑌�𝑖)2𝜎𝑖22𝑛𝑖=1  
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𝑆𝑆𝐵𝐺′ = ��𝑌�𝑖 − 𝑌��2
𝜎𝑖1
2 +𝑛
𝑖=1
�𝑌�𝑖 − 𝑌��
2
𝜎𝑖2
2  
The coefficient of determination in an unequal (but known up to a constant) 
variance ANOVA is then 
𝑅2
′ = 𝑆𝑆𝐵𝐺′
𝑆𝑆𝑇′
 
To correct for multiple testing error, we generated random permutations of the 
dataset. For each permutation, twin pairs are reassigned such that each pair of individuals 
is are unrelated. For each iteration j of these new random assignments, we calculated a 
test statistic 𝑅𝑗2
′∗. We claimed that there is significant genetic component to the variation 
in RDD levels at this site, if our value of 𝑅2′ derived from the true assignment of twin 
pairs is greater than the (1 – α)th percentile of 𝑅2′∗, where α is the false positive rate. We 
then calculated the false discovery rate as the following: 
𝐹𝐷𝑅 = number of expected false positivesnumber of RDD sites rejected ≤ 𝑁 ∗ 𝛼number of RDD sites rejected 
where N is the total number of RDD positions tested.
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Chapter 6. Conclusion 
6.1 Summary of Work and Future Directions 
With the completion of the human genome sequence, the next challenge for the 
genomics community lies in the proper annotation of functional elements and transcribed 
regions in the genome. Continual advances in sequencing technology have facilitated 
such research, enabling unprecedented interrogation of DNA and RNA sequence at the 
single-nucleotide level. These advances have spurred progress toward complete 
characterization of all transcribed elements in a population of cells, increasing the 
catalogue of known genes. In particular, the single-nucleotide resolution afforded by 
RNA-Seq has allowed for detailed analysis of alternative transcription start sites, 
alternative polyadenylation, alternative splicing, and RNA editing, and led as well to the 
discovery of sequence differences between RNA and DNA that cannot be explained by 
known mechanisms. 
In chapter 2, we explored the use of next-generation sequencing technology to 
study the expression landscape in humans. We sequenced complementary DNA 
fragments derived from the RNA of human B-cell cell lines and obtained over 800 
million reads comprising roughly 40 Gigabases of sequence. The abundance of sequence 
information allowed us to analyze the expression profile of the human transcriptome in 
depth and evaluate the experimental parameters necessary for sequencing-based studies. 
We measured the expression of 20,766 genes and 67,453 of their alternatively-spliced 
transcripts. We found that the vast majority (90%) of genes with multiple exons undergo 
alternative splicing. Our analyses of the appropriate sequencing depths for most 
transcriptome studies revealed that while a depth of 100 million reads is sufficient to 
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detect the presence of genes, at least 500 million reads are required to accurately measure 
their expression levels. Since the time this study began in 2008, advances in sequencing 
technology have lowered the cost of sequencing and greatly increased the throughput of a 
sequencing run. As the issue of attaining sequencing information becomes moot, greater 
emphasis will be placed on how to extract meaningful conclusions from the abundance of 
expression information on the transcriptome. Efforts to detect differential gene 
expression between various conditions (Robinson et al. 2010) and the ability to identify 
lowly expressed but functionally important genes (Halvardson et al. 2013; Mercer et al. 
2012) remain top priorities.  
 Beyond the detection and quantification of genes, RNA-Seq technology allows 
for detailed comparisons of sequence. In particular, next-generation sequencing 
technology has paved the way for various studies focused on systematic sequence 
differences between DNA and RNA. In addition to A-to-G and C-to-T sequence 
differences in RNA as catalyzed by RNA editing processes, various researchers identified 
all 12 types of RNA-DNA sequence differences (RDDs), the majority of which cannot be 
explained by known mechanisms. In chapter 3, we describe an initial study performed in 
the Cheung laboratory in which comparisons of RNA and DNA sequences of 27 
unrelated individuals uncovered over 10,000 exonic sites containing sequence differences 
between DNA and RNA. These RDDs were presumably non-random as many sites were 
found in different individuals and cell types.  
The discovery of these noncanonical RDDs was shortly met thereafter with claims 
that technical artifacts explain the majority of these sequence differences. In chapter 4, 
we developed a detection theory approach for the optimal thresholds and parameters for 
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minimizing the false discovery rate of RDD identification. In particular, we generated 
synthetic datasets containing RDDs at known locations and evaluated the sensitivity and 
specificity of RDD detection using various aligners and within different regions of the 
genome. We also identified the major sources contributing to false positive RDDs and 
found that nonrandom sequencing errors present in experimental RNA-Seq datasets 
generated by Illumina sequencing technology play a major part in the false discovery rate 
of RDD detection. Moreover, we used our pipeline for the analysis of RDDs in a human 
cell line for which DNA and RNA data is readily available. We identified over 9,000 
RDD events, the majority of which are A-to-G differences. The most common 
noncanonical RDD types we found were A-to-C and T-to-G differences, which have been 
shown to be the most common sequencing error. Furthermore, we found that the 
alignment quality for noncanonical RDD sites were in general of lower quality than that 
of A-to-G sites. Overall, we concluded that the evidence for widespread noncanonical 
RDDs in humans is weak. 
RDD events can be viewed as a quantitative attribute that lends itself to genetic 
analyses. In chapter 5, we explored the genetic basis for RDDs by defining the RDD 
level, or proportion of reads at an RDD site containing the sequence difference allele, as a 
quantitative phenotype. In particular, we developed statistical methods for analyzing the 
variation in RDD levels among unrelated individuals, accounting for differences in 
sequencing depths and multiple testing error. We applied our algorithms to a real dataset 
comprising RNA-Seq data for 27 unrelated individuals. Overall, we found that nearly 
10% of the sites for which we had sufficient coverage showed significant variation in 
RDD levels among samples. Previous studies on RNA editing levels in glutamate 
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receptors in contrast found consistent levels of editing across individuals. Future work 
will involve understanding the functional consequence of such variation.  
In addition to asking whether RDD levels vary among unrelated individuals, we 
assessed whether such variation is explained by genetic factors. We formulated statistical 
tests for measuring the genetic component to variation in RDD levels using RNA-Seq 
data. In particular, we used an unequal variance ANOVA approach and accounted for 
variation in RNA-Seq coverage. We tested our algorithm on a RNA-Seq dataset derived 
from 10 monozygotic twin pairs. We found that nearly 20% of the sites with sufficient 
coverage had a significant genetic basis to the variation in RDD levels. Future directions 
include uncovering the specific cis- or trans-factors that influence such variation.  
While many reports have challenged the initial discovery of RDDs by Cheung and 
colleagues, it is still unclear whether noncanonical sequence differences exist in humans. 
Most studies have focused on the high false discovery rates associated with studying 
RDDs using next-generation sequencing technology and not the identification of singular 
sites. If noncanonical RDDs do exist, the signal to noise ratio may be too low to allow 
detection in a genome-wide manner. Recent studies, however, have found previously 
unknown modifications in the transcriptome (Schaefer et al. 2009; Song et al. 2012). It 
will be interesting to see whether these differences overlap RDD sites. 
 In conclusion, next-generation sequencing technology is a powerful tool for 
examining the transcriptome in great detail. It provides a detailed and quantitative 
account of expression profiles, facilitating global studies of gene expression as well as 
specific analyses of sequence differences. RNA-Seq has paved the way for discovery into 
unchartered waters, and great restraint and discipline is required for proper analysis of 
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such novel and exciting data. We have entered an age where data collection has far 
outpaced data analysis, and now more than ever, do we need to develop methods for lucid 
and accurate interpretation of the genome.   
 
 213 
Bibliography 
1000 Genomes Project Consortium. A map of human genome variation from population-
scale sequencing. Nature 467, 1061-1073, doi:10.1038/nature09534 (2010). 
 
Albers, C. A. et al. Dindel: accurate indel calls from short-read data. Genome research 
21, 961-973, doi:10.1101/gr.112326.110 (2011). 
 
Alon, S. et al. Systematic identification of edited microRNAs in the human brain. 
Genome research 22, 1533-1540, doi:10.1101/gr.131573.111 (2012). 
 
Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local 
alignment search tool. Journal of molecular biology 215, 403-410, 
doi:10.1016/S0022-2836(05)80360-2 (1990). 
 
Anders, S. & Huber, W. Differential expression analysis for sequence count data. 
Genome biology 11, R106, doi:10.1186/gb-2010-11-10-r106 (2010). 
 
Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene 
Ontology Consortium. Nature genetics 25, 25-29, doi:10.1038/75556 (2000). 
 
Athanasiadis, A., Rich, A. & Maas, S. Widespread A-to-I RNA editing of Alu-containing 
mRNAs in the human transcriptome. PLoS biology 2, e391, 
doi:10.1371/journal.pbio.0020391 (2004). 
 
Au, K. F., Jiang, H., Lin, L., Xing, Y. & Wong, W. H. Detection of splice junctions from 
paired-end RNA-Seq data by SpliceMap. Nucleic acids research 38, 4570-4578, 
doi:10.1093/nar/gkq211 (2010). 
 
Backus, J. W. & Smith, H. C. Specific 3' sequences flanking a minimal apolipoprotein B 
(apoB) mRNA editing 'cassette' are critical for efficient editing in vitro. 
Biochimica et biophysica acta 1217, 65-73 (1994). 
 
Bahn, J. H. et al. Accurate identification of A-to-I RNA editing in human by 
transcriptome sequencing. Genome research 22, 142-150, 
doi:10.1101/gr.124107.111 (2012). 
 
Bailey, J. A. et al. Recent segmental duplications in the human genome. Science 297, 
1003-1007, doi:10.1126/science.1072047 (2002). 
 
Bailey, J. A., Yavor, A. M., Massa, H. F., Trask, B. J. & Eichler, E. E. Segmental 
duplications: organization and impact within the current human genome project 
assembly. Genome research 11, 1005-1017, doi:10.1101/gr.187101 (2001). 
 
 214 
Balzer, S., Malde, K., Lanzen, A., Sharma, A. & Jonassen, I. Characteristics of 454 
pyrosequencing data--enabling realistic simulation with flowsim. Bioinformatics 
26, i420-425, doi:10.1093/bioinformatics/btq365 (2010). 
 
Barski, A. et al. High-resolution profiling of histone methylations in the human genome. 
Cell 129, 823-837, doi:10.1016/j.cell.2007.05.009 (2007). 
 
Bass, B. L. RNA editing by adenosine deaminases that act on RNA. Annual review of 
biochemistry 71, 817-846, doi:10.1146/annurev.biochem.71.110601.135501 
(2002). 
 
Bass, B. L. & Weintraub, H. An unwinding activity that covalently modifies its double-
stranded RNA substrate. Cell 55, 1089-1098 (1988). 
 
Batzer, M. A. & Deininger, P. L. Alu repeats and human genomic diversity. Nature 
reviews. Genetics 3, 370-379, doi:10.1038/nrg798 (2002). 
 
Beer, L. A., Tang, H. Y., Sriswasdi, S., Barnhart, K. T. & Speicher, D. W. Systematic 
discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling 
coupled with label-free quantitation. Journal of proteome research 10, 1126-
1138, doi:10.1021/pr1008866 (2011). 
 
Benne, R. et al. Major transcript of the frameshifted coxII gene from trypanosome 
mitochondria contains four nucleotides that are not encoded in the DNA. Cell 46, 
819-826 (1986). 
 
Bentley, D. R. et al. Accurate whole human genome sequencing using reversible 
terminator chemistry. Nature 456, 53-59, doi:10.1038/nature07517 (2008). 
 
Bertone, P. et al. Global identification of human transcribed sequences with genome 
tiling arrays. Science 306, 2242-2246, doi:10.1126/science.1103388 (2004). 
 
Bhogal, B. et al. Modulation of dADAR-dependent RNA editing by the Drosophila 
fragile X mental retardation protein. Nature neuroscience 14, 1517-1524, 
doi:10.1038/nn.2950 (2011). 
 
Bianchetti, L., Kieffer, D., Federkeil, R. & Poch, O. Increased frequency of single base 
substitutions in a population of transcripts expressed in cancer cells. BMC cancer 
12, 509, doi:10.1186/1471-2407-12-509 (2012). 
 
Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene 
expression profiling. Nature 406, 536-540, doi:10.1038/35020115 (2000). 
 
Blank, A., Gallant, J. A., Burgess, R. R. & Loeb, L. A. An RNA polymerase mutant with 
reduced accuracy of chain elongation. Biochemistry 25, 5920-5928 (1986). 
 
 215 
Bock, R., Hermann, M. & Kossel, H. In vivo dissection of cis-acting determinants for 
plastid RNA editing. The EMBO journal 15, 5052-5059 (1996). 
 
Bock, R., Kossel, H. & Maliga, P. Introduction of a heterologous editing site into the 
tobacco plastid genome: the lack of RNA editing leads to a mutant phenotype. 
The EMBO journal 13, 4623-4628 (1994). 
 
Boguski, M. S., Tolstoshev, C. M. & Bassett, D. E., Jr. Gene discovery in dbEST. 
Science 265, 1993-1994 (1994). 
 
Borchert, G. M. et al. Adenosine deamination in human transcripts generates novel 
microRNA binding sites. Human molecular genetics 18, 4801-4807, 
doi:10.1093/hmg/ddp443 (2009). 
 
Borukhov, S., Sagitov, V. & Goldfarb, A. Transcript cleavage factors from E. coli. Cell 
72, 459-466 (1993). 
 
Bourara, K., Litvak, S. & Araya, A. Generation of G-to-A and C-to-U changes in HIV-1 
transcripts by RNA editing. Science 289, 1564-1566 (2000). 
 
Boyle, A. P. et al. High-resolution mapping and characterization of open chromatin 
across the genome. Cell 132, 311-322, doi:10.1016/j.cell.2007.12.014 (2008). 
 
Braslavsky, I., Hebert, B., Kartalov, E. & Quake, S. R. Sequence information can be 
obtained from single DNA molecules. Proceedings of the National Academy of 
Sciences of the United States of America 100, 3960-3964, 
doi:10.1073/pnas.0230489100 (2003). 
 
Brem, R. B., Yvert, G., Clinton, R. & Kruglyak, L. Genetic dissection of transcriptional 
regulation in budding yeast. Science 296, 752-755, doi:10.1126/science.1069516 
(2002). 
 
Brenner, S. et al. Gene expression analysis by massively parallel signature sequencing 
(MPSS) on microbead arrays. Nature biotechnology 18, 630-634, 
doi:10.1038/76469 (2000). 
 
Brockman, W. et al. Quality scores and SNP detection in sequencing-by-synthesis 
systems. Genome research 18, 763-770, doi:10.1101/gr.070227.107 (2008). 
 
Brueckner, F., Hennecke, U., Carell, T. & Cramer, P. CPD damage recognition by 
transcribing RNA polymerase II. Science 315, 859-862, 
doi:10.1126/science.1135400 (2007). 
 
Brulliard, M. et al. Nonrandom variations in human cancer ESTs indicate that mRNA 
heterogeneity increases during carcinogenesis. Proceedings of the National 
 216 
Academy of Sciences of the United States of America 104, 7522-7527, 
doi:10.1073/pnas.0611076104 (2007). 
 
Bruno, V. M. et al. Comprehensive annotation of the transcriptome of the human fungal 
pathogen Candida albicans using RNA-seq. Genome research 20, 1451-1458, 
doi:10.1101/gr.109553.110 (2010). 
 
Brusa, R. et al. Early-onset epilepsy and postnatal lethality associated with an editing-
deficient GluR-B allele in mice. Science 270, 1677-1680 (1995). 
 
Bryant, D. W., Jr., Wong, W. K. & Mockler, T. C. QSRA: a quality-value guided de novo 
short read assembler. BMC bioinformatics 10, 69, doi:10.1186/1471-2105-10-69 
(2009). 
 
Burger, G., Yan, Y., Javadi, P. & Lang, B. F. Group I-intron trans-splicing and mRNA 
editing in the mitochondria of placozoan animals. Trends in genetics : TIG 25, 
381-386, doi:10.1016/j.tig.2009.07.003 (2009). 
 
Burns, C. M. et al. Regulation of serotonin-2C receptor G-protein coupling by RNA 
editing. Nature 387, 303-308, doi:10.1038/387303a0 (1997). 
 
Burrows, M. & Wheeler, D. A block-sorting lossless data compression algorithm. SRC 
Research Reports 124 (1994). 
 
Butler, J. et al. ALLPATHS: de novo assembly of whole-genome shotgun microreads. 
Genome research 18, 810-820, doi:10.1101/gr.7337908 (2008). 
 
Campagna, D. et al. PASS: a program to align short sequences. Bioinformatics 25, 967-
968, doi:10.1093/bioinformatics/btp087 (2009). 
 
Campbell, P. J. et al. Identification of somatically acquired rearrangements in cancer 
using genome-wide massively parallel paired-end sequencing. Nature genetics 40, 
722-729, doi:10.1038/ng.128 (2008). 
 
Cann, H. M. CEPH maps. Current opinion in genetics & development 2, 393-399 (1992). 
 
Cattaneo, R., Kaelin, K., Baczko, K. & Billeter, M. A. Measles virus editing provides an 
additional cysteine-rich protein. Cell 56, 759-764 (1989). 
 
Chaisson, M. J., Brinza, D. & Pevzner, P. A. De novo fragment assembly with short 
mate-paired reads: Does the read length matter? Genome research 19, 336-346, 
doi:10.1101/gr.079053.108 (2009). 
 
Chaisson, M. J. & Pevzner, P. A. Short read fragment assembly of bacterial genomes. 
Genome research 18, 324-330, doi:10.1101/gr.7088808 (2008). 
 
 217 
Chan, L. Apolipoprotein B, the major protein component of triglyceride-rich and low 
density lipoproteins. The Journal of biological chemistry 267, 25621-25624 
(1992). 
 
Chaudhuri, S., Carrer, H. & Maliga, P. Site-specific factor involved in the editing of the 
psbL mRNA in tobacco plastids. The EMBO journal 14, 2951-2957 (1995). 
 
Chen, K. et al. BreakDancer: an algorithm for high-resolution mapping of genomic 
structural variation. Nature methods 6, 677-681, doi:10.1038/nmeth.1363 (2009). 
 
Chen, S. H. et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-
specific in-frame stop codon. Science 238, 363-366 (1987). 
 
Chen, X. et al. Integration of external signaling pathways with the core transcriptional 
network in embryonic stem cells. Cell 133, 1106-1117, 
doi:10.1016/j.cell.2008.04.043 (2008). 
 
Chepelev, I. Detection of RNA editing events in human cells using high-throughput 
sequencing. Methods Mol Biol 815, 91-102, doi:10.1007/978-1-61779-424-7_8 
(2012). 
 
Chester, A., Scott, J., Anant, S. & Navaratnam, N. RNA editing: cytidine to uridine 
conversion in apolipoprotein B mRNA. Biochimica et biophysica acta 1494, 1-13 
(2000). 
 
Chiang, D. Y. et al. High-resolution mapping of copy-number alterations with massively 
parallel sequencing. Nature methods 6, 99-103, doi:10.1038/nmeth.1276 (2009). 
 
Cho, R. J. et al. A genome-wide transcriptional analysis of the mitotic cell cycle. 
Molecular cell 2, 65-73 (1998). 
 
Cho, R. J. et al. Transcriptional regulation and function during the human cell cycle. 
Nature genetics 27, 48-54, doi:10.1038/83751 (2001). 
 
Cloonan, N. et al. Stem cell transcriptome profiling via massive-scale mRNA 
sequencing. Nature methods 5, 613-619, doi:10.1038/nmeth.1223 (2008). 
 
Cocquet, J., Chong, A., Zhang, G. & Veitia, R. A. Reverse transcriptase template 
switching and false alternative transcripts. Genomics 88, 127-131, 
doi:10.1016/j.ygeno.2005.12.013 (2006). 
 
Cokus, S. J. et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals 
DNA methylation patterning. Nature 452, 215-219, doi:10.1038/nature06745 
(2008). 
 
 218 
Conticello, S. G. The AID/APOBEC family of nucleic acid mutators. Genome biology 9, 
229, doi:10.1186/gb-2008-9-6-229 (2008). 
 
Conticello, S. G. Creative deaminases, self-inflicted damage, and genome evolution. 
Annals of the New York Academy of Sciences 1267, 79-85, doi:10.1111/j.1749-
6632.2012.06614.x (2012). 
 
Cooper, T. A., Wan, L. & Dreyfuss, G. RNA and disease. Cell 136, 777-793, 
doi:10.1016/j.cell.2009.02.011 (2009). 
 
Covello, P. S. & Gray, M. W. RNA editing in plant mitochondria. Nature 341, 662-666, 
doi:10.1038/341662a0 (1989). 
 
Crawford, J. E. et al. De novo transcriptome sequencing in Anopheles funestus using 
Illumina RNA-Seq technology. PloS one 5, e14202, 
doi:10.1371/journal.pone.0014202 (2010). 
 
Crick, F. Central dogma of molecular biology. Nature 227, 561-563 (1970). 
 
Damsma, G. E., Alt, A., Brueckner, F., Carell, T. & Cramer, P. Mechanism of 
transcriptional stalling at cisplatin-damaged DNA. Nature structural & molecular 
biology 14, 1127-1133, doi:10.1038/nsmb1314 (2007). 
 
Dausset, J. et al. Centre d'etude du polymorphisme humain (CEPH): collaborative genetic 
mapping of the human genome. Genomics 6, 575-577 (1990). 
 
Davuluri, R. V., Suzuki, Y., Sugano, S., Plass, C. & Huang, T. H. The functional 
consequences of alternative promoter use in mammalian genomes. Trends in 
genetics : TIG 24, 167-177, doi:10.1016/j.tig.2008.01.008 (2008). 
 
De Bona, F., Ossowski, S., Schneeberger, K. & Ratsch, G. Optimal spliced alignments of 
short sequence reads. Bioinformatics 24, i174-180, 
doi:10.1093/bioinformatics/btn300 (2008). 
 
de Godoy, L. M. et al. Status of complete proteome analysis by mass spectrometry: 
SILAC labeled yeast as a model system. Genome biology 7, R50, doi:10.1186/gb-
2006-7-6-r50 (2006). 
 
de Mercoyrol, L., Corda, Y., Job, C. & Job, D. Accuracy of wheat-germ RNA 
polymerase II. General enzymatic properties and effect of template 
conformational transition from right-handed B-DNA to left-handed Z-DNA. 
European journal of biochemistry / FEBS 206, 49-58 (1992). 
 
Denoeud, F. et al. Annotating genomes with massive-scale RNA sequencing. Genome 
biology 9, R175, doi:10.1186/gb-2008-9-12-r175 (2008). 
 
 219 
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-
generation DNA sequencing data. Nature genetics 43, 491-498, 
doi:10.1038/ng.806 (2011). 
 
DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human 
cancer. Nature genetics 14, 457-460, doi:10.1038/ng1296-457 (1996). 
 
Deutsch, E. W. et al. A guided tour of the Trans-Proteomic Pipeline. Proteomics 10, 
1150-1159, doi:10.1002/pmic.200900375 (2010). 
 
DeVeale, B., van der Kooy, D. & Babak, T. Critical evaluation of imprinted gene 
expression by RNA-Seq: a new perspective. PLoS genetics 8, e1002600, 
doi:10.1371/journal.pgen.1002600 (2012). 
 
Di Giammartino, D. C., Nishida, K. & Manley, J. L. Mechanisms and consequences of 
alternative polyadenylation. Molecular cell 43, 853-866, 
doi:10.1016/j.molcel.2011.08.017 (2011). 
 
Diguistini, S. et al. De novo genome sequence assembly of a filamentous fungus using 
Sanger, 454 and Illumina sequence data. Genome biology 10, R94, 
doi:10.1186/gb-2009-10-9-r94 (2009). 
 
Dixon, A. L. et al. A genome-wide association study of global gene expression. Nature 
genetics 39, 1202-1207, doi:10.1038/ng2109 (2007). 
 
Djebali, S. et al. Landscape of transcription in human cells. Nature 489, 101-108, 
doi:10.1038/nature11233 (2012). 
 
Dohm, J. C., Lottaz, C., Borodina, T. & Himmelbauer, H. SHARCGS, a fast and highly 
accurate short-read assembly algorithm for de novo genomic sequencing. Genome 
research 17, 1697-1706, doi:10.1101/gr.6435207 (2007). 
 
Dohm, J. C., Lottaz, C., Borodina, T. & Himmelbauer, H. Substantial biases in ultra-short 
read data sets from high-throughput DNA sequencing. Nucleic acids research 36, 
e105, doi:10.1093/nar/gkn425 (2008). 
 
Dolan, M. E. et al. Heritability and linkage analysis of sensitivity to cisplatin-induced 
cytotoxicity. Cancer research 64, 4353-4356, doi:10.1158/0008-5472.CAN-04-
0340 (2004). 
 
Dorrell, R. G. & Howe, C. J. Functional remodeling of RNA processing in replacement 
chloroplasts by pathways retained from their predecessors. Proceedings of the 
National Academy of Sciences of the United States of America, 
doi:10.1073/pnas.1212270109 (2012). 
 
 220 
Dressman, D., Yan, H., Traverso, G., Kinzler, K. W. & Vogelstein, B. Transforming 
single DNA molecules into fluorescent magnetic particles for detection and 
enumeration of genetic variations. Proceedings of the National Academy of 
Sciences of the United States of America 100, 8817-8822, 
doi:10.1073/pnas.1133470100 (2003). 
 
Drmanac, R. et al. Human genome sequencing using unchained base reads on self-
assembling DNA nanoarrays. Science 327, 78-81, doi:10.1126/science.1181498 
(2010). 
 
Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome. 
Nature 489, 57-74, doi:10.1038/nature11247 (2012). 
 
Eaves, H. L. & Gao, Y. MOM: maximum oligonucleotide mapping. Bioinformatics 25, 
969-970, doi:10.1093/bioinformatics/btp092 (2009). 
 
Eid, J. et al. Real-time DNA sequencing from single polymerase molecules. Science 323, 
133-138, doi:10.1126/science.1162986 (2009). 
 
Elias, J. E., Haas, W., Faherty, B. K. & Gygi, S. P. Comparative evaluation of mass 
spectrometry platforms used in large-scale proteomics investigations. Nature 
methods 2, 667-675, doi:10.1038/nmeth785 (2005). 
 
Erie, D. A., Hajiseyedjavadi, O., Young, M. C. & von Hippel, P. H. Multiple RNA 
polymerase conformations and GreA: control of the fidelity of transcription. 
Science 262, 867-873 (1993). 
 
Ewing, B. & Green, P. Base-calling of automated sequencer traces using phred. II. Error 
probabilities. Genome research 8, 186-194 (1998). 
 
Fang, Y. et al. A complete sequence and transcriptomic analyses of date palm (Phoenix 
dactylifera L.) mitochondrial genome. PloS one 7, e37164, 
doi:10.1371/journal.pone.0037164 (2012). 
 
Farnham, P. J. Insights from genomic profiling of transcription factors. Nature reviews. 
Genetics 10, 605-616, doi:10.1038/nrg2636 (2009). 
 
Fedurco, M., Romieu, A., Williams, S., Lawrence, I. & Turcatti, G. BTA, a novel reagent 
for DNA attachment on glass and efficient generation of solid-phase amplified 
DNA colonies. Nucleic acids research 34, e22, doi:10.1093/nar/gnj023 (2006). 
 
Feng, J. et al. GFOLD: a generalized fold change for ranking differentially expressed 
genes from RNA-Seq data. Bioinformatics, doi:10.1093/bioinformatics/bts515 
(2012). 
 
 221 
Flicek, P. & Birney, E. Sense from sequence reads: methods for alignment and assembly. 
Nature methods 6, S6-S12, doi:10.1038/nmeth.1376 (2009). 
 
Flusberg, B. A. et al. Direct detection of DNA methylation during single-molecule, real-
time sequencing. Nature methods 7, 461-465, doi:10.1038/nmeth.1459 (2010). 
 
Fodor, S. P. et al. Multiplexed biochemical assays with biological chips. Nature 364, 
555-556, doi:10.1038/364555a0 (1993). 
 
Freyer, R., Kiefer-Meyer, M. C. & Kossel, H. Occurrence of plastid RNA editing in all 
major lineages of land plants. Proceedings of the National Academy of Sciences of 
the United States of America 94, 6285-6290 (1997). 
 
Gnerre, S. et al. High-quality draft assemblies of mammalian genomes from massively 
parallel sequence data. Proceedings of the National Academy of Sciences of the 
United States of America 108, 1513-1518, doi:10.1073/pnas.1017351108 (2011). 
 
Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction 
by gene expression monitoring. Science 286, 531-537 (1999). 
 
Gott, J. M. & Emeson, R. B. Functions and mechanisms of RNA editing. Annual review 
of genetics 34, 499-531, doi:10.1146/annurev.genet.34.1.499 (2000). 
 
Gott, J. M., Visomirski, L. M. & Hunter, J. L. Substitutional and insertional RNA editing 
of the cytochrome c oxidase subunit 1 mRNA of Physarum polycephalum. The 
Journal of biological chemistry 268, 25483-25486 (1993). 
 
Grabherr, M. G. et al. Full-length transcriptome assembly from RNA-Seq data without a 
reference genome. Nature biotechnology 29, 644-652, doi:10.1038/nbt.1883 
(2011). 
 
Grant, G. R. et al. Comparative analysis of RNA-Seq alignment algorithms and the RNA-
Seq unified mapper (RUM). Bioinformatics 27, 2518-2528, 
doi:10.1093/bioinformatics/btr427 (2011). 
 
Graveley, B. R. et al. The developmental transcriptome of Drosophila melanogaster. 
Nature 471, 473-479, doi:10.1038/nature09715 (2011). 
 
Greenberger, S. et al. Consistent levels of A-to-I RNA editing across individuals in 
coding sequences and non-conserved Alu repeats. BMC genomics 11, 608, 
doi:10.1186/1471-2164-11-608 (2010). 
 
Greeve, J., Altkemper, I., Dieterich, J. H., Greten, H. & Windler, E. Apolipoprotein B 
mRNA editing in 12 different mammalian species: hepatic expression is reflected 
in low concentrations of apoB-containing plasma lipoproteins. Journal of lipid 
research 34, 1367-1383 (1993). 
 222 
 
Gregg, C. et al. High-resolution analysis of parent-of-origin allelic expression in the 
mouse brain. Science 329, 643-648, doi:10.1126/science.1190830 (2010). 
 
Grewe, F., Viehoever, P., Weisshaar, B. & Knoop, V. A trans-splicing group I intron and 
tRNA-hyperediting in the mitochondrial genome of the lycophyte Isoetes 
engelmannii. Nucleic acids research 37, 5093-5104, doi:10.1093/nar/gkp532 
(2009). 
 
Grohmann, M. et al. Alternative splicing and extensive RNA editing of human TPH2 
transcripts. PloS one 5, e8956, doi:10.1371/journal.pone.0008956 (2010). 
 
Gualberto, J. M., Lamattina, L., Bonnard, G., Weil, J. H. & Grienenberger, J. M. RNA 
editing in wheat mitochondria results in the conservation of protein sequences. 
Nature 341, 660-662, doi:10.1038/341660a0 (1989). 
 
Gualberto, J. M., Weil, J. H. & Grienenberger, J. M. Editing of the wheat coxIII 
transcript: evidence for twelve C to U and one U to C conversions and for 
sequence similarities around editing sites. Nucleic acids research 18, 3771-3776 
(1990). 
 
Guttman, M. et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse 
reveals the conserved multi-exonic structure of lincRNAs. Nature biotechnology 
28, 503-510, doi:10.1038/nbt.1633 (2010). 
 
Halvardson, J., Zaghlool, A. & Feuk, L. Exome RNA sequencing reveals rare and novel 
alternative transcripts. Nucleic acids research 41, e6, doi:10.1093/nar/gks816 
(2013). 
 
Harbers, M. & Carninci, P. Tag-based approaches for transcriptome research and genome 
annotation. Nature methods 2, 495-502, doi:10.1038/nmeth768 (2005). 
 
Harismendy, O. et al. Evaluation of next generation sequencing platforms for population 
targeted sequencing studies. Genome biology 10, R32, doi:10.1186/gb-2009-10-3-
r32 (2009). 
 
Harrow, J. et al. GENCODE: producing a reference annotation for ENCODE. Genome 
biology 7 Suppl 1, S4 1-9, doi:10.1186/gb-2006-7-s1-s4 (2006). 
 
Heap, G. A. et al. Genome-wide analysis of allelic expression imbalance in human 
primary cells by high-throughput transcriptome resequencing. Human molecular 
genetics 19, 122-134, doi:10.1093/hmg/ddp473 (2010). 
 
Hendrickson, P. G. & Silliker, M. E. RNA editing in six mitochondrial ribosomal protein 
genes of Didymium iridis. Current genetics 56, 203-213, doi:10.1007/s00294-
010-0292-4 (2010). 
 223 
 
Hernandez, D., Francois, P., Farinelli, L., Osteras, M. & Schrenzel, J. De novo bacterial 
genome sequencing: millions of very short reads assembled on a desktop 
computer. Genome research 18, 802-809, doi:10.1101/gr.072033.107 (2008). 
 
Hersberger, M. & Innerarity, T. L. Two efficiency elements flanking the editing site of 
cytidine 6666 in the apolipoprotein B mRNA support mooring-dependent editing. 
The Journal of biological chemistry 273, 9435-9442 (1998). 
 
Hersberger, M., Patarroyo-White, S., Arnold, K. S. & Innerarity, T. L. Phylogenetic 
analysis of the apolipoprotein B mRNA-editing region. Evidence for a secondary 
structure between the mooring sequence and the 3' efficiency element. The 
Journal of biological chemistry 274, 34590-34597 (1999). 
 
Hiesel, R., Combettes, B. & Brennicke, A. Evidence for RNA editing in mitochondria of 
all major groups of land plants except the Bryophyta. Proceedings of the National 
Academy of Sciences of the United States of America 91, 629-633 (1994). 
 
Hiesel, R., Wissinger, B., Schuster, W. & Brennicke, A. RNA editing in plant 
mitochondria. Science 246, 1632-1634 (1989). 
 
Higuchi, M. et al. Point mutation in an AMPA receptor gene rescues lethality in mice 
deficient in the RNA-editing enzyme ADAR2. Nature 406, 78-81, 
doi:10.1038/35017558 (2000). 
 
Hoch, B., Maier, R. M., Appel, K., Igloi, G. L. & Kossel, H. Editing of a chloroplast 
mRNA by creation of an initiation codon. Nature 353, 178-180, 
doi:10.1038/353178a0 (1991). 
 
Homer, N., Merriman, B. & Nelson, S. F. BFAST: an alignment tool for large scale 
genome resequencing. PloS one 4, e7767, doi:10.1371/journal.pone.0007767 
(2009). 
 
Hoopengardner, B., Bhalla, T., Staber, C. & Reenan, R. Nervous system targets of RNA 
editing identified by comparative genomics. Science 301, 832-836, 
doi:10.1126/science.1086763 (2003). 
 
Hormozdiari, F., Alkan, C., Eichler, E. E. & Sahinalp, S. C. Combinatorial algorithms for 
structural variation detection in high-throughput sequenced genomes. Genome 
research 19, 1270-1278, doi:10.1101/gr.088633.108 (2009). 
 
Horton, T. L. & Landweber, L. F. Evolution of four types of RNA editing in 
myxomycetes. RNA 6, 1339-1346 (2000). 
 
 224 
Horton, T. L. & Landweber, L. F. Rewriting the information in DNA: RNA editing in 
kinetoplastids and myxomycetes. Current opinion in microbiology 5, 620-626 
(2002). 
 
Hospattankar, A. V., Higuchi, K., Law, S. W., Meglin, N. & Brewer, H. B., Jr. 
Identification of a novel in-frame translational stop codon in human intestine 
apoB mRNA. Biochemical and biophysical research communications 148, 279-
285 (1987). 
 
Hossain, M. S., Azimi, N. & Skiena, S. Crystallizing short-read assemblies around seeds. 
BMC bioinformatics 10 Suppl 1, S16, doi:10.1186/1471-2105-10-S1-S16 (2009). 
 
Hundley, H. A., Krauchuk, A. A. & Bass, B. L. C. elegans and H. sapiens mRNAs with 
edited 3' UTRs are present on polysomes. RNA 14, 2050-2060, 
doi:10.1261/rna.1165008 (2008). 
 
Idury, R. M. & Waterman, M. S. A new algorithm for DNA sequence assembly. Journal 
of computational biology : a journal of computational molecular cell biology 2, 
291-306 (1995). 
 
Inada, M., Sasaki, T., Yukawa, M., Tsudzuki, T. & Sugiura, M. A systematic search for 
RNA editing sites in pea chloroplasts: an editing event causes diversification from 
the evolutionarily conserved amino acid sequence. Plant & cell physiology 45, 
1615-1622, doi:10.1093/pcp/pch191 (2004). 
 
Innerarity, T. L. et al. Familial defective apolipoprotein B-100: a mutation of 
apolipoprotein B that causes hypercholesterolemia. Journal of lipid research 31, 
1337-1349 (1990). 
 
International HapMap Consortium. The International HapMap Project. Nature 426, 789-
796, doi:10.1038/nature02168 (2003). 
 
International HapMap Consortium. A haplotype map of the human genome. Nature 437, 
1299-1320, doi:10.1038/nature04226 (2005). 
 
Iyer, V. R. et al. The transcriptional program in the response of human fibroblasts to 
serum. Science 283, 83-87 (1999). 
 
Izban, M. G. & Luse, D. S. The RNA polymerase II ternary complex cleaves the nascent 
transcript in a 3'----5' direction in the presence of elongation factor SII. Genes & 
development 6, 1342-1356 (1992). 
 
Jackson, C. J. et al. Broad genomic and transcriptional analysis reveals a highly derived 
genome in dinoflagellate mitochondria. BMC biology 5, 41, doi:10.1186/1741-
7007-5-41 (2007). 
 
 225 
Jeck, W. R. et al. Extending assembly of short DNA sequences to handle error. 
Bioinformatics 23, 2942-2944, doi:10.1093/bioinformatics/btm451 (2007). 
 
Jepson, J. E. & Reenan, R. A. RNA editing in regulating gene expression in the brain. 
Biochimica et biophysica acta 1779, 459-470, doi:10.1016/j.bbagrm.2007.11.009 
(2008). 
 
Jepson, J. E., Savva, Y. A., Jay, K. A. & Reenan, R. A. Visualizing adenosine-to-inosine 
RNA editing in the Drosophila nervous system. Nature methods 9, 189-194, 
doi:10.1038/nmeth.1827 (2012). 
 
Jiang, H. & Wong, W. H. SeqMap: mapping massive amount of oligonucleotides to the 
genome. Bioinformatics 24, 2395-2396, doi:10.1093/bioinformatics/btn429 
(2008). 
 
Johnson, D. S., Mortazavi, A., Myers, R. M. & Wold, B. Genome-wide mapping of in 
vivo protein-DNA interactions. Science 316, 1497-1502, 
doi:10.1126/science.1141319 (2007). 
 
Ju, Y. S. et al. Extensive genomic and transcriptional diversity identified through 
massively parallel DNA and RNA sequencing of eighteen Korean individuals. 
Nature genetics 43, 745-752, doi:10.1038/ng.872 (2011). 
 
Kane, J. P., Hardman, D. A. & Paulus, H. E. Heterogeneity of apolipoprotein B: isolation 
of a new species from human chylomicrons. Proceedings of the National 
Academy of Sciences of the United States of America 77, 2465-2469 (1980). 
 
Kao, W. C. & Song, Y. S. naiveBayesCall: an efficient model-based base-calling 
algorithm for high-throughput sequencing. Journal of computational biology : a 
journal of computational molecular cell biology 18, 365-377, 
doi:10.1089/cmb.2010.0247 (2011). 
 
Kao, W. C., Stevens, K. & Song, Y. S. BayesCall: A model-based base-calling algorithm 
for high-throughput short-read sequencing. Genome research 19, 1884-1895, 
doi:10.1101/gr.095299.109 (2009). 
 
Karijolich, J. & Yu, Y. T. Converting nonsense codons into sense codons by targeted 
pseudouridylation. Nature 474, 395-398, doi:10.1038/nature10165 (2011). 
 
Kashkina, E. et al. Template misalignment in multisubunit RNA polymerases and 
transcription fidelity. Molecular cell 24, 257-266, 
doi:10.1016/j.molcel.2006.10.001 (2006). 
 
Kawahara, Y. et al. Glutamate receptors: RNA editing and death of motor neurons. 
Nature 427, 801, doi:10.1038/427801a (2004). 
 
 226 
Kawahara, Y. et al. Frequency and fate of microRNA editing in human brain. Nucleic 
acids research 36, 5270-5280, doi:10.1093/nar/gkn479 (2008). 
 
Kawahara, Y. et al. Redirection of silencing targets by adenosine-to-inosine editing of 
miRNAs. Science 315, 1137-1140, doi:10.1126/science.1138050 (2007). 
 
Keegan, L. P., Gallo, A. & O'Connell, M. A. The many roles of an RNA editor. Nature 
reviews. Genetics 2, 869-878, doi:10.1038/35098584 (2001). 
 
Kent, W. J. BLAT--the BLAST-like alignment tool. Genome research 12, 656-664, 
doi:10.1101/gr.229202. Article published online before March 2002 (2002). 
 
Kent, W. J. et al. The human genome browser at UCSC. Genome research 12, 996-1006, 
doi:10.1101/gr.229102. Article published online before print in May 2002 (2002). 
 
Kertesz, M. et al. Genome-wide measurement of RNA secondary structure in yeast. 
Nature 467, 103-107, doi:10.1038/nature09322 (2010). 
 
Kidd, J. M. et al. Mapping and sequencing of structural variation from eight human 
genomes. Nature 453, 56-64, doi:10.1038/nature06862 (2008). 
 
Kim, J. B. et al. Polony multiplex analysis of gene expression (PMAGE) in mouse 
hypertrophic cardiomyopathy. Science 316, 1481-1484, 
doi:10.1126/science.1137325 (2007). 
 
Kim, J. I. et al. A highly annotated whole-genome sequence of a Korean individual. 
Nature 460, 1011-1015, doi:10.1038/nature08211 (2009). 
 
Kim, S. R. et al. Rice OGR1 encodes a pentatricopeptide repeat-DYW protein and is 
essential for RNA editing in mitochondria. The Plant journal : for cell and 
molecular biology 59, 738-749, doi:10.1111/j.1365-313X.2009.03909.x (2009). 
 
Kim, Y. J. et al. ProbeMatch: rapid alignment of oligonucleotides to genome allowing 
both gaps and mismatches. Bioinformatics 25, 1424-1425, 
doi:10.1093/bioinformatics/btp178 (2009). 
 
Kiran, A. & Baranov, P. V. DARNED: a DAtabase of RNa EDiting in humans. 
Bioinformatics 26, 1772-1776, doi:10.1093/bioinformatics/btq285 (2010). 
 
Kircher, M., Stenzel, U. & Kelso, J. Improved base calling for the Illumina Genome 
Analyzer using machine learning strategies. Genome biology 10, R83, 
doi:10.1186/gb-2009-10-8-r83 (2009). 
 
Kireeva, M. L. et al. Transient reversal of RNA polymerase II active site closing controls 
fidelity of transcription elongation. Molecular cell 30, 557-566, 
doi:10.1016/j.molcel.2008.04.017 (2008). 
 227 
 
Kleinman, C. L., Adoue, V. & Majewski, J. RNA editing of protein sequences: A rare 
event in human transcriptomes. RNA 18, 1586-1596, doi:10.1261/rna.033233.112 
(2012). 
 
Kleinman, C. L. & Majewski, J. Comment on "Widespread RNA and DNA sequence 
differences in the human transcriptome". Science 335, 1302; author reply 1302, 
doi:10.1126/science.1209658 (2012). 
 
Knoop, V. When you can't trust the DNA: RNA editing changes transcript sequences. 
Cellular and molecular life sciences : CMLS 68, 567-586, doi:10.1007/s00018-
010-0538-9 (2011). 
 
Koboldt, D. C. et al. VarScan: variant detection in massively parallel sequencing of 
individual and pooled samples. Bioinformatics 25, 2283-2285, 
doi:10.1093/bioinformatics/btp373 (2009). 
 
Kodzius, R. et al. CAGE: cap analysis of gene expression. Nature methods 3, 211-222, 
doi:10.1038/nmeth0306-211 (2006). 
 
Korbel, J. O. et al. PEMer: a computational framework with simulation-based error 
models for inferring genomic structural variants from massive paired-end 
sequencing data. Genome biology 10, R23, doi:10.1186/gb-2009-10-2-r23 (2009). 
 
Korbel, J. O. et al. Paired-end mapping reveals extensive structural variation in the 
human genome. Science 318, 420-426, doi:10.1126/science.1149504 (2007). 
 
Kotera, E., Tasaka, M. & Shikanai, T. A pentatricopeptide repeat protein is essential for 
RNA editing in chloroplasts. Nature 433, 326-330, doi:10.1038/nature03229 
(2005). 
 
Krawitz, P. et al. Microindel detection in short-read sequence data. Bioinformatics 26, 
722-729, doi:10.1093/bioinformatics/btq027 (2010). 
 
Kugita, M., Yamamoto, Y., Fujikawa, T., Matsumoto, T. & Yoshinaga, K. RNA editing 
in hornwort chloroplasts makes more than half the genes functional. Nucleic acids 
research 31, 2417-2423 (2003). 
 
Kuhn, C. D. et al. Functional architecture of RNA polymerase I. Cell 131, 1260-1272, 
doi:10.1016/j.cell.2007.10.051 (2007). 
 
Landegren, U., Kaiser, R., Sanders, J. & Hood, L. A ligase-mediated gene detection 
technique. Science 241, 1077-1080 (1988). 
 
 228 
Langmead, B., Hansen, K. D. & Leek, J. T. Cloud-scale RNA-sequencing differential 
expression analysis with Myrna. Genome biology 11, R83, doi:10.1186/gb-2010-
11-8-r83 (2010). 
 
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome biology 10, 
R25, doi:10.1186/gb-2009-10-3-r25 (2009). 
 
Lau, N. C. et al. Characterization of the piRNA complex from rat testes. Science 313, 
363-367, doi:10.1126/science.1130164 (2006). 
 
Laurencikiene, J., Kallman, A. M., Fong, N., Bentley, D. L. & Ohman, M. RNA editing 
and alternative splicing: the importance of co-transcriptional coordination. EMBO 
reports 7, 303-307, doi:10.1038/sj.embor.7400621 (2006). 
 
Le, S. Q. & Durbin, R. SNP detection and genotyping from low-coverage sequencing 
data on multiple diploid samples. Genome research 21, 952-960, 
doi:10.1101/gr.113084.110 (2011). 
 
Leamon, J. H. et al. A massively parallel PicoTiterPlate based platform for discrete 
picoliter-scale polymerase chain reactions. Electrophoresis 24, 3769-3777, 
doi:10.1002/elps.200305646 (2003). 
 
Lee, R. D., Song, M. Y. & Lee, J. K. Large-scale profiling and identification of potential 
regulatory mechanisms for allelic gene expression in colorectal cancer cells. Gene 
512, 16-22, doi:10.1016/j.gene.2012.10.001 (2013). 
 
Lee, S., Hormozdiari, F., Alkan, C. & Brudno, M. MoDIL: detecting small indels from 
clone-end sequencing with mixtures of distributions. Nature methods 6, 473-474, 
doi:10.1038/nmeth.f.256 (2009). 
 
Legendre, P., Forstera, B., Juttner, R. & Meier, J. C. Glycine Receptors Caught between 
Genome and Proteome - Functional Implications of RNA Editing and Splicing. 
Frontiers in molecular neuroscience 2, 23, doi:10.3389/neuro.02.023.2009 
(2009). 
 
Levanon, E. Y. et al. Systematic identification of abundant A-to-I editing sites in the 
human transcriptome. Nature biotechnology 22, 1001-1005, doi:10.1038/nbt996 
(2004). 
 
Levin, J. Z. et al. Targeted next-generation sequencing of a cancer transcriptome 
enhances detection of sequence variants and novel fusion transcripts. Genome 
biology 10, R115, doi:10.1186/gb-2009-10-10-r115 (2009). 
 
 229 
Li, B., Ruotti, V., Stewart, R. M., Thomson, J. A. & Dewey, C. N. RNA-Seq gene 
expression estimation with read mapping uncertainty. Bioinformatics 26, 493-500, 
doi:10.1093/bioinformatics/btp692 (2010). 
 
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 25, 1754-1760, doi:10.1093/bioinformatics/btp324 
(2009). 
 
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 
2078-2079, doi:10.1093/bioinformatics/btp352 (2009). 
 
Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and calling variants 
using mapping quality scores. Genome research 18, 1851-1858, 
doi:10.1101/gr.078212.108 (2008). 
 
Li, J. B. et al. Genome-wide identification of human RNA editing sites by parallel DNA 
capturing and sequencing. Science 324, 1210-1213, doi:10.1126/science.1170995 
(2009). 
 
Li, M., Nordborg, M. & Li, L. M. Adjust quality scores from alignment and improve 
sequencing accuracy. Nucleic acids research 32, 5183-5191, 
doi:10.1093/nar/gkh850 (2004). 
 
Li, M. et al. Widespread RNA and DNA sequence differences in the human 
transcriptome. Science 333, 53-58, doi:10.1126/science.1207018 (2011). 
 
Li, R. et al. The sequence and de novo assembly of the giant panda genome. Nature 463, 
311-317, doi:10.1038/nature08696 (2010). 
 
Li, R. et al. SNP detection for massively parallel whole-genome resequencing. Genome 
research 19, 1124-1132, doi:10.1101/gr.088013.108 (2009). 
 
Li, R., Li, Y., Kristiansen, K. & Wang, J. SOAP: short oligonucleotide alignment 
program. Bioinformatics 24, 713-714, doi:10.1093/bioinformatics/btn025 (2008). 
 
Li, R. et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics 
25, 1966-1967, doi:10.1093/bioinformatics/btp336 (2009). 
 
Li, R. et al. De novo assembly of human genomes with massively parallel short read 
sequencing. Genome research 20, 265-272, doi:10.1101/gr.097261.109 (2010). 
 
Liang, H. & Landweber, L. F. Hypothesis: RNA editing of microRNA target sites in 
humans? RNA 13, 463-467, doi:10.1261/rna.296407 (2007). 
 
Libby, R. T. & Gallant, J. A. The role of RNA polymerase in transcriptional fidelity. 
Molecular microbiology 5, 999-1004 (1991). 
 230 
 
Licatalosi, D. D. & Darnell, R. B. RNA processing and its regulation: global insights into 
biological networks. Nature reviews. Genetics 11, 75-87, doi:10.1038/nrg2673 
(2010). 
 
Lin, H., Zhang, Z., Zhang, M. Q., Ma, B. & Li, M. ZOOM! Zillions of oligos mapped. 
Bioinformatics 24, 2431-2437, doi:10.1093/bioinformatics/btn416 (2008). 
 
Lin, S., Zhang, H., Spencer, D. F., Norman, J. E. & Gray, M. W. Widespread and 
extensive editing of mitochondrial mRNAS in dinoflagellates. Journal of 
molecular biology 320, 727-739 (2002). 
 
Lin, W., Piskol, R., Tan, M. H. & Li, J. B. Comment on "Widespread RNA and DNA 
sequence differences in the human transcriptome". Science 335, 1302; author 
reply 1302, doi:10.1126/science.1210624 (2012). 
 
Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. The 
Journal of experimental medicine 174, 561-569 (1991). 
 
Lister, R. et al. Highly integrated single-base resolution maps of the epigenome in 
Arabidopsis. Cell 133, 523-536, doi:10.1016/j.cell.2008.03.029 (2008). 
 
Locke, D. P. et al. Comparative and demographic analysis of orang-utan genomes. 
Nature 469, 529-533, doi:10.1038/nature09687 (2011). 
 
Lomeli, H. et al. Control of kinetic properties of AMPA receptor channels by nuclear 
RNA editing. Science 266, 1709-1713 (1994). 
 
Lu, T. et al. Function annotation of the rice transcriptome at single-nucleotide resolution 
by RNA-seq. Genome research 20, 1238-1249, doi:10.1101/gr.106120.110 
(2010). 
 
Lunter, G. & Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping 
of Illumina sequence reads. Genome research 21, 936-939, 
doi:10.1101/gr.111120.110 (2011). 
 
Luo, C., Tsementzi, D., Kyrpides, N., Read, T. & Konstantinidis, K. T. Direct 
comparisons of Illumina vs. Roche 454 sequencing technologies on the same 
microbial community DNA sample. PloS one 7, e30087, 
doi:10.1371/journal.pone.0030087 (2012). 
 
Lutz, C. S. Alternative polyadenylation: a twist on mRNA 3' end formation. ACS 
chemical biology 3, 609-617, doi:10.1021/cb800138w (2008). 
 
Maas, S., Patt, S., Schrey, M. & Rich, A. Underediting of glutamate receptor GluR-B 
mRNA in malignant gliomas. Proceedings of the National Academy of Sciences of 
 231 
the United States of America 98, 14687-14692, doi:10.1073/pnas.251531398 
(2001). 
 
Mahendran, R., Spottswood, M. R. & Miller, D. L. RNA editing by cytidine insertion in 
mitochondria of Physarum polycephalum. Nature 349, 434-438, 
doi:10.1038/349434a0 (1991). 
 
Maher, C. A. et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 
458, 97-101, doi:10.1038/nature07638 (2009). 
 
Malek, O., Lattig, K., Hiesel, R., Brennicke, A. & Knoop, V. RNA editing in bryophytes 
and a molecular phylogeny of land plants. The EMBO journal 15, 1403-1411 
(1996). 
 
Malone, C. D. & Hannon, G. J. Small RNAs as guardians of the genome. Cell 136, 656-
668, doi:10.1016/j.cell.2009.01.045 (2009). 
 
Maniatis, T. & Tasic, B. Alternative pre-mRNA splicing and proteome expansion in 
metazoans. Nature 418, 236-243, doi:10.1038/418236a (2002). 
 
Mardis, E. R. Next-generation DNA sequencing methods. Annual review of genomics 
and human genetics 9, 387-402, doi:10.1146/annurev.genom.9.081307.164359 
(2008). 
 
Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre 
reactors. Nature 437, 376-380, doi:10.1038/nature03959 (2005). 
 
Martin, G. & Keller, W. RNA-specific ribonucleotidyl transferases. RNA 13, 1834-1849, 
doi:10.1261/rna.652807 (2007). 
 
Martin, J. et al. Rnnotator: an automated de novo transcriptome assembly pipeline from 
stranded RNA-Seq reads. BMC genomics 11, 663, doi:10.1186/1471-2164-11-663 
(2010). 
 
Martin, J. A. & Wang, Z. Next-generation transcriptome assembly. Nature reviews. 
Genetics 12, 671-682, doi:10.1038/nrg3068 (2011). 
 
Martinez, H. D. et al. RNA editing of androgen receptor gene transcripts in prostate 
cancer cells. The Journal of biological chemistry 283, 29938-29949, 
doi:10.1074/jbc.M800534200 (2008). 
 
Matise, T. C. et al. A 3.9-centimorgan-resolution human single-nucleotide polymorphism 
linkage map and screening set. American journal of human genetics 73, 271-284 
(2003). 
 
 232 
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for 
analyzing next-generation DNA sequencing data. Genome research 20, 1297-
1303, doi:10.1101/gr.107524.110 (2010). 
 
McKernan, K. J. et al. Sequence and structural variation in a human genome uncovered 
by short-read, massively parallel ligation sequencing using two-base encoding. 
Genome research 19, 1527-1541, doi:10.1101/gr.091868.109 (2009). 
 
Meacham, F. et al. Identification and correction of systematic error in high-throughput 
sequence data. BMC bioinformatics 12, 451, doi:10.1186/1471-2105-12-451 
(2011). 
 
Mehta, A., Kinter, M. T., Sherman, N. E. & Driscoll, D. M. Molecular cloning of apobec-
1 complementation factor, a novel RNA-binding protein involved in the editing of 
apolipoprotein B mRNA. Molecular and cellular biology 20, 1846-1854 (2000). 
 
Meier, J. C. et al. RNA editing produces glycine receptor alpha3(P185L), resulting in 
high agonist potency. Nature neuroscience 8, 736-744, doi:10.1038/nn1467 
(2005). 
 
Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and 
differentiated cells. Nature 454, 766-770, doi:10.1038/nature07107 (2008). 
 
Mercer, T. R. et al. Targeted RNA sequencing reveals the deep complexity of the human 
transcriptome. Nature biotechnology 30, 99-104, doi:10.1038/nbt.2024 (2012). 
 
Metzker, M. L. Emerging technologies in DNA sequencing. Genome research 15, 1767-
1776, doi:10.1101/gr.3770505 (2005). 
 
Metzker, M. L. Sequencing in real time. Nature biotechnology 27, 150-151, 
doi:10.1038/nbt0209-150 (2009). 
 
Metzker, M. L. Sequencing technologies - the next generation. Nature reviews. Genetics 
11, 31-46, doi:10.1038/nrg2626 (2010). 
 
Michalski, A., Cox, J. & Mann, M. More than 100,000 detectable peptide species elute in 
single shotgun proteomics runs but the majority is inaccessible to data-dependent 
LC-MS/MS. Journal of proteome research 10, 1785-1793, 
doi:10.1021/pr101060v (2011). 
 
Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-
committed cells. Nature 448, 553-560, doi:10.1038/nature06008 (2007). 
 
Miller, J. R. et al. Aggressive assembly of pyrosequencing reads with mates. 
Bioinformatics 24, 2818-2824, doi:10.1093/bioinformatics/btn548 (2008). 
 
 233 
Mills, R. E. et al. Mapping copy number variation by population-scale genome 
sequencing. Nature 470, 59-65, doi:10.1038/nature09708 (2011). 
 
Minoche, A. E., Dohm, J. C. & Himmelbauer, H. Evaluation of genomic high-throughput 
sequencing data generated on Illumina HiSeq and genome analyzer systems. 
Genome biology 12, R112, doi:10.1186/gb-2011-12-11-r112 (2011). 
 
Montgomery, S. B. et al. Transcriptome genetics using second generation sequencing in a 
Caucasian population. Nature 464, 773-777, doi:10.1038/nature08903 (2010). 
 
Moore, M. J. & Proudfoot, N. J. Pre-mRNA processing reaches back to transcription and 
ahead to translation. Cell 136, 688-700, doi:10.1016/j.cell.2009.02.001 (2009). 
 
Morley, M. et al. Genetic analysis of genome-wide variation in human gene expression. 
Nature 430, 743-747, doi:10.1038/nature02797 (2004). 
 
Morse, D. P. & Bass, B. L. Long RNA hairpins that contain inosine are present in 
Caenorhabditis elegans poly(A)+ RNA. Proceedings of the National Academy of 
Sciences of the United States of America 96, 6048-6053 (1999). 
 
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and 
quantifying mammalian transcriptomes by RNA-Seq. Nature methods 5, 621-628, 
doi:10.1038/nmeth.1226 (2008). 
 
Nagalakshmi, U. et al. The transcriptional landscape of the yeast genome defined by 
RNA sequencing. Science 320, 1344-1349, doi:10.1126/science.1158441 (2008). 
 
Nakamura, K. et al. Sequence-specific error profile of Illumina sequencers. Nucleic acids 
research 39, e90, doi:10.1093/nar/gkr344 (2011). 
 
Ng, S. B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki 
syndrome. Nature genetics 42, 790-793, doi:10.1038/ng.646 (2010). 
 
Ng, S. B. et al. Exome sequencing identifies the cause of a mendelian disorder. Nature 
genetics 42, 30-35, doi:10.1038/ng.499 (2010). 
 
Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. 
Nature 461, 272-276, doi:10.1038/nature08250 (2009). 
 
Nielsen, R., Paul, J. S., Albrechtsen, A. & Song, Y. S. Genotype and SNP calling from 
next-generation sequencing data. Nature reviews. Genetics 12, 443-451, 
doi:10.1038/nrg2986 (2011). 
 
Nishikura, K. Editor meets silencer: crosstalk between RNA editing and RNA 
interference. Nature reviews. Molecular cell biology 7, 919-931, 
doi:10.1038/nrm2061 (2006). 
 234 
 
Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annual 
review of biochemistry 79, 321-349, doi:10.1146/annurev-biochem-060208-
105251 (2010). 
 
Novo, F. J., Kruszewski, A., MacDermot, K. D., Goldspink, G. & Gorecki, D. C. Editing 
of human alpha-galactosidase RNA resulting in a pyrimidine to purine 
conversion. Nucleic acids research 23, 2636-2640 (1995). 
 
O'Roak, B. J. et al. Exome sequencing in sporadic autism spectrum disorders identifies 
severe de novo mutations. Nature genetics 43, 585-589, doi:10.1038/ng.835 
(2011). 
 
Okoniewski, M. J. & Miller, C. J. Hybridization interactions between probesets in short 
oligo microarrays lead to spurious correlations. BMC bioinformatics 7, 276, 
doi:10.1186/1471-2105-7-276 (2006). 
 
Okuda, K. et al. The pentatricopeptide repeat protein OTP82 is required for RNA editing 
of plastid ndhB and ndhG transcripts. The Plant journal : for cell and molecular 
biology 61, 339-349, doi:10.1111/j.1365-313X.2009.04059.x (2010). 
 
Orlandi, C., Barbon, A. & Barlati, S. Activity regulation of adenosine deaminases acting 
on RNA (ADARs). Molecular neurobiology 45, 61-75, doi:10.1007/s12035-011-
8220-2 (2012). 
 
Ozsolak, F. et al. Comprehensive polyadenylation site maps in yeast and human reveal 
pervasive alternative polyadenylation. Cell 143, 1018-1029, 
doi:10.1016/j.cell.2010.11.020 (2010). 
 
Ozsolak, F. & Milos, P. M. Transcriptome profiling using single-molecule direct RNA 
sequencing. Methods Mol Biol 733, 51-61, doi:10.1007/978-1-61779-089-8_4 
(2011). 
 
Ozsolak, F. et al. Direct RNA sequencing. Nature 461, 814-818, 
doi:10.1038/nature08390 (2009). 
 
Palladino, M. J., Keegan, L. P., O'Connell, M. A. & Reenan, R. A. A-to-I pre-mRNA 
editing in Drosophila is primarily involved in adult nervous system function and 
integrity. Cell 102, 437-449 (2000). 
 
Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative 
splicing complexity in the human transcriptome by high-throughput sequencing. 
Nature genetics 40, 1413-1415, doi:10.1038/ng.259 (2008). 
 
 235 
Park, E., Williams, B., Wold, B. J. & Mortazavi, A. RNA editing in the human ENCODE 
RNA-Seq data. Genome research 22, 1626-1633, doi:10.1101/gr.134957.111 
(2012). 
 
Paschen, W., Hedreen, J. C. & Ross, C. A. RNA editing of the glutamate receptor 
subunits GluR2 and GluR6 in human brain tissue. Journal of neurochemistry 63, 
1596-1602 (1994). 
 
Peng, Z. et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing 
in a human transcriptome. Nature biotechnology 30, 253-260, 
doi:10.1038/nbt.2122 (2012). 
 
Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based protein 
identification by searching sequence databases using mass spectrometry data. 
Electrophoresis 20, 3551-3567, doi:10.1002/(SICI)1522-
2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2 (1999). 
 
Peters, P. J., Neefjes, J. J., Oorschot, V., Ploegh, H. L. & Geuze, H. J. Segregation of 
MHC class II molecules from MHC class I molecules in the Golgi complex for 
transport to lysosomal compartments. Nature 349, 669-676, 
doi:10.1038/349669a0 (1991). 
 
Pevzner, P. A., Borodovsky, M. & Mironov, A. A. Linguistics of nucleotide sequences. 
II: Stationary words in genetic texts and the zonal structure of DNA. Journal of 
biomolecular structure & dynamics 6, 1027-1038 (1989). 
 
Pevzner, P. A., Tang, H. & Waterman, M. S. An Eulerian path approach to DNA 
fragment assembly. Proceedings of the National Academy of Sciences of the 
United States of America 98, 9748-9753, doi:10.1073/pnas.171285098 (2001). 
 
Phreaner, C. G., Williams, M. A. & Mulligan, R. M. Incomplete editing of rps12 
transcripts results in the synthesis of polymorphic polypeptides in plant 
mitochondria. The Plant cell 8, 107-117, doi:10.1105/tpc.8.1.107 (1996). 
 
Pickrell, J. K., Gilad, Y. & Pritchard, J. K. Comment on "Widespread RNA and DNA 
sequence differences in the human transcriptome". Science 335, 1302; author 
reply 1302, doi:10.1126/science.1210484 (2012). 
 
Pickrell, J. K., Pai, A. A., Gilad, Y. & Pritchard, J. K. Noisy splicing drives mRNA 
isoform diversity in human cells. PLoS genetics 6, e1001236, 
doi:10.1371/journal.pgen.1001236 (2010). 
 
Polson, A. G. & Bass, B. L. Preferential selection of adenosines for modification by 
double-stranded RNA adenosine deaminase. The EMBO journal 13, 5701-5711 
(1994). 
 
 236 
Pomerantz, R. T., Temiakov, D., Anikin, M., Vassylyev, D. G. & McAllister, W. T. A 
mechanism of nucleotide misincorporation during transcription due to template-
strand misalignment. Molecular cell 24, 245-255, 
doi:10.1016/j.molcel.2006.08.014 (2006). 
 
Powell, L. M. et al. A novel form of tissue-specific RNA processing produces 
apolipoprotein-B48 in intestine. Cell 50, 831-840 (1987). 
 
Pruitt, K. D., Tatusova, T., Brown, G. R. & Maglott, D. R. NCBI Reference Sequences 
(RefSeq): current status, new features and genome annotation policy. Nucleic 
acids research 40, D130-135, doi:10.1093/nar/gkr1079 (2012). 
 
Pullirsch, D. & Jantsch, M. F. Proteome diversification by adenosine to inosine RNA 
editing. RNA biology 7, 205-212 (2010). 
 
Qi, J., Zhao, F., Buboltz, A. & Schuster, S. C. inGAP: an integrated next-generation 
genome analysis pipeline. Bioinformatics 26, 127-129, 
doi:10.1093/bioinformatics/btp615 (2010). 
 
Qian, L., Quadros, E. V., Regec, A., Zittoun, J. & Rothenberg, S. P. Congenital 
transcobalamin II deficiency due to errors in RNA editing. Blood cells, molecules 
& diseases 28, 134-142; discussion 143-135 (2002). 
 
Qu, W., Hashimoto, S. & Morishita, S. Efficient frequency-based de novo short-read 
clustering for error trimming in next-generation sequencing. Genome research 19, 
1309-1315, doi:10.1101/gr.089151.108 (2009). 
 
Quail, M. A. et al. A tale of three next generation sequencing platforms: comparison of 
Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC genomics 
13, 341, doi:10.1186/1471-2164-13-341 (2012). 
 
Quinlan, A. R., Stewart, D. A., Stromberg, M. P. & Marth, G. T. Pyrobayes: an improved 
base caller for SNP discovery in pyrosequences. Nature methods 5, 179-181, 
doi:10.1038/nmeth.1172 (2008). 
 
Ramaswami, G. et al. Accurate identification of human Alu and non-Alu RNA editing 
sites. Nature methods, doi:10.1038/nmeth.1982 (2012). 
 
Ramaswami, G. et al. Identifying RNA editing sites using RNA sequencing data alone. 
Nature methods 10, 128-132, doi:10.1038/nmeth.2330 (2013). 
 
Reid, J. G. et al. Mouse let-7 miRNA populations exhibit RNA editing that is constrained 
in the 5'-seed/ cleavage/anchor regions and stabilize predicted mmu-let-7a:mRNA 
duplexes. Genome research 18, 1571-1581, doi:10.1101/gr.078246.108 (2008). 
 
 237 
Robbins, J. C., Heller, W. P. & Hanson, M. R. A comparative genomics approach 
identifies a PPR-DYW protein that is essential for C-to-U editing of the 
Arabidopsis chloroplast accD transcript. RNA 15, 1142-1153, 
doi:10.1261/rna.1533909 (2009). 
 
Roberts, A., Trapnell, C., Donaghey, J., Rinn, J. L. & Pachter, L. Improving RNA-Seq 
expression estimates by correcting for fragment bias. Genome biology 12, R22, 
doi:10.1186/gb-2011-12-3-r22 (2011). 
 
Robertson, G. et al. De novo assembly and analysis of RNA-Seq data. Nature methods 7, 
909-912, doi:10.1038/nmeth.1517 (2010). 
 
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data. Bioinformatics 26, 
139-140, doi:10.1093/bioinformatics/btp616 (2010). 
 
Rodriguez, J., Menet, J. S. & Rosbash, M. Nascent-seq indicates widespread 
cotranscriptional RNA editing in Drosophila. Molecular cell 47, 27-37, 
doi:10.1016/j.molcel.2012.05.002 (2012). 
 
Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M. & Nyren, P. Real-time DNA 
sequencing using detection of pyrophosphate release. Analytical biochemistry 
242, 84-89, doi:10.1006/abio.1996.0432 (1996). 
 
Ronaghi, M., Uhlen, M. & Nyren, P. A sequencing method based on real-time 
pyrophosphate. Science 281, 363, 365 (1998). 
 
Rosenberg, B. R., Hamilton, C. E., Mwangi, M. M., Dewell, S. & Papavasiliou, F. N. 
Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing 
targets in transcript 3' UTRs. Nature structural & molecular biology 18, 230-236, 
doi:10.1038/nsmb.1975 (2011). 
 
Rosenberger, R. F. & Hilton, J. The frequency of transcriptional and translational errors 
at nonsense codons in the lacZ gene of Escherichia coli. Molecular & general 
genetics : MGG 191, 207-212 (1983). 
 
Rosenbloom, K. R. et al. ENCODE whole-genome data in the UCSC Genome Browser. 
Nucleic acids research 38, D620-625, doi:10.1093/nar/gkp961 (2010). 
 
Rosenthal, J. J. & Bezanilla, F. Extensive editing of mRNAs for the squid delayed 
rectifier K+ channel regulates subunit tetramerization. Neuron 34, 743-757 
(2002). 
 
Ross, R. Cell biology of atherosclerosis. Annual review of physiology 57, 791-804, 
doi:10.1146/annurev.ph.57.030195.004043 (1995). 
 
 238 
Rothberg, J. M. et al. An integrated semiconductor device enabling non-optical genome 
sequencing. Nature 475, 348-352, doi:10.1038/nature10242 (2011). 
 
Rothberg, J. M. & Leamon, J. H. The development and impact of 454 sequencing. Nature 
biotechnology 26, 1117-1124, doi:10.1038/nbt1485 (2008). 
 
Rottman, F. M., Bokar, J. A., Narayan, P., Shambaugh, M. E. & Ludwiczak, R. N6-
adenosine methylation in mRNA: substrate specificity and enzyme complexity. 
Biochimie 76, 1109-1114 (1994). 
 
Rueter, S. M., Burns, C. M., Coode, S. A., Mookherjee, P. & Emeson, R. B. Glutamate 
receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. 
Science 267, 1491-1494 (1995). 
 
Rueter, S. M., Dawson, T. R. & Emeson, R. B. Regulation of alternative splicing by RNA 
editing. Nature 399, 75-80, doi:10.1038/19992 (1999). 
 
Rumble, S. M. et al. SHRiMP: accurate mapping of short color-space reads. PLoS 
computational biology 5, e1000386, doi:10.1371/journal.pcbi.1000386 (2009). 
 
Sakurai, M., Yano, T., Kawabata, H., Ueda, H. & Suzuki, T. Inosine cyanoethylation 
identifies A-to-I RNA editing sites in the human transcriptome. Nature chemical 
biology 6, 733-740, doi:10.1038/nchembio.434 (2010). 
 
Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A. & Burge, C. B. Proliferating cells 
express mRNAs with shortened 3' untranslated regions and fewer microRNA 
target sites. Science 320, 1643-1647, doi:10.1126/science.1155390 (2008). 
 
Sanger, F., Nicklen, S. & Coulson, A. R. DNA sequencing with chain-terminating 
inhibitors. Proceedings of the National Academy of Sciences of the United States 
of America 74, 5463-5467 (1977). 
 
Sawada, J. et al. Effects of antidepressants on GluR2 Q/R site-RNA editing in modified 
HeLa cell line. Neuroscience research 64, 251-258, 
doi:10.1016/j.neures.2009.03.009 (2009). 
 
Schaefer, M., Pollex, T., Hanna, K. & Lyko, F. RNA cytosine methylation analysis by 
bisulfite sequencing. Nucleic acids research 37, e12, doi:10.1093/nar/gkn954 
(2009). 
 
Schatz, M. C. CloudBurst: highly sensitive read mapping with MapReduce. 
Bioinformatics 25, 1363-1369, doi:10.1093/bioinformatics/btp236 (2009). 
 
Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. Quantitative monitoring of gene 
expression patterns with a complementary DNA microarray. Science 270, 467-
470 (1995). 
 239 
 
Schoft, V. K., Schopoff, S. & Jantsch, M. F. Regulation of glutamate receptor B pre-
mRNA splicing by RNA editing. Nucleic acids research 35, 3723-3732, 
doi:10.1093/nar/gkm314 (2007). 
 
Schones, D. E. et al. Dynamic regulation of nucleosome positioning in the human 
genome. Cell 132, 887-898, doi:10.1016/j.cell.2008.02.022 (2008). 
 
Schrider, D. R., Gout, J. F. & Hahn, M. W. Very few RNA and DNA sequence 
differences in the human transcriptome. PloS one 6, e25842, 
doi:10.1371/journal.pone.0025842 (2011). 
 
Schulz, M. H., Zerbino, D. R., Vingron, M. & Birney, E. Oases: robust de novo RNA-
Seq assembly across the dynamic range of expression levels. Bioinformatics 28, 
1086-1092, doi:10.1093/bioinformatics/bts094 (2012). 
 
Schuster, S. C. et al. Complete Khoisan and Bantu genomes from southern Africa. Nature 
463, 943-947, doi:10.1038/nature08795 (2010). 
 
Schuster, W., Hiesel, R., Wissinger, B. & Brennicke, A. RNA editing in the cytochrome 
b locus of the higher plant Oenothera berteriana includes a U-to-C transition. 
Molecular and cellular biology 10, 2428-2431 (1990). 
 
Seeburg, P. H. & Hartner, J. Regulation of ion channel/neurotransmitter receptor function 
by RNA editing. Current opinion in neurobiology 13, 279-283 (2003). 
 
Shah, R. R. et al. Sequence requirements for the editing of apolipoprotein B mRNA. The 
Journal of biological chemistry 266, 16301-16304 (1991). 
 
Sharma, P. M., Bowman, M., Madden, S. L., Rauscher, F. J., 3rd & Sukumar, S. RNA 
editing in the Wilms' tumor susceptibility gene, WT1. Genes & development 8, 
720-731 (1994). 
 
Shendure, J. & Ji, H. Next-generation DNA sequencing. Nature biotechnology 26, 1135-
1145, doi:10.1038/nbt1486 (2008). 
 
Shendure, J. et al. Accurate multiplex polony sequencing of an evolved bacterial genome. 
Science 309, 1728-1732, doi:10.1126/science.1117389 (2005). 
 
Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic acids 
research 29, 308-311 (2001). 
 
Silberberg, G., Lundin, D., Navon, R. & Ohman, M. Deregulation of the A-to-I RNA 
editing mechanism in psychiatric disorders. Human molecular genetics 21, 311-
321, doi:10.1093/hmg/ddr461 (2012). 
 
 240 
Simpson, J. T. et al. ABySS: a parallel assembler for short read sequence data. Genome 
research 19, 1117-1123, doi:10.1101/gr.089532.108 (2009). 
 
Skuse, G. R., Cappione, A. J., Sowden, M., Metheny, L. J. & Smith, H. C. The 
neurofibromatosis type I messenger RNA undergoes base-modification RNA 
editing. Nucleic acids research 24, 478-485 (1996). 
 
Smit, A. F. The origin of interspersed repeats in the human genome. Current opinion in 
genetics & development 6, 743-748 (1996). 
 
Smith, A. D., Xuan, Z. & Zhang, M. Q. Using quality scores and longer reads improves 
accuracy of Solexa read mapping. BMC bioinformatics 9, 128, doi:10.1186/1471-
2105-9-128 (2008). 
 
Smith, D. R. et al. Rapid whole-genome mutational profiling using next-generation 
sequencing technologies. Genome research 18, 1638-1642, 
doi:10.1101/gr.077776.108 (2008). 
 
Smith, H. C., Bennett, R. P., Kizilyer, A., McDougall, W. M. & Prohaska, K. M. 
Functions and regulation of the APOBEC family of proteins. Seminars in cell & 
developmental biology 23, 258-268, doi:10.1016/j.semcdb.2011.10.004 (2012). 
 
Smith, H. C., Gott, J. M. & Hanson, M. R. A guide to RNA editing. RNA 3, 1105-1123 
(1997). 
 
Sodek, K. L. et al. Identification of pathways associated with invasive behavior by 
ovarian cancer cells using multidimensional protein identification technology 
(MudPIT). Molecular bioSystems 4, 762-773, doi:10.1039/b717542f (2008). 
 
Sommer, B., Kohler, M., Sprengel, R. & Seeburg, P. H. RNA editing in brain controls a 
determinant of ion flow in glutamate-gated channels. Cell 67, 11-19 (1991). 
 
Song, C. X., Yi, C. & He, C. Mapping recently identified nucleotide variants in the 
genome and transcriptome. Nature biotechnology 30, 1107-1116, 
doi:10.1038/nbt.2398 (2012). 
 
Sper-Whitis, G. L., Moody, J. L. & Vaughn, J. C. Universality of mitochondrial RNA 
editing in cytochrome-c oxidase subunit I (coxI) among the land plants. 
Biochimica et biophysica acta 1307, 301-308 (1996). 
 
Sper-Whitis, G. L., Russell, A. L. & Vaughn, J. C. Mitochondrial RNA editing of 
cytochrome c oxidase subunit II (coxII) in the primitive vascular plant Psilotum 
nudum. Biochimica et biophysica acta 1218, 218-220 (1994). 
 
Steinhauser, S., Beckert, S., Capesius, I., Malek, O. & Knoop, V. Plant mitochondrial 
RNA editing. Journal of molecular evolution 48, 303-312 (1999). 
 241 
 
Stern, A. S. et al. Purification to homogeneity and partial characterization of interleukin 2 
from a human T-cell leukemia. Proceedings of the National Academy of Sciences 
of the United States of America 81, 871-875 (1984). 
 
Sultan, M. et al. A global view of gene activity and alternative splicing by deep 
sequencing of the human transcriptome. Science 321, 956-960, 
doi:10.1126/science.1160342 (2008). 
 
Surget-Groba, Y. & Montoya-Burgos, J. I. Optimization of de novo transcriptome 
assembly from next-generation sequencing data. Genome research 20, 1432-
1440, doi:10.1101/gr.103846.109 (2010). 
 
Sutton, C. A., Zoubenko, O. V., Hanson, M. R. & Maliga, P. A plant mitochondrial 
sequence transcribed in transgenic tobacco chloroplasts is not edited. Molecular 
and cellular biology 15, 1377-1381 (1995). 
 
Sydow, J. F. et al. Structural basis of transcription: mismatch-specific fidelity 
mechanisms and paused RNA polymerase II with frayed RNA. Molecular cell 34, 
710-721, doi:10.1016/j.molcel.2009.06.002 (2009). 
 
Sydow, J. F. & Cramer, P. RNA polymerase fidelity and transcriptional proofreading. 
Current opinion in structural biology 19, 732-739, doi:10.1016/j.sbi.2009.10.009 
(2009). 
 
Taft, R. J. et al. Nuclear-localized tiny RNAs are associated with transcription initiation 
and splice sites in metazoans. Nature structural & molecular biology 17, 1030-
1034, doi:10.1038/nsmb.1841 (2010). 
 
Tan, B. Z., Huang, H., Lam, R. & Soong, T. W. Dynamic regulation of RNA editing of 
ion channels and receptors in the mammalian nervous system. Molecular brain 2, 
13, doi:10.1186/1756-6606-2-13 (2009). 
 
Temiakov, D. et al. Structural basis for substrate selection by t7 RNA polymerase. Cell 
116, 381-391 (2004). 
 
Temple, G. et al. The completion of the Mammalian Gene Collection (MGC). Genome 
research 19, 2324-2333, doi:10.1101/gr.095976.109 (2009). 
 
Tennessen, J. A. et al. Evolution and functional impact of rare coding variation from deep 
sequencing of human exomes. Science 337, 64-69, doi:10.1126/science.1219240 
(2012). 
 
Thomas, M. J., Platas, A. A. & Hawley, D. K. Transcriptional fidelity and proofreading 
by RNA polymerase II. Cell 93, 627-637 (1998). 
 
 242 
Thomas, S. M., Lamb, R. A. & Paterson, R. G. Two mRNAs that differ by two 
nontemplated nucleotides encode the amino coterminal proteins P and V of the 
paramyxovirus SV5. Cell 54, 891-902 (1988). 
 
Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer 
(IGV): high-performance genomics data visualization and exploration. Briefings 
in bioinformatics, doi:10.1093/bib/bbs017 (2012). 
 
Tillich, M. et al. Editing of plastid RNA in Arabidopsis thaliana ecotypes. The Plant 
journal : for cell and molecular biology 43, 708-715, doi:10.1111/j.1365-
313X.2005.02484.x (2005). 
 
Tonkin, L. A. et al. RNA editing by ADARs is important for normal behavior in 
Caenorhabditis elegans. The EMBO journal 21, 6025-6035 (2002). 
 
Toung, J. M., Morley, M., Li, M. & Cheung, V. G. RNA-sequence analysis of human B-
cells. Genome research 21, 991-998, doi:10.1101/gr.116335.110 (2011). 
 
Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with 
RNA-Seq. Bioinformatics 25, 1105-1111, doi:10.1093/bioinformatics/btp120 
(2009). 
 
Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-Seq 
experiments with TopHat and Cufflinks. Nature protocols 7, 562-578, 
doi:10.1038/nprot.2012.016 (2012). 
 
Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nature 
biotechnology 28, 511-515, doi:10.1038/nbt.1621 (2010). 
 
Tsudzuki, T., Wakasugi, T. & Sugiura, M. Comparative analysis of RNA editing sites in 
higher plant chloroplasts. Journal of molecular evolution 53, 327-332, 
doi:10.1007/s002390010222 (2001). 
 
Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480-
484, doi:10.1038/nature07540 (2009). 
 
Turner, T. L., Bourne, E. C., Von Wettberg, E. J., Hu, T. T. & Nuzhdin, S. V. Population 
resequencing reveals local adaptation of Arabidopsis lyrata to serpentine soils. 
Nature genetics 42, 260-263, doi:10.1038/ng.515 (2010). 
 
Twine, N. A., Janitz, K., Wilkins, M. R. & Janitz, M. Whole transcriptome sequencing 
reveals gene expression and splicing differences in brain regions affected by 
Alzheimer's disease. PloS one 6, e16266, doi:10.1371/journal.pone.0016266 
(2011). 
 
 243 
Underwood, J. G. et al. FragSeq: transcriptome-wide RNA structure probing using high-
throughput sequencing. Nature methods 7, 995-1001, doi:10.1038/nmeth.1529 
(2010). 
 
van Leeuwen, F. W. et al. Frameshift mutants of beta amyloid precursor protein and 
ubiquitin-B in Alzheimer's and Down patients. Science 279, 242-247 (1998). 
 
Vassylyev, D. G. et al. Structural basis for substrate loading in bacterial RNA 
polymerase. Nature 448, 163-168, doi:10.1038/nature05931 (2007). 
 
Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Serial analysis of gene 
expression. Science 270, 484-487 (1995). 
 
Vidal, S., Curran, J. & Kolakofsky, D. Editing of the Sendai virus P/C mRNA by G 
insertion occurs during mRNA synthesis via a virus-encoded activity. Journal of 
virology 64, 239-246 (1990a). 
 
Vidal, S., Curran, J. & Kolakofsky, D. A stuttering model for paramyxovirus P mRNA 
editing. The EMBO journal 9, 2017-2022 (1990b). 
 
Wahlstedt, H., Daniel, C., Enstero, M. & Ohman, M. Large-scale mRNA sequencing 
determines global regulation of RNA editing during brain development. Genome 
research 19, 978-986, doi:10.1101/gr.089409.108 (2009). 
 
Wang, D. et al. Structural basis of transcription: backtracked RNA polymerase II at 3.4 
angstrom resolution. Science 324, 1203-1206, doi:10.1126/science.1168729 
(2009). 
 
Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 
456, 470-476, doi:10.1038/nature07509 (2008). 
 
Wang, J. et al. The diploid genome sequence of an Asian individual. Nature 456, 60-65, 
doi:10.1038/nature07484 (2008). 
 
Wang, K. et al. MapSplice: accurate mapping of RNA-Seq reads for splice junction 
discovery. Nucleic acids research 38, e178, doi:10.1093/nar/gkq622 (2010). 
 
Wang, L., Feng, Z., Wang, X., Wang, X. & Zhang, X. DEGseq: an R package for 
identifying differentially expressed genes from RNA-Seq data. Bioinformatics 26, 
136-138, doi:10.1093/bioinformatics/btp612 (2010). 
 
Wang, Q., Khillan, J., Gadue, P. & Nishikura, K. Requirement of the RNA editing 
deaminase ADAR1 gene for embryonic erythropoiesis. Science 290, 1765-1768 
(2000). 
 
 244 
Wang, W., Wu, Y. & Messing, J. The Mitochondrial Genome of an Aquatic Plant, 
Spirodela polyrhiza. PloS one 7, e46747, doi:10.1371/journal.pone.0046747 
(2012). 
 
Warf, M. B., Shepherd, B. A., Johnson, W. E. & Bass, B. L. Effects of ADARs on small 
RNA processing pathways in C. elegans. Genome research 22, 1488-1498, 
doi:10.1101/gr.134841.111 (2012). 
 
Warren, R. L., Sutton, G. G., Jones, S. J. & Holt, R. A. Assembling millions of short 
DNA sequences using SSAKE. Bioinformatics 23, 500-501, 
doi:10.1093/bioinformatics/btl629 (2007). 
 
Wedekind, J. E., Dance, G. S., Sowden, M. P. & Smith, H. C. Messenger RNA editing in 
mammals: new members of the APOBEC family seeking roles in the family 
business. Trends in genetics : TIG 19, 207-216, doi:10.1016/S0168-
9525(03)00054-4 (2003). 
 
Wederell, E. D. et al. Global analysis of in vivo Foxa2-binding sites in mouse adult liver 
using massively parallel sequencing. Nucleic acids research 36, 4549-4564, 
doi:10.1093/nar/gkn382 (2008). 
 
Wheeler, D. A. et al. The complete genome of an individual by massively parallel DNA 
sequencing. Nature 452, 872-876, doi:10.1038/nature06884 (2008). 
 
Wilhelm, B. T. et al. Dynamic repertoire of a eukaryotic transcriptome surveyed at 
single-nucleotide resolution. Nature 453, 1239-1243, doi:10.1038/nature07002 
(2008). 
 
Wolf, P. G., Rowe, C. A. & Hasebe, M. High levels of RNA editing in a vascular plant 
chloroplast genome: analysis of transcripts from the fern Adiantum capillus-
veneris. Gene 339, 89-97, doi:10.1016/j.gene.2004.06.018 (2004). 
 
Wommack, K. E., Bhavsar, J. & Ravel, J. Metagenomics: read length matters. Applied 
and environmental microbiology 74, 1453-1463, doi:10.1128/AEM.02181-07 
(2008). 
 
Wu, D., Lamm, A. T. & Fire, A. Z. Competition between ADAR and RNAi pathways for 
an extensive class of RNA targets. Nature structural & molecular biology 18, 
1094-1101, doi:10.1038/nsmb.2129 (2011). 
 
Wu, H., Irizarry, R. A. & Bravo, H. C. Intensity normalization improves color calling in 
SOLiD sequencing. Nature methods 7, 336-337, doi:10.1038/nmeth0510-336 
(2010). 
 
 245 
Wu, H., Wang, C. & Wu, Z. A new shrinkage estimator for dispersion improves 
differential expression detection in RNA-Seq data. Biostatistics, 
doi:10.1093/biostatistics/kxs033 (2012). 
 
Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing 
in short reads. Bioinformatics 26, 873-881, doi:10.1093/bioinformatics/btq057 
(2010). 
 
Wulff, B. E. & Nishikura, K. Substitutional A-to-I RNA editing. Wiley interdisciplinary 
reviews. RNA 1, 90-101, doi:10.1002/wrna.10 (2010). 
 
Xia, Q. et al. Complete resequencing of 40 genomes reveals domestication events and 
genes in silkworm (Bombyx). Science 326, 433-436, 
doi:10.1126/science.1176620 (2009). 
 
Yamanaka, S., Poksay, K. S., Arnold, K. S. & Innerarity, T. L. A novel translational 
repressor mRNA is edited extensively in livers containing tumors caused by the 
transgene expression of the apoB mRNA-editing enzyme. Genes & development 
11, 321-333 (1997). 
 
Yang, W. et al. Modulation of microRNA processing and expression through RNA 
editing by ADAR deaminases. Nature structural & molecular biology 13, 13-21, 
doi:10.1038/nsmb1041 (2006). 
 
Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth 
approach to detect break points of large deletions and medium sized insertions 
from paired-end short reads. Bioinformatics 25, 2865-2871, 
doi:10.1093/bioinformatics/btp394 (2009). 
 
Yi, X. et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science 
329, 75-78, doi:10.1126/science.1190371 (2010). 
 
Yoshinaga, K., Iinuma, H., Masuzawa, T. & Uedal, K. Extensive RNA editing of U to C 
in addition to C to U substitution in the rbcL transcripts of hornwort chloroplasts 
and the origin of RNA editing in green plants. Nucleic acids research 24, 1008-
1014 (1996). 
 
Yu, Q. B., Jiang, Y., Chong, K. & Yang, Z. N. AtECB2, a pentatricopeptide repeat 
protein, is required for chloroplast transcript accD RNA editing and early 
chloroplast biogenesis in Arabidopsis thaliana. The Plant journal : for cell and 
molecular biology 59, 1011-1023, doi:10.1111/j.1365-313X.2009.03930.x (2009). 
 
Zauner, S., Greilinger, D., Laatsch, T., Kowallik, K. V. & Maier, U. G. Substitutional 
editing of transcripts from genes of cyanobacterial origin in the dinoflagellate 
Ceratium horridum. FEBS letters 577, 535-538, doi:10.1016/j.febslet.2004.10.060 
(2004). 
 246 
 
Zehrmann, A., Verbitskiy, D., van der Merwe, J. A., Brennicke, A. & Takenaka, M. A 
DYW domain-containing pentatricopeptide repeat protein is required for RNA 
editing at multiple sites in mitochondria of Arabidopsis thaliana. The Plant cell 
21, 558-567, doi:10.1105/tpc.108.064535 (2009). 
 
Zenkin, N., Yuzenkova, Y. & Severinov, K. Transcript-assisted transcriptional 
proofreading. Science 313, 518-520, doi:10.1126/science.1127422 (2006). 
 
Zerbino, D. R. & Birney, E. Velvet: algorithms for de novo short read assembly using de 
Bruijn graphs. Genome research 18, 821-829, doi:10.1101/gr.074492.107 (2008). 
 
Zhang, W. et al. A practical comparison of de novo genome assembly software tools for 
next-generation sequencing technologies. PloS one 6, e17915, 
doi:10.1371/journal.pone.0017915 (2011). 
 
Zhou, W. et al. The Arabidopsis gene YS1 encoding a DYW protein is required for 
editing of rpoB transcripts and the rapid development of chloroplasts during early 
growth. The Plant journal : for cell and molecular biology 58, 82-96, 
doi:10.1111/j.1365-313X.2008.03766.x (2009). 
 
Zhu, H. et al. Quantitative analysis of focused a-to-I RNA editing sites by ultra-high-
throughput sequencing in psychiatric disorders. PloS one 7, e43227, 
doi:10.1371/journal.pone.0043227 (2012). 
 
 
 
